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ABSTRACT 
 
 Vaccination has proven a cost-effective method of managing infectious diseases, 
but attempts to develop an effective fetal vaccine have proven difficult due to the 
immaturity of the immune system and the propensity of the developing immune system 
to induce tolerance to immunizing antigens. This thesis is concerned with the induction 
of specific immunity in the second trimester ovine fetus using the oral DNA 
immunization method. In utero oral delivery of naked DNA plasmid was selected as the 
method of immunization due to previous successes in the third trimester ovine fetus and 
the immunostimulatory properties of the bacterial DNA backbone, which may help 
overcome developmental tolerance. Transfection and expression studies in the third 
trimester ovine fetus revealed the oral mucosal epithelium as the primary site of 
transgene expression and functionally active antigen was also localized to lymph nodes 
draining the oral cavity. Efficient transfection and expression of plasmid following oral 
delivery was specific to the fetus and correlated with a lesser degree of epithelial 
differentiation. Oral DNA delivery in the second trimester resulted in detection of 
transgene activity in 100% of treated fetuses and the level of transgene activity was 
greater than in fetuses treated in the mid-third trimester. Using a plasmid encoding the 
gene for bovine herpesvirus-1 truncated glycoprotein D (tgD), immunization studies 
were then conducted in the second trimester fetus. A new lower age limit for fetal 
immunization was established at 55-60 days gestation (gestation period is 148 days), 
which coincides with the appearance of lymphocytes in peripheral tissues. Antigen-
specific antibody, interferon-  responses and/or neonatal anamnestic responses were 
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detected in 66% of fetuses immunized between 55 and 84 days gestation. The duration 
of fetal primary immune responses was equivalent to that achieved in young lambs 
following optimized DNA vaccination, but the magnitude of fetal immune responses 
was limited. The persistence of immune memory from the second trimester to birth was 
consistent with experimental data which showed that the duration of immune memory 
had a stronger correlation to the duration, as compared to the magnitude, of the primary 
antibody response. Overall, the experiments within showed that oral DNA immunization 
of the early second trimester fetus is feasible and not associated with the induction of 
tolerance. These findings suggest that it may be possible to protect against mother-to-
child transmission of infectious pathogens by targeting protection at the level of the 
fetus.  
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CHAPTER 1 
 
LITERATURE REVIEW 
 
1.1. Introduction 
 Vaccination has proven to be a cost-effective method of managing infectious 
diseases; however, to date, advances in disease prevention and the development of 
vaccines have failed to decrease the rate of infection by vertically transmitted and 
neonatal pathogens, such as human immunodeficiency virus (HIV), hepatitis and 
Chlamydia spp.. In 2005, an estimated 700,000 infants worldwide became infected with 
HIV, primarily through mother-to-child transmission (UNAIDS/WHO 2005). In 2000, 
the mortality rate of children under the age of 5 in areas such as sub-Sahara Africa was 
estimated at 9.5%, with the majority of deaths occurring in the first year of life (Ventor 
2002). The rapid rate of viral and bacterial replication in the immunologically naïve 
fetus or neonate may result in such an overwhelming pathogen load that vaccinating the 
infant after infection may result in the naïve immune system being unable to catch up 
with the rate of disease progression. An alternative strategy to infant vaccination or 
prophylaxis is the development of an effective fetal vaccine that would prevent in utero 
disease transmission and extend protection to the neonatal period. A number of obstacles 
must be overcome before an effective fetal vaccine can be developed. These include: (i) 
maternal antibodies, which interfere with subunit and killed vaccines before they can be 
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properly presented to the fetal immune system (Reynolds and Griffin 1990; van Maanen, 
Bruin et al. 1992; Blasco, Lambot et al. 2001); (ii) high cortisol levels (Munroe 1971; 
Berdusco, Hammond et al. 1993; Nathaniels 1994) and immaturity of the immune 
system, both of which can skew responses towards a type-2 response, which in many 
cases are ineffective and in some cases pathological (Bondada, Wu et al. 2001; Liu, Tu 
et al. 2001; Liu, Tu et al. 2001); (iii) low numbers of B cells and immature memory, 
requiring repeated boosting (Siegrist 2001); and (iv) the immaturity of the immune 
system, which is unable to deliver adequate co-stimulatory signals and, therefore, 
increases the risk of tolerance induction (Bondada, Wu et al. 2001; Tschernig, Debertin 
et al. 2001; Matzinger 2002). There is substantial data in the literature to suggest that it 
is possible to design an effective fetal immunization protocol, and induction of either 
tolerance or protective immunity is dependent upon a number of combined factors, 
including the route, dose and nature of the vaccinating antigen and the gestational age of 
the fetus at the time of immunization. As these factors appear to be species specific, an 
animal model that is relevant to the human developing immune system is also required.  
 This thesis is concerned with the induction of antigen-specific immune responses 
in the early ovine fetus. We specifically asked whether a vaccine could be delivered in 
such a manner as to avoid the induction of tolerance in the second trimester ovine fetus 
and whether the second trimester ovine fetus would respond to DNA immunization by 
developing an antigen-specific protective immune response that persisted into the 
neonate. The following is a review of the scientific literature pertaining to these 
questions. As induction of fetal immune responses has often been described as a break in 
self-tolerance, theories of immune induction with a focus on mechanisms of self/non-
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self discrimination are discussed. This is followed by a review of immune memory: 
without immune memory, neither immune-mediated protection nor tolerance can persist 
into the neonate. A summary is provided of experiments which have demonstrated either 
the induction of tolerance or immune protection following fetal antigenic exposure, with 
particular focus on experiments conducted in the fetal lamb model. Lastly, there is a 
review of the literature on DNA vaccines, which appear to be a method of antigen 
delivery well suited to the induction of protective fetal immune responses.   
 
1.2.  Tolerance and Immune Protection During Development 
 There are four ways in which the immune system can respond to an antigen. It 
can (i) mount a protective immune response characterized by humoral and/or cell-
mediated immunity (CMI), (ii) actively suppress humoral and/or CMI responses to an 
antigen via induction of tolerance, (iii) mount a non-protective immune reponse, or (iv) 
“ignore” the antigen by neither inducing a protective immune response nor inducing 
tolerance (Matzinger 2002). Induction of either protection or tolerance depends on 
whether the immune system perceives an antigen to be self or non-self. Therefore, the 
following is a short review of the literature pertaining to self/non-self discrimination and 
how it is regulated during development of the immune system. 
  
1.2.1. Mechanisms of Self-Non-Self discrimination 
 One of the most widely accepted models of immune induction is the Bretscher-
Cohn Two-Signal Theory of Lymphocyte Activation (1970). In addition to describing a 
mechanism of lymphocyte activation, it also provides a framework for tolerance 
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induction. According to the original hypothesis, activation of precursor lymphocytes 
requires the recognition of two linked antigenic epitopes: the first epitope is recognized 
by the precursor cell (signal 1) and the second epitope is recognized by a carrier 
antibody (signal 2). In its modern context, signal 1 is provided by either T cell receptor 
(TCR) recognition of an antigen presented in the context of a major histocompatibility 
complex (MHC) molecule or recognition of an epitope by surface-bound 
immunoglobulins (sIg), and signal 2 is delivered by an antigen-presenting cell (APC) 
usually in the form of a cytokine, such as interleukin (IL)-2, -4, -10 or interferon (IFN)-  
(Swain, McKenzie et al. 1988), or by cell-to-cell contact (e.g., CD28 interaction with 
B7, or CD40 interaction with CD154). Generation of signal 1 in the absence of signal 2 
leads to inactivation of the lymphocyte and immunological tolerance (Bretscher and 
Cohn 1970). Since signal 2 for B cells is provided by T cells, the Two-Signal Theory 
also provided a mechanism by which induction of antigen-specific unresponsiveness in 
the peripheral B cell population could be entirely attributed to antigen-specific tolerance 
in the T cell compartment (Chiller, Habicht et al. 1971), i.e., that central tolerance could 
be achieved by T cell regulation alone. 
 Within the framework of the Two-Signal Model, it was hypothesized that CD4+ 
T helper (Th) cells played a large role in determining whether the immune response 
deviated to either a humoral or CMI response (Parish 1972; Zinkernagel and Doherty 
1975). In an inflammatory environment, signal 2 includes IFN  which results in the 
preferential induction of type-1 CD4+ T helper (Th1) cells and CMI. Alternately, the 
presence of IL-4 and -10 during antigen presentation results in the induction of type-2 
CD4+ T helper (Th2) cells and humoral immunity. What is often perceived as tolerance 
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may actually be immune deviation (Oldstone and Dixon 1967). This is especially true 
for tolerance to many intracellular pathogens, where lack of CMI results from the 
induction of a non-protective antibody response. Deviation towards a Th2 response can 
also result in allogeneic graft acceptance, as demonstrated in miniature swine (Haller, 
Esnaola et al. 1999). One method of inducing antibody responses (and Th2 immune 
deviation) is the intravenous (IV) administration of high doses of an antigen in the 
absence of adjuvant, i.e., high dose tolerance (Power, Wei et al. 1998).  
 A modification of the Two-Signal Theory is Matzinger’s Danger Hypothesis 
(2002). According to this model, antigens are regarded as either non-infectious self 
(tolerized) or infectious non-self (not tolerized). The latter category includes antigens 
that cause cell stress or lytic cell death. Often, for an antigen to be recognized as 
infectious non-self, a third signal is required that warns the immune system of imminent 
danger. This “danger signal” can be pathogen-derived or endogenously-expressed and is 
required for activation of signal 2, thus providing an alternative mechanism for self/non-
self discrimination. In the absence of a danger signal, an antigen is perceived as non-
infectious self and tolerized. Examples of this third signal include bacterial 
lipopolysaccharides (LPS), unmethylated cytosine-guanine motifs (CpGs), inflammatory 
mediators and defensins, all of which have been utilized as vaccine adjuvants.  
 There are many experimental examples of adjuvants breaking tolerance to self-
antigens, e.g., (i) administration of myelin basic protein in complete Freund’s adjuvant 
(CFA) induced experimental autoimmune encephalomyelitis in mice (Panitch and 
Ciccone 1981), and (ii) immunization with retinal S antigen in either CFA or pertussis 
toxin induced experimental autoimmune uveoretinitis (EAU) in mice (McAllister, 
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Vistica et al. 1986). In contrast, when retinal S antigen was delivered with incomplete 
Freund’s adjuvant, mice were immunized against EAU induction. Each danger signal or 
adjuvant mediates its activity via a specific pathway.  For example, APCs can be 
stimulated by activating toll-like receptors (TLRs), which are expressed in or on the 
surface of APCs, and this results in the delivery of signal 2. The Danger Model also 
bears striking resemblance to Cohen’s Immunological Homunculus model (1992), 
according to which, protective immune responses are induced when antigens are 
presented to naïve T cells in the presence of pro-inflammatory mediators. In his model, 
Cohen paid particular attention to the role of endogenous heat shock proteins as inducers 
of co-stimulatory signals in infection and autoimmunity.  
 
1.2.2. Developmental Tolerance 
 The concept that self versus non-self is established during ontogeny of the 
immune system was first proposed in the Natural Selection Theory of Antibody 
Formation (Jerne 1955). According to this theory, the random generation of natural 
antibodies results in a broad immunological repertoire that includes self-reactivity and to  
prevent autoimmunity, autoreactive antibodies are deleted during ontogeny while the 
immune system is immature. These postulates were expanded upon in the Clonal Theory 
of Selection, in which Burnet (1959) proposed that deletion of self-reactive antibody-
forming cells occurs during ontogeny as a result of immature cells undergoing a period 
of hyper-responsiveness to antigen-induced suppression or deletion. As a result, 
exposure to an antigen sufficiently early in life results in a reduced ability to react to that 
antigen at a later period in life. As a corollary, a B cell can only mature in an 
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environment devoid of its corresponding antigen. This process was described by Burnet 
as “actively acquired tolerance”. 
 The notion of a developmental tolerogenic period has become immunological 
dogma on the basis of a few seminal experiments. One of the earliest reports of 
immunological tolerance was written by Traub (1938), who observed that in utero or 
neonatal infection of mice with lymphocytic choriomeningitis virus (LCMV) resulted in 
a percentage of mice becoming chronically infected. In utero infection also resulted in 
the lowest levels of LCMV-specific serum antibodies, the least immune-mediated 
pathology and the highest levels of viremia for the longest duration. In contrast, adult 
mice infected with LCMV experienced a subclinical infection and virus was cleared in 
approximately 3 weeks. Traub interpreted persistent infection as a “failure” or 
accommodation of the immune system. Similarly, in humans, hepatitis B virus infection 
in adults results in an acute clinical onset that persists for a few months. In contrast, 
infants born to infected mothers become chronically infected (WHO 1977) and this 
outcome is thought to reflect the immunological status of the fetus at the time of 
infection. Developmental induction of tolerance to MHC alloantigens has been described 
in dizygotic twin cattle (Owen 1945). Vascular anastomosis between placentas of twins 
results in erythrocytic chimeras with shared blood types composed of a 50/50 to 60/40 
mixture of red blood cells from each of the twins. Chimerism is stable for the lifetime of 
the animal, thus showing that the erythrocytic precursors from one twin confers 
tolerance in the congeneic twin. Tolerance also extends to skin grafts from one twin to 
the other later in life (Rawles 1948). Chimerism between twins is not specific to cattle 
and has also been described in humans (Dunsford, Bowley et al. 1953).  
 8 
 In 1953, Billingham et al. conducted a series of tolerance studies in mice and 
chickens. Eleven-day embryonic chicks (incubation period is 21 days) were injected 
intravenously (IV) with allogeneic blood cells. Three of 5 chicks developed partial 
tolerance to postnatal skin grafts from the original donor, while the remaining two 
chicks developed complete tolerance. Similarly, grafting experiments were conducted 
between CBA and A strain mice. Injection of strain A donor cells into recipient CBA 
mice at 15-16 days gestation (dg) (gestation length is 20-21 days) resulted in the 
induction of tolerance to postnatal strain A skin grafts in 3 of 5 mice. Of the three 
tolerized mice, two were completely tolerant of the postnatal skin graft and the third 
mouse showed delayed rejection of the graft. In the two mice that failed to develop 
tolerance to postnatal skin grafts, there was no evidence of an in utero immune response 
to the priming dose of strain A cells. Billingham et al. (1953) referred to this period of 
fetal development, during which a foreign antigen either failed to induce a detectable 
immune response or induced specific tolerance, as an “immunological null period”. In 
other experiments, the observation that non-inherited maternal antigens are tolerized by 
offspring also supports the concept of an immunological null period during fetal 
development. Exposure of fetal H-2b/b mice to the non-inherited maternal antigen H-2d 
resulted in graded postnatal tolerance to the H-2d antigen (Andrassy, Kusaka et al. 
2003). Postnatal tolerance was demonstrated by the acceptance of H-2d/d heart 
transplants by 57% of mice exposed as fetuses to the non-inherited maternal antigen and  
tolerance encompassed CD8
+
, Th1 (decreased IL-2, IFN  and IgG2a) and Th2 (IL-5, -4 
and IgG1) mediated immune responses.  
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1.2.3. Regulation of Developmental Tolerance 
 Tolerance is regulated at two levels (reviewed by Starr, Jameson et al. 2003). 
The deletion of autoreactive immature thymocytes in the thymus (clonal deletion or 
thymic deletion) is referred to as central tolerance; however, the continual generation of 
cells in the periphery, thymic involution and the presence of the blood-thymic barrier, 
which limits the entry of peripheral antigens into the thymus, necessitate a second tier of 
immune regulation referred to as peripheral tolerance. Fetal vaccination is concerned 
with avoiding central tolerance and breaking peripheral tolerance.  
 The current model suggests that clonal deletion of developing thymocytes occurs 
as a result of high affinity/avidity interaction of TCRs with (self) antigen-MHC 
complexes, which results in activation-induced apoptosis (Ashton, Rockardt et al. 1994). 
Some of the studies that support this model are described here. In one study, pregnant 
mice expressing the transgene for LCMV-specific TCR were infected with LCMV. Two 
days after infection, virus particles were detected in fetal thymuses and this was 
followed by the thymic deletion of both double positive CD4+CD8+ thymocytes and 
single positive CD8+ thymocytes (Pircher, Burki et al. 1989). Smith et al. (1989), then 
showed that clonal deletion could be mediated through high affinity binding of the 
CD3/TCR complex. The addition of anti-CD3 antibodies to organ cultures of fetal 
mouse thymocytes resulted in apoptosis, with double positive CD4+CD8+ thymocytes 
accounting for 83% of dying cells. Clonal deletion can also be mediated by engaging 
only the TCR. TCR-V 17a binds to the MHC class-II IE protein with high affinity. 
Expression of the TCR-V 17a transgene in IE mice resulted in the deletion of V 17a+ 
cells from the mature thymocyte and peripheral T cell pools, but not from the immature 
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thymocyte pool (Kappler, Roehm et al. 1987; Kappler, Wade et al. 1987). More recent 
studies have implicated several protein kinases in the apoptotic pathway, including a 21 
kDa tyrosine kinase activity on the intracellular portion of the TCR, MINK serine-
threonine kinase and Jun kinase (McCarty, Paust et al. 2005). Together, these signals 
lead to activation of the apoptotic pathway.  
  Clonal deletion can occur during either the double negative (CD8-CD4-) stage or 
as T cells progress to the single positive stage (Starr, Jameson et al. 2003). The stage 
during which deletion occurs depends on the location of antigen within the thymus. 
Double-negative thymocytes are located in the cortical region of the thymus, which is an 
antigen-privileged zone due to the presence of the thymic-blood barrier that functions to 
reduce the number of peripheral antigens entering the cortical parenchyma. As with all 
thymocytes, negative selection is mediated by high affinity binding of the TCR (Viret C, 
Sant'Angelo et al. 2001). Due to the presence of the blood-thymic barrier, there is little 
negative selection of double negative T cells specific for self-antigens. This is consistent 
with their role in the periphery, which is to suppress autoreactive T cells (Priatel, Utting 
et al. 2001).  
 In comparison, deletion of single positive (CD4+ or CD8+) thymocytes occurs 
mostly in the thymic medulla. Experimental evidence has suggested that self-antigens 
are presented on the surface of either medullary thymic epithelial cells (MTECs) or bone 
marrow-derived APCs, such as dendritic cells (DCs) and monocytes (Gallegos and 
Bevan 2004). Interaction with APCs is required for the deletion of CD4+ thymocytes 
and, to a lesser extent, CD8+ thymocytes. APCs can acquire peripheral antigens en route 
from the bone marrow (Zinkernagel, Ehl et al. 1997) or, in species with hemichorial 
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placentation, antigens might be delivered to the thymic medulla via maternal cells 
entering the fetal circulation (Andrassy, Kusaka et al. 2003). MTECs, which are 
primarily involved in the deletion of CD8+ thymocytes, express ectopic antigens under 
the control of the autoimmune regulator (AIRE) protein (Sospedra, Ferrer-Francesch et 
al. 1998). These tissue-specific antigens include anatomically privileged antigens, such 
as myelin basic protein and retinal S antigen, and antigens that are expressed only at 
certain stages of development, including pregnancy and lactation-associated antigens 
that are expressed after thymic involution. MTECs have a reduced ability to express co-
stimulatory signals relative to other APCs (Anderson, Venanzi et al. 2005) and, 
therefore, are ideal for presentation of self-antigen for the purpose of clonal deletion. 
Deficiency in AIRE has been shown to result in increased numbers of autoreactive 
CD8+ and CD4+ T cells, as well as an increase in the incidence of multi-organ 
autoimmune disease in both mice and humans (Aaltonen, Bjorses et al. 1997; Anderson, 
Venanzi et al. 2002). Although clonal deletion has been formally demonstrated for anti-
hapten, anti-viral and anti-MHC thymocytes (Kappler, Roehm et al. 1987; Smith, 
Williams et al. 1989), thymic exposure to antigen could also result in the induction of an 
anergic state or the positive selection of antigen-specific suppressor cells (Schönrich, 
Momburg et al. 1992; Jordan, Boesteanu et al. 2001).  
 Clonal deletion may also occur in the bone marrow of mice, resulting in B cell 
tolerance. Experiments in cytochrome c-transgenic mice have shown that the pre-B cell 
pool contains many clonal precursors specific for cytochrome c, the number being 
analogous to that for a comparable foreign peptide (Jemmerson, Minnerath et al. 1998). 
In contrast, there are far fewer cytochrome c-specific cells in the mature B cell pool, thus 
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suggesting that an in vivo purging of the self-reactive repertoire occurs during the pre-B 
to B transition. Exposure of pre-B cells to self-antigen in the presence of T cell help 
(signal 1 plus signal 2) can override the tolerogenic potential of signal 1 alone and result 
in antibody-producing clones (Linton, Rudie et al. 1991). The sensitivity of the B cell to 
down-regulation appears to depend upon the stage of cellular differentiation (Nossal 
1983). In order of decreasing susceptibility, these are: cells in transition from the pre-B 
to B cell stage (self-antigens first interact with developing B cells at this stage), 
immature B cells, mature B cells and plasma cells. Despite mechanisms for clonal 
deletion of autoreactive B cells, B cell tolerance is achieved, for the most part, through 
tolerance in the T cell compartment (Chiller, Habicht et al. 1971). 
 Mechanisms other than clonal deletion may also limit fetal immune responses to 
antigen exposure. These include: (i) immaturity of the immune system and the low 
frequency of lymphocytes present during development, (ii) lack of immune memory 
resulting in a higher threshold for lymphocyte activation, (iii) interference by maternal 
antibodies, and (iv) general suppression of the immune system by periparturient 
increases in cortisol levels (Anderson, Flint et al. 1975). Corticosteroid-induced 
apoptosis of thymocytes may result in the elimination of immature thymocytes specific 
for new maternal and environmental antigens immediately before birth (Munroe 1971; 
Cahill, Kimpton et al. 1997).  
 Experiments with human cord blood-derived APCs have also shown a reduced 
capacity for antigen presentation in the fetus. Cord-blood derived B cells expressed 
lower levels of MHC class-II and CD86 on their surface, and demonstrated reduced 
antigen-specific proliferation relative to adult-derived B cells. Both of these deficits 
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could be overcome, however, by stimulation with CpGs (Tasker and Mashall-Clarke 
2003); but, CpGs could not overcome homing defects in cord blood-derived B cells 
(Tasker and Mashall-Clarke 2003). Also, cord blood-derived DCs produced less IFN  
upon stimulation with CpGs than adult-derived DCs (DeWit, Olislagers et al. 2004). The 
induction of peripheral tolerance mechanisms may also be involved in the lack of 
immune responses following fetal immunization. 
 
1.2.4. Fetal Immunity 
 The concept of developmental tolerance was established by Billingham et al. 
(1953), who showed that injecting newborn mice with allogeneic bone marrow cells 
resulted in the induction of tolerance to future grafts from the same donor. Further 
studies in the area of fetal and neonatal tolerance suggested that the lack of CMI was due 
to a quantitative lack in the number of DCs (Liu, Tu et al. 2001; Tschernig, Debertin et 
al. 2001) and the inability of DCs to deliver appropriate co-stimulatory signals upon 
activation (Bondada, Wu et al. 2001; Liu, Tu et al. 2001). The limited ability to produce 
type-1 cytokines might also explain the frequently observed Th2 bias in neonatal 
immune responses (Adkins, Ghanei et al. 1994; Bondada, Wu et al. 2001).  
 Many of the studies that support the developmental tolerance dogma have been 
conducted in the mouse model, using traditional vaccines or transplantation antigens, 
and a narrow definition of “tolerance”. These studies have overshadowed a body of 
research conducted in large animal, primate and human models which have 
demonstrated that fetal immune responses can be induced to specific antigens. 
Unfortunately, studies in these alternative animal models have been limited by 
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prohibitive costs, facilities and ethical considerations. Interpretation of data obtained 
from large animal experiments has also been complicated by the high degree of 
variability among individuals in an outbred species. The first laboratory experiments to 
demonstrate successful fetal immunization were conducted in the fetal calf (Fennestad 
and Borg-Petersen 1957) and fetal lamb models (Silverstein, Uhr et al. 1963; Silverstein 
and Prendergast 1964). Table 1.1 summarizes fetal immunization experiments in animal 
models other than sheep and a summary of immunization experiments in the fetal lamb 
model is presented in Section 1.3.  
 In 1996, Otsyula et al. (Table 1.1) reported that in utero immunization of rhesus 
macaques with attenuated simian immunodeficiency virus (SIV) resulted in the 
induction of SIV-specific fetal antibody titers and post-natal protection from challenge 
with pathogenic SIV. There are also studies showing the induction of fetal immunity in 
premature human infants (Uhr, Dancis et al. 1960; Uhr, Dancis et al. 1962). Post-
mortem examination of a 5-month old human fetus that had succumbed to syphilis 
revealed inflammatory lesions with large numbers of plasma cells and cells with a 
phenotype consistent with DCs (Silverstein 1962). CD45RO+ memory T cells have also 
been detected in the cord blood of premature infants (23-29 weeks gestation) with brain 
injury (Duggan, Maalouf et al. 2001). The antigenic specificity of these memory cells 
was not determined but, their presence in the preterm infant suggested that priming by a 
specific antigen had previously occurred.  
 While there is evidence of antigen-specific fetal immune responsiveness, a 
review of the literature also suggests that the fetal immune system has a limited 
antigenic repertoire and minimum immunogenicity threshold to which it can respond.  
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Table 1.1. Fetal immunization experiments in species other than sheep  
Species Time of fetal 
immunization
1 
(gestational 
length in days) 
Vaccine 
/route of delivery 
Method of 
read-out 
Response
2 
Reference 
Rhesus 
macaque 
65 dg 
(160-170 d) 
Attenuated simian 
immunodeficiency 
virus 
/NS 
Protection 
from virulent 
SIV challenge 
at 17 mo of 
age 
2° antibody titers 
(2/3) but no CTL 
responses 
(Otsyula, 
Miller et al. 
1996) 
Rhesus 
macaque 
70-114 dg 
(160-170 d) 
Group 1: 100 mg 
BSA; Group 2: 1-8 
mg BSA in adjuvant 
/NS 
Response to 
neonatal boost 
Group 1: 5/6 
macaques were 
tolerized; Group 2: 
developed 
transient fetal 
antibodies 
(Cotes, 
Hobbs et al. 
1966) 
Baboon 3 repeats: 
90 + 120 + 150 
dg 
(180 d) 
Recombivax HB 
(commercial HBsAg 
subunit vaccine) 
/NS 
Fetal IgG 6/8 (Watts, 
Stanley et al. 
1999) 
Pig Group 1: 90 
dg; Group 2: 
104 dg 
(114 d) 
HBsAg DNA vaccine 
/IM 
Fetal antibody 
and neonatal 
memory 
Group 1: 
Precolostrum titers 
(5/9); Group 2: no 
responses (7/7) 
(Fazio, Ria et 
al. 2004) 
Cow 214-223 dg
 
(280 d) 
L. saxkoebing in 
guinea pig liver 
suspension 
/intracotyledon 
Fetal antibody Precolostrum titers 
(3/3) 
(Fennestad 
and Borg-
Petersen 
1957) 
Mouse Post-coitus 
(20-21 d) 
Viral antigen DNA 
vaccine 
/transplacental 
Post-birth 
anamnestic 
responses 
Significant 
increase in 
anamnestic 
responses of 
offspring of 
immunized mice
 
(Okuda, Xin 
et al. 2001) 
Human Premature 
newborn 
Phage X174 
/NS 
Postnatal, 
primary 
antibody 
Titers >0.3 
(11/11); no 
controls were 
reported 
(Uhr, Dancis 
et al. 1962) 
Human Premature 
newborn 
dNFB 
/NS 
dNFB patches 
at 4 w 
DTH (3/10) (Uhr, Dancis 
et al. 1960) 
 
BSA = bovine serum albumin; dg = days gestation; dNFB = dinitro-fluorbenzene; DTH = 
delayed type hypersensitivity; HBsAg = Hepatitis B surface antigen; IM = intramuscular; 
NS = not specified. 
 
1 In many of the experiments, fetuses at different gestational ages were grouped  
  together.  
 
2 Numbers refer to the number of responders relative to the total number of animals that  
  were immunized.  
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In the studies by Watt et al. (1999), Fazio et al. (2004) and Gerdts et al. (2002) (Table 
1.1), using hepatitis B surface antigen (HBsAg) as the model antigen resulted in 
detection of HBsAg-specific fetal immune responses. HBsAg self-assembles into a 
secreted, non-soluble, slow-degrading virus-like particle (VLP) (Petit, Maillard et al. 
1986) that has superior immunogenicity when compared with monomeric or dimeric 
equivalents (Fernandez, Conner et al. 1998). It has been suggested that the 
immunogenicity of HBsAg is due to the highly repetitive nature of the VLP, which has 
been shown to facilitate T cell-independent B cell expansion (Fehr, Skrastina et al. 1998) 
and enhance presentation on MHC class-I molecules (Abbing, Blaschke et al. 2004). 
These results suggest that there may be a correlation between the degree of 
immunogenicity of the antigen and successful fetal immunization. Other model antigens 
with a lesser degree of immunogenicity may be less effective at overcoming the reduced 
immune competence of the fetal immune system. 
 Induction of fetal immune responses have also been demonstrated using DNA 
vaccines (Gerdts, Babiuk et al. 2000; Okuda, Xin et al. 2001; Gerdts, Snider et al. 2002; 
Fazio, Ria et al. 2004). The in utero oral DNA immunization studies by Gerdts et al. 
(2000; 2002) are discussed in Section 1.6. Okuda et al. (2001) (Table 1.1) injected 
pregnant mice with DNA plasmid encoding either -galactosidase, HIV-1 antigen or 
influenza virus antigen. Reverse transcriptase-polymerase chain reaction (PCR) and X-
gal staining were used to show transgene expression in fetal tissues and activation of the 
fetal immune system was shown indirectly by the detection of anamnestic responses 
following intranasal DNA immunization at 6 weeks of age.  
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 Aside from those studies conducted in our laboratory, the only other study to 
examine the in utero delivery of naked plasmid in a large animal model is Fazio et al. 
(2004) (Table 1.1). In their study, 200 μg of HBsAg-plasmid was injected into the 
semimembranous muscle of fetal pigs in the third trimester of gestation (at either 90 or 
104 dg; gestation length approximately 115 days). HBsAg-specific antibody titers were 
detected in precolostrum sera in 5 of 9 piglets immunized at 90 dg. The authors 
suggested that fetal antibody responses might have waned in three additional piglets 
based on the observation that boosting with plasmid at 1 week of age resulted in the 
induction of protective antibody titers in 8 of 9 piglets that had been immunized as 
fetuses, but not in control piglets. In a second set of experiments, seven piglets that had 
been immunized with plasmid at 104 dg did not possess detectable precolostrum 
antibody titers. The authors suggested that immune memory might have been detected in 
three of the pigs postnatally, but the lack of age-matched controls (for the 104 dg group) 
made data difficult to interpret. CMI responses were not examined in piglets immunized 
at either 90 or 104 dg. To date, two independent groups (Gerdts, Babiuk et al. 2000, 
2002; Fazio, Ria et al. 2004) have reported the successful induction of fetal antibody 
responses and neonatal immune memory following immunization with naked DNA 
plasmid in the third trimester fetus.  
 Gerdts et al. (2000) hypothesized that fetal immune responses were induced as a 
result of the inherent immunogenicity of the bacterial DNA plasmid backbone which 
contains immunostimulatory CpG and polyG motifs. In brief, CpGs stimulate DCs to 
upregulate MHC class-II, co-stimulatory molecules and inflammatory cytokines 
(Yamamoto, Yamamoto et al. 1992; Yi, Chace et al. 1996; Yi, Klinman et al. 1996; 
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Roman, Martin-Orozco et al. 1997). Experiments on full-term human cord blood-derived 
B cells have shown that CpGs enhance expression of MHC class-II and CD86 despite 
high cortisol levels (Tasker and Mashall-Clarke 2003) and immunization studies in 
neonatal mice have shown that DNA vaccines can overcome developmental tolerance 
(Forsthuber, Yip et al. 1996; Sarzotti, Dean et al. 1997; Bot, Bot et al. 1998). There are 
many aspects of the developing immune system which are not influenced by CpGs: 
stimulation with CpGs did not stimulate full-term human cord blood-derived DCs to 
express IFN  (DeWit, Olislagers et al. 2004); nor, could CpGs reverse the homing 
deficits in cord blood-derived B cells that prevent their entering peripheral lymph nodes 
(LNs) (Tasker and Mashall-Clarke 2003). There is one report of DNA immunization in 
neonatal mice with plasmid containing the gene for Plasmodium yoelii circumsporozoite 
protein that resulted in the induction of tolerance (Mor, Yamshchikov et al. 1996). 
Tolerance, however, was overcome by co-immunization with plasmid expressing 
granulocyte-macrophage colony-stimulating factor (GM-CSF) (Ishii, Weiss et al. 2000), 
therefore suggesting that certain DNA plasmids might lack appropriate co-stimulatory 
activity.  
 
1.2.5. Split Tolerance: Immune Deviation in the Fetus 
 Immune deviation, which was first described by Parish (1972) and demonstrated 
by Zinkernagel and Doherty (1975), is characteristic of fetal and neonatal immune 
responses and has implications for fetal vaccination. A review of the literature also 
suggests that the concept of immune deviation was first observed in fetal and neonatal 
immunization studies and coined as “split tolerance” (Asherson 1967). “Split tolerance” 
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refers to the impairment of CTL and Th1-mediated immune responses, which are 
required for the resolution of intracellular infections, and may be a more accurate 
description of the fetal immune response to antigenic stimulation than “developmental 
tolerance”.   
 In the original study of LCVM-infection in fetal mice (Traub 1938), infection 
failed to induce detectable complement-fixing or neutralizing antibodies and it was 
concluded that fetal mice became persistently infected as a result of developmental 
tolerance. In 1967, Oldstone and Dixon repeated Traub’s experiment and LCMV-
specific IgG were found in the kidneys of neonatally infected mice. Despite the presence 
of antibodies, 80% of these mice became chronically infected and some gave birth to 
persistently infected or “tolerized” offspring who also had LCMV-specific IgG deposits 
in glomeruli. This finding suggested that the fetal immune system was capable of 
responding to LCMV infection, albeit in a non-protective manner.  
 Split tolerance has also been reported in other studies. In the macaque study by 
Otsyula et al. (1996) (Table 1.1), fetal immunization with attenuated SIV resulted in 
detection of SIV-specific antibody titers, but not CTL responses. When the immunized 
macaques were challenged at 17 months of age, 2 of 3 animals mounted detectable SIV-
specific CTL responses, suggesting that, with respect to SIV, an antibody-type response 
had not imprinted upon the the developing immune system. In contrast, inoculation of 
fetal mice with LCMV did result in these mice developing a permanent deviation 
towards humoral immunity with respect to future LCMV challenge (Oldstone and Dixon 
1967) (Table 1.1).  
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 Tolerance, like protective immunity, is actively acquired and as such, can be 
expected to diminish with time unless boosting occurs. In the case of the SIV-infected 
macaques, tolerance may have been lost as a result of the gradual loss of suppressor or 
anergic cells, or as a result of the lymphocyte pool being replenished with new, 
randomly generated precursors cells. In contrast, studies of immune memory duration 
have shown that LCMV-specific CD8+ memory cells are permissive and easily 
stimulated by other, non-related viruses (Selin, Nahill et al. 1994). The same may also 
be true of LCMV-specific memory suppressor cells.  
 Split tolerance appears to be conceptually synonymous with immune deviation in 
which the cytokine environment, antigen dose and method of antigen presentation have 
resulted in the preferential induction of a Th2 response; however, reference to the 
original fetal sheep studies by Silverstein et al. (1963; 1964) (Section 1.4) also raises the 
possibility that split tolerance occurs as a result of Th2 immune responses developing 
prior to Th1 and CTL responses. It was observed that antigen-specific humoral 
responses could be induced in the fetal lamb as early as 60-66 dg (Silverstein, Uhr et al. 
1963). In contrast, delayed-type hypersensitivity (DTH) responses did not develop until 
74-76 dg (Silverstein and Prendergast 1964). Therefore, split tolerance may occur if the 
fetal immune system is exposed to a specific antigen at a time when Th2 cells are 
functional, but Th1 and CD8+ T cells are not.  
 Split tolerance may also reflect the immunosuppressive nature of pregnancy, 
which prevents the dam from rejecting the conceptus (Hansen 1998). Given the data 
which support the association of pregnancy with a Th2 cytokine environment and the 
number of studies demonstrating split tolerance, it is interesting that a large number of 
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studies use CMI and DTH as measures for the immune status of the fetus. This is 
especially true of transplantation studies, where fetuses have been described as 
immunologically incompetent based on the long-term survival of a third-party allograft 
in the absence of immunosuppressive treatment. 
 
1.3.  Immune Memory 
 Immune memory is an important component of fetal vaccination. For a vaccine 
to be effective, immunity must endure until the time of exposure to the pathogen. 
Achieving long-term immune memory in the fetus is especially challenging since the 
placenta acts as a barrier against cross-reactive environmental antigens and low levels of 
specific antigen, which are otherwise capable of boosting the waning immune response. 
Due to the placental barrier, fetal immunization must induce a memory component 
capable of persisting into the perinatal period, during which there is the greatest risk of 
infection.  
 
1.3.1. Models of Immune Memory Generation 
 There are four popular models of memory cell induction. In the classic model of 
B cell differentiation (Ahmed and Gray 1996), a single B cell precursor has the potential 
to give rise to either effector or memory cells. The type of progeny that is produced 
depends on the environment: large amounts of antigen in an inflammatory environment 
favor differentiation into plasma cells, whereas antigen plus costimulation in the absence 
of inflammation preferentially activates memory B cells. As a result, effector cells tend 
to be generated during the early stages of an infection while cells that encounter antigen 
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later in the infection process tend to develop into memory cells. This model has also 
been proposed for the generation of CD4+ memory T cells; specifically, naïve CD4+ T 
cells that enter the draining LNs at later times after immunization divide less and 
eventually give rise to progeny with the phenotype of central memory cells (Catron, 
Rusch et al. 2006).  
 According to the linear differentiation model, memory cells are derived from 
effector cells (Liu and Janeway 1990; Swain 1994). Swain established an adoptive 
transfer model in which CD4+ helper T cells activated in vitro and adoptively 
transferred into host mice gave rise to populations of memory cells with a defined Th1 
or Th2 response as determined by the cytokine milieu at the time of in vitro activation. 
Following the initial expansion stage, over 95% of activated T cells underwent cell death 
while the remaining 5% of cells, characterized by higher affinity TCR and IL-2R
lo 
CD44
+
CD45RB
lo
, entered the memory cell population. According to this model, the 
induction of a primary immune response should always give rise to a minority 
population of memory cells. The efficacy of many vaccines has been evaluated with this 
model in mind, i.e., an effective vaccine is one with a large primary effector response.  
 The two less popular models are the Klinman lineage hypothesis (Klinman 1997) 
and the decreasing potential model (Renno, Hahne et al. 1995; Miethke, Vabulas et al. 
1996). The Klinman lineage hypothesis was based on the identification of two precursor 
subpopulations in the spleens of naïve mice (Linton, Decker et al. 1989). The 
predominant Ia+ J11D
hi
 B cell population, upon exposure to antigen and T cell help, 
formed primary antibody producing cells with a short half-life. The remaining 10-15% 
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of B cells were Ia+ J11D
lo
, had a longer half-life and possessed the ability to acquire 
somatic mutations, thus giving rise to memory cells with increased diversity. 
 According to the decreasing potential or terminal differentiation model, antigenic 
stimulation of naïve T cells results in their differentiation into memory cells. With each 
successive antigenic stimulation, the potential of the cell to undergo apoptosis increases 
(Renno, Hahne et al. 1995; Miethke, Vabulas et al. 1996). Based on this model, high 
doses of antigen over a prolonged period will lead to terminal differentiation of all 
clonal progeny and the lack of immune memory. 
 In each of the above four models of memory cell generation, the number of 
memory cells generated is proportional to the size of the primary lymphocyte burst. 
Accordingly, most vaccines have been designed to elicit as large a primary immune 
response as possible (Hou, Hyland et al. 1994; Kaech and Ahmed 2001; Kaech, Wherry 
et al. 2002; Campos and Godson 2003); however, the size of the primary burst is 
unlikely to influence the longevity of immune memory. Gray and Skarvall (1988) have 
suggested that the longevity of humoral memory is not dependent upon intrinsic 
properties of the B cell, but rather the constant activation and turnover of B cells in 
response to persisting antigen in the form of antigen reservoirs or periodic infection. 
Primary activation by antigen has been hypothesized to produce a subset of B cells with 
a very low stimulation threshold that can be chronically activated by either low levels of 
persistent antigen, cross-reactive environmental antigens or anti-idiotypic interactions 
(reviewed by Klaus, Humphrey et al. 1980). 
 Until recently, the majority of molecular signaling pathways required for 
activation of naïve T cells have been assumed relevant to both effector and memory cell 
 24 
induction. Induction of memory T cells does require TCR-recognition of antigen in the 
context of MHC class-I or -II along with a simultaneous second signal, such as B7.1 
(CD80) interacting with CD28 (Liu, Jones et al. 1992); however, the induction of a 
strong primary immune response is not always accompanied by the induction of immune 
memory. This suggests that induction of immune memory requires signals/mechanisms 
in addition to or different from those required for the induction of effector cells. Recent 
experiments have shown that induction of memory Th1 cells requires the transcriptional 
activator protein STAT-1 (Maecker, Varfolomeev et al. 2005). Many hypothetical 
requirements have been suggested for memory CD8+ T cell induction. These include IL-
2, -7, -15 and type-1 IFN (Sprent, Zhang et al. 1999; Schluns and Lefrancois 2003). 
IFN-1 induces macrophages to synthesize IL-15 which binds to the IL-2  receptor 
expressed by CD8+, but not CD4+, cells (Sprent, Zhang et al. 1999). It has also been 
suggested that induction of memory CD8+ T cells requires that low levels of antigen be 
presented in the context of MHC class-1 molecules on the surface of follicular DCs 
(fDCs) (Belz, Wilson et al. 2006).  
 Induction of memory B cells also requires signals in addition to antigen and 
interaction of B7 with CD28 which is expressed on the surface of T cells. Differentiation 
of memory B cells in vitro was dependent on the presence of antigen-antibody 
complexes on fDCs (Phipps, Mandel et al. 1984). In vivo memory B cell differentiation 
occurred in germinal centers (GCs) and was dependent on CD40 interaction with CD154 
(a.k.a. CD40 ligand) (Gray, Dullforce et al. 1994). CD40-CD154 interaction activates 
the transcription factor B-cell specific activator protein (a.k.a. B-cell activating factor) 
(Neurath, Stuber et al. 1995; Manser 2004). CD40-CD154 interaction also stabilizes 
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CFLIP, which inhibits the Fas-mediated apoptotic pathway (DiSanto, Bonnefoy et al. 
1993; van Eijk, Medema et al. 2001). Within GCs, CFLIP inhibition of the apoptotic 
pathway is also sustained by B cell interaction with fDCs. A subpopulation of CD4+ T 
cells, named follicular B helper T cells, has also been identified and these cells secrete 
cytokines that are conducive to memory B cell survival (Vinuesa, Tangye et al. 2005). 
There is also a population of +CD3+CD4+ T cells that can substitute for follicular B 
helper T cells in GC formation; however, B cells activated in this manner can only 
express IgM following primary and secondary immunization (Zheng, Marinova et al. 
2003).  
 Overall, the literature pertaining to immune memory suggests that immune 
memory is not always induced during primary activation of the immune system.  
It may be possible to devise strategies to enhance both the quantity and quality of 
memory cells that are generated during primary immunization.  
  
1.3.2. The Role of Antigen in Immune Memory 
 It is known that memory T cells are a stable population with the ability to avoid 
Fas-Fas ligand (CD95-CD178)-mediated apoptosis (Inaba, Kurasawa et al. 1999). 
Relative to naïve lymphocytes, they express a larger number and variety of adhesion 
molecules, including the higher-affinity IL-2 receptor and high affinity TCR, which 
allows them to better respond to low doses of antigen (Zheng, Xue et al. 1994).  
Currently, the debate exists as to whether memory T cells can survive for long periods in 
the absence of antigen or require repeated, low-levels of antigenic stimulation. It is 
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generally accepted that memory B cells can survive for long periods in the absence of 
continued antigenic stimulation 
 Chronic antigenic stimulus can result from incidental exposure to cross-reactive 
environmental antigens (Selin, Nahill et al. 1994), low-grade persistent infections 
(Sarkar, Mitra et al. 1973; Friedman, Phillip et al. 1989; Lievano, Papania et al. 2004) or 
long-term antigen deposits in the spleen and LNs. Antigen-antibody complexes are 
maintained on the surfaces of both B cells and fDCs in the spleen, but only fDCs in LNs 
(Tew, Mandel et al. 1979). Experiments with human serum albumin, which is easily 
catabolized, have shown that antigen is very stable when retained on the surface of fDCs 
(Tew, Mandel et al. 1979). These stable depots can theoretically stimulate the peripheral 
pool of memory cells as they periodically recirculate through the LNs. Interestingly, 
both splenic and LN antigen depots are susceptible to cortisol treatment (Tew, Mandel et 
al. 1979), suggesting that loss of antigen depots and a subsequent reduction in immune 
memory cells may contribute to the lower level of immune resistance associated with 
pregnancy and parturition. 
  Experimental evidence argues both for and against the need for persistent 
antigen. With regard to memory B cells, it was previously thought that survival 
depended on persistent antigen depots on fDCs since adoptive transfer of primed B cells 
into naïve rats resulted in the loss of immune memory after 6-12 weeks (Gray and 
Matzinger 1991). In 2000, (Maruyama, Lam et al.), designed an experiment in which an 
inducible recombinase transgene was used to “turn off” the antigenic specificity of 
primed B cells following adoptive transfer into naïve recipient mice. In doing so, the 
possible effects of residual antigen being carried over by donor T and B cells into naïve 
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recipients was negated. Using this experimental system, memory B cells persisted up to 
15 weeks in the absence of antigenic stimulation. As a result of this finding, the role of 
fDCs in the maintenance of B cell memory has come under severe scrutiny and fDCs are 
now hypothesized to play a role in CD40-CD154 interaction (Hannum, Haberman et al. 
2000; William, Euler et al. 2002).  
 The debate also exists as to whether or not survival of memory T cells is 
dependent upon chronic or repeated antigen exposure. Gray and Matzinger (1991) 
hypothesized that memory T cell survival was dependent upon continuous exposure to 
antigen. Upon transfer into naïve syngeneic hosts, primed CD4+ T cells had a half-life 
of 2-3 weeks. In comparison, cells were still viable after 7 months when adoptive 
transfer was accompanied by the simultaneous injection of antigen. On the other side of 
the debate, adoptive transfer of IL-2R
lo 
CD44+
 
CD45RB
lo 
CD4+ memory T cells into 
naïve mice in the absence of antigen was followed by survival of cells for up to 9 
months (Swain 1994). The use of different antigens in the above experimental systems 
may have contributed to the difference in duration of survival of memory CD4+ T cells. 
 It is generally accepted that CTL-mediated immune memory persists for a longer 
duration than CD4+ T cell-mediated immune memory (Nanan, Rauch et al. 2000; 
Crotty, Felgner et al. 2003) and survival of memory mCTLs is less dependent on 
persistent antigen (Hou, Hyland et al. 1994; Lau, Jamieson et al. 1994). The exception to 
this generalization is a study by Oehen et al. (1992), which showed that survival of 
mCTLs was both antigen-dependent and short-lived (approximately 13 weeks in the 
presence of antigen). In this study, CTL responses were measured in donor mice that had 
received splenocytes from mice that had been primed 7 days earlier with major nuclear 
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protein antigen from LCMV (delivered in the form of live LCMV or using vaccinia 
virus as a vector). The short period between primary immunization and adoptive transfer 
suggests that the authors may have been observing a long-lived primary CTL response 
that was sustained by the continued presence of high levels of infectious virus and not a 
true population of mCTLs. In studies where there was an extended duration between 
primary immunization with a live virus and adoptive transfer into naïve hosts, CTL 
responses were detected after a much longer period. mCTLs specific for the H-Y antigen 
survived between 6-16 weeks following adoptive transfer into naïve female recipient 
mice (Gray and Matzinger 1991). At 28 weeks post-transfer, mCTL activity was still 
evident in 2 of 5 mice. Mullbacher (1994) reported that mCTLs in the spleen survived 
up to 25 weeks in the absence of persistent antigen and Sendai-virus specific mCTLs 
survived up to 35 weeks following adoptive transfer into naïve recipient mice (Hou, 
Hyland et al. 1994). Lastly, mCTLs isolated from mice infected with LCMV and sorted 
by a fluorescent-activated cell sorter (FACS) to remove any contaminating APCs, 
survived for 26 months following adoptive transfer into naïve recipients (Lau, Jamieson 
et al. 1994). Therefore, the bulk of the literature suggests that CTL memory can persist 
for a reasonable duration in the apparent absence of the specific immunizing antigen. 
 Among the studies presented above, the duration of mCTL survival ranged from 
6 weeks to 26 months. The range in survival times may have been due to differences in 
specific antigen, the method of antigen delivery, strain-specific differences between 
mice used in different experiments or differences in experimental methods. The duration 
of memory may also depend upon the subpopulation of mCTLs being examined. Two 
subpopulations of mCTLs have recently been defined: (i) central mCTLs have a 
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CD62L
+
CCR7
+
 phenotype, a high rate of proliferation, a longer half-life and the ability 
to home to the spleen and LNs, and (ii) “effector-memory” CTLs express IFN , are 
present in high numbers following contraction of the primary burst, have a relatively 
shorter half-life and are limited to peripheral tissues (Lau, Jamieson et al. 1994; Crotty, 
Felgner et al. 2003; Combadiere, Boissonnas et al. 2004). Given that antigen depots in 
the spleen and LNs are susceptible to cortisol treatment (Tew, Mandel et al. 1979; Tew, 
Mandel et al. 1979), there may be a higher ratio of effector-memory:central-memory 
CTLs in the neonate.  
 The survival of CTL-mediated memory responses for years following certain 
viral infections, such as measles and vaccinia virus, is dependent on stimulation by an 
antigen, but not necessarily the immunizing antigen (Selin, Nahill et al. 1994; Nanan, 
Rauch et al. 2000; Crotty, Felgner et al. 2003). The stimulatory antigen could 
hypothetically exist in the form of an MHC-restricted self-antigen or heterologous virus. 
Support for the former comes from a study in which adoptive transfer of mCTLs into 
MHC class-I-deficient mice resulted in shortening of the survival time of cells by two-
thirds relative to controls (Hou, Hyland et al. 1994); however, adoptively transferred 
CD44
hi 
mCTLs have also been shown to survive indefinitely in the absence of MHC 
class-I (Murali-Krishna, Lau et al. 1999). The stimulation of mCTLs by heterologous 
virus has been implicated as a mechanism for survival independent of the immunizing 
antigen and is based on the observation that mCTLs from mice immunized with LCMV 
could be stimulated in vivo and in vitro with either Pichinde or vaccinia virus (Selin, 
Nahill et al. 1994). Similarly, in vitro stimulation of mCTLs, from Pichinde or vaccinia 
virus-immunized mice, with LCMV resulted in low levels of proliferation. The ability to 
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undergo repeated stimulation by cross-reactive antigens is likely due to the lower 
threshold of activation specific to memory cells. The localization of central mCTLs in 
the spleen, blood and LNs (Lau, Jamieson et al. 1994) is likely to enhance contact with 
cross-reactive antigens, thus ensuring the low level renewal of mCTLs. 
 Overall, reports in the literature suggest that the duration of humoral immune 
memory is limited by the survival of memory CD4+ T cells, which is antigen-dependent. 
Memory CTL responses are also antigen-dependent, but the permissiveness of the TCR 
may enable continuous stimulation by antigens with low levels of cross-reactivity. Based 
upon these conclusions, it may be possible to extend the duration of immune memory 
following vaccination by delivering antigen in such a manner as to be presented in the 
context of MHC-class I molecules. Alternately, if the goal is to induce long-lasting 
humoral immune memory, it may be advantageous to deliver antigen in a stable, 
persistent or self-renewing form.  
 
1.4.  The Fetal Lamb Model 
 There are a number of reasons for selecting the fetal lamb as our model for in 
utero immunization studies. Of particular importance is the fact that the development of 
the ovine immune system has been well characterized in numerous studies and specific 
characteristics of immune development are closely related to that in humans. 
Furthermore, established protocols for timed breeding allow for experimentation at 
specific stages of immune development and surgical manipulation throughout most of 
the 148 day gestation period is associated with a low risk of abortion, thus allowing for 
in vivo fetal studies (Hein and Griebel 2003). Lastly, the organization of the ovine 
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placenta excludes maternal antibodies as well as most environmental antigens, thus 
ensuring that the fetus is truly immunologically naïve. As a result, it is possible to study 
the induction of a fetal immune response to a specific antigen, without having to account 
for the effects of cross-environmental antigens or prior immune status.  
 
1.4.1. Ovine Placentation 
 Immune ontogeny in the ovine fetus differs from that in mice or humans due to 
the nature of the syndesmochorial (or syndesmo-epitheliochorial) ovine placenta. Unlike 
the hemichorial placenta found in mice and humans, the ovine placenta effectively 
blocks both maternal antibodies and naturally occurring environmental antigens from 
accessing the amniotic cavity (Needham 1931; Wild 1979). Thus, the lamb is 
immunologically naïve at birth, except in the event of infection with pathogens capable 
of crossing the ovine placenta or in the event that the placenta is disrupted. 
Immunological naïvety is reflected in the lack of GC formation in lymphatic tissues in 
the normal ovine fetus (Pearson, Simpson-Morgan et al. 1976).   
 In the ovine placenta, six layers of tissue separate fetal from maternal blood. 
These are (i) the endothelium of the fetal capillaries, (ii) fetal connective tissue, (iii) fetal 
chorionic epithelium, (iv) maternal uterine epithelium, (v) maternal connective tissue, 
and (vi) maternal endothelium. From 86 dg onwards, degeneration of the maternal 
epithelium and phagocytosis by cells in the chorionic epithelium result in areas of the 
placentome consisting of only 5 tissue layers that are collectively referred to as the 
syndesmochorion (Stevens 1975). The multiple layers of the syndesmochorial placenta 
prevent the passive transmission of metabolites, molecules and infectious agents 
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(Needham 1931; Wild 1979). The ovine placenta also excludes maternal antibodies 
(Evans and Smith 1963; Richardson, Conner et al. 1971), thus ensuring that antibodies 
found in the fetal circulation are produced by the fetus. In addition, sheep are prone to 
multiple conception and fetuses develop in separate fetal membranes. The lack of 
vascular anastamoses between twin fetuses (Mellor 1969) enables surgical or 
immunological manipulation of only one twin while reserving the other as a control.  
 
1.4.2.  Immune Organ Development and Lymphopoiesis  
 Major events in ovine immune ontogeny are summarized in Table 1.2. Immune 
ontogeny in the fetal lamb is similar to that in humans in the sense that the thymus is 
functional and all of the cellular components of the peripheral immune system are 
present, albeit not necessarily functional, by the end of the first trimester (Bryden 1969; 
Griebel 1998). Functional maturation of the immune organs occurs primarily in the 
second and third trimesters of gestation and by parturition, the immune system is well 
developed. This contrasts with mice, where lymphoid organs, including the thymus,  
spleen and LNs undergo the majority of their development postnatally as a result of the 
short gestation period (21 days) (Abbas, Litchman et al. 1994).  
 In the fetal lamb, hematopoiesis occurs in the yolk sac between 19-27 dg (Table 
1.2). The thymus reaches its definitive position at 31 dg and CD5+ immature thymocytes 
are present by 35 dg (reviewed in Cahill, Kimpton et al. 1999). By 50-55 dg, there is 
significant T cell emigration from the thymus to the spleen and LNs and, by 65 dg, the 
size of the T cell pool in the fetus is approximately 10% of that in the neonate (Hein, 
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Table 1.2. Immune development in the fetal lamb 
Days 
gestation 
Organ/tissue/cell Developmental event Reference 
31 Thymus Reaches definitive position (Bryden 1969) 
35-40 Thymus, T cells 
Appearance of CD5+ 
thymocytes in the cervical 
thymus 
(Bryden 1969; Cahill, 
Kimpton et al. 1999) 
45-48 Spleen, B cells 
B cells appear in spleen; 
detection of Ig  V gene 
diversification 
(Press, Hein et al. 1993; 
Griebel 1998) 
50-55 B cells Appearance of sIg 
(Symons and Binns 1975; 
Press, Hein et al. 1993) 
50-55 T cells 
Appearance of T cells in 
spleen and LNs 
(Griebel 1998; Cahill, 
Kimpton et al. 1999) 
55-60  End of the “preimmune” period (Flake, Harrison et al. 1986) 
65 Jejunal PP Appearance of IgM+ cells 
(Alitheen, McClure et al. 
2003) 
66 Humoral response 
Natural antibodies are present 
in serum and earliest 
detection of antigen-specific 
antibody responses 
(Silverstein, Thorbecke et al. 
1963; Silverstein, Uhr et al. 
1963; Hashiguchi, Nanba et 
al. 1979) 
68-70 Ileal PP Appearance of IgM+ cells 
(Press, Hein et al. 1993; 
Alitheen, McClure et al. 
2003) 
75 Jejunal PP 
Appearance of primary 
follicles 
(Reynolds and Morris 1983) 
77-85 CTLs 
Earliest rejection of allogeneic 
tissue grafts (DTH) and virus-
specific CD8 activity 
(Silverstein and Prendergast 
1964; Hashiguchi, Nanba et 
al. 1979) 
78 Lymphatic network  Becomes fully functional 
(Pearson, Simpson-Morgan 
et al. 1976) 
92 
Pharyngeal and 
palatine tonsils 
Appearance of lymphoid cells (Chen, Alley et al. 1990) 
98-100 Ileal PP 
Appearance of primary 
follicles 
(Reynolds 1986) 
120 Thymus 
Reaches maximum size as % 
body weight 
(Pearson, Simpson-Morgan 
et al. 1976) 
130 Ileal PP 
Becomes major lymphopoietic 
organ 
(Reynolds 1986; Reynolds 
1987) 
130 LNs 
Appearance of primary 
follicles in naïve fetus 
(Pearson, Simpson-Morgan 
et al. 1976) 
135 GALT 
Appearance of gut-homing T 
cells 
(Cunningham, Cahill et al. 
1999) 
148  Parturition  
 
DTH = delayed-type hypersensitivity; GALT = gut-associated lymphoid tissue; sIg = 
surface immunoglobulins; LNs = lymph nodes; PP = Peyer’s patch. 
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Dudler et al. 1990). Between 65-75 dg, there is a significant expansion of the -T cell 
pool, which is consistent with the time of onset of humoral responses and graft rejection 
(Silverstein, Uhr et al. 1963; Silverstein and Prendergast 1964). The increase in the size 
of the thymus, from 0.5 to 1.7 g at 85 dg, is concomitant with increased lymphopoiesis  
and by 120 dg, the thymus reaches its maximum size as a percentage of body weight 
(Pearson, Simpson-Morgan et al. 1976). 
  Two subpopulations of thymic emigrants have been identified in the fetal lamb. 
Lymphocytes that target the spleen are primarily short-lived CD8+ T cells, while those 
that target the peripheral LNs tend to be longer-lived and have a ratio of CD4:CD8:  
equal to 6:2:1 (Cahill, Kimpton et al. 1999). With respect to fetal oral immunization, 
where the immunizing antigen is being targeted to LNs draining the oral cavity, the 
longevity of T cells potentially results in a relative increase in both the overall number of 
T cells and the frequency of T cells with a single antigenic specificity in the LNs at any 
time.  
 In the peripheral immune system, IgM+ immature B cells first appear in the 
spleen at 45-48 dg (reviewed by Griebel 1998; Yasuda, Jenne et al. 2006) consistent 
with the detection of -chain expression at 48 dg (Table 1.2). From 50 to 100 dg, the 
spleen is the primary organ of B cell development. Clusters of B cell lymphopoiesis are 
detectable by 60-80 dg and from the spleen, pre-B cells migrate to the LNs, bone 
marrow, liver, intestines and blood. IgM+ cells are first detected in the ileum at 68-70 
dg; however, primary follicles do not appear in the ileal Peyer’s patch (PP) until 97 dg.  
 Prior to development of the gut-associated lymphoid tissue (GALT), the majority 
of B cells emigrate from the spleen to LNs. Development of LNs and lymphatics are 
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closely related to one another. The lymphatics develop from mesenchymal cell clusters 
that are arranged in parallel to the veins, which are used as a scaffold for growth (Bailey 
and Weiss 1975). The LNs develop at lymphatic sacs where connective tissue 
invaginations form the framework of the LN. Infiltration of lymphocytes into spaces 
within the connective tissue results in the formation of early fetal LNs. The superficial 
cervical (SCv) LNs are the first to form in the fetus and are the largest individual nodes 
until 140 dg (Washington, Kimpton et al. 1992). In the normal, immunologically naïve 
fetus, cortico-medullary junctions appear in the SCv LNs at 75 dg and primary follicles 
are absent before 130 dg (Pearson, Simpson-Morgan et al. 1976; Cahill, Kimpton et al. 
1999). Between 120 dg and 4 weeks of age, the size of the SCv LNs increases by 25-fold 
and the number of B cells in these nodes increases by 3.5-fold as a percentage of LN 
weight (Kimpton, Washington et al. 1990; Cunningham, Cahill et al. 1999).  
 Although the lymphatics are not fully formed until 78 dg, lymphocytes do 
recirculate through sections of the lymphatics as early as 65 dg (Pearson, Simpson-
Morgan et al. 1976) (Table 1.2). In both LNs and spleen, approximately 90% of thymic 
immigrants become resident cells while the remaining 10% enter the recirculating 
lymphocyte pool (RLP) and migrate between the lymphatic system, secondary lymphoid 
organs, the blood and peripheral tissues (Cahill, Kimpton et al. 1999; Cunningham, 
Cahill et al. 1999). The lymphatics provide a mechanism by which soluble antigen 
introduced into the fetus can enter the LNs. Alternately, processed antigen could be 
delivered to fetal lymph nodes via antigen presenting cells (Kimpton, Washington et al. 
1995). 
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Table 1.3. Lymphopoiesis in the fetal lamb 
Age 
GALT-associated 
lymphocytes 
(cells/h) 
Recirculating 
lymphocyte pool 
(cells/L) 
Total T cells 
Superficial cervical  
lymph nodes 
afferent output 
(cells/h) 
65-75 dg ND 8 x 10
7
 <3 x 10
6
 ND 
77-100dg ND 1.8 x 10
8
 ND ND 
100-130dg ND 5 x 10
8
 2.6 x 10
10
 2 x 10
7
 
130dg – birth 40-80 x 10
6
 1.2 x 10
10
 ND ND 
2 weeks  30 x 10
7
 2.5 x 10
10
 2 x 10
11
 1 x 10
8
 
3 months  60-120 x 10
7
 70-80 x 10
10
 ND 2.5 x 10
8
 
 
ND = not determined. 
 
(Pearson, Simpson-Morgan et al. 1976; Kimpton, Washington et al. 1995; Cunningham, 
Cahill et al. 1999) 
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 Between 70 to 100 dg, there are few changes to the fetal immune system other 
than an increase in the size of the lymphocyte pool (Table 1.3). At 100-105 dg, the ileal 
PPs replace the spleen as the primary organ of B cell lymphopoiesis - this differs 
significantly from the mouse model where the bone marrow is the primary B cell organ. 
Following development of the ileal PPs, there is a sudden increase in the percentage of B 
cells in the peripheral lymphocyte pool, an increase in the number of both T and B cells 
and an expansion in the immunological repertoire (Cahill, Kimpton et al. 1999; Yasuda, 
Jenne et al. 2006). From 70 dg to birth, both the rate and density of T cells flowing 
through the lymphatic system increases by 150-fold (Pearson, Simpson-Morgan et al. 
1976) (Table 1.3). Viewed from another perspective, the RLP at 65-70 dg contains only 
0.7% of the number of lymphocytes present at birth. This is significant with respect to 
limiting the number of antigen-specific clones, and therefore, the number of antigens 
recognized by the fetal immune system, as well as limiting the frequency of cells 
specific to any one antigen.  
 At 130 dg, the rate of lymphopoiesis (5.2% of cells per hour) in the ileal PP is 15 
to 20-fold greater than in the thymus (Reynolds 1987). B cell lymphopoiesis in the fetal 
lamb is antigen-independent and only 5% of progeny survive while the rest undergo 
apoptosis (Reynolds 1986). Apoptosis occurs following cross-linking of surface Ig 
molecules (Mousavi, Rabbani et al. 1998) and cells that survive apoptosis emigrate from 
the ileals PPs to the peripheral lymphoid compartment, including the RLP and LNs 
(Reynolds 1986; Reynolds, Kennedy et al. 1991). Emigration of B cells from the ileal 
PPs is responsible for the significant increase in the size of the RLP between 120 dg and 
3 months of age (Table 1.3) (Cunningham, Cahill et al. 1999) and surgical removal of 
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the ileal PPs from neonates was reported to cause a prolonged, systemic B cell 
deficiency (Gerber, Morris et al. 1986).  
 By the mid-third trimester fetus (120-145 dg), B cells and T cells constitute 
approximately 8% and 92% of the peripheral RLP, respectively. Of the latter 
compartment, approximately 23% are CD8+, less than 18% are + and the remainder 
are CD4+ (Cunningham, Kimpton et al. 2001). Fetal T cells have a relatively long 
lifespan with a half-life of approximately 20 days and a rate of recirculation through the 
peripheral tissues, including the skin and gut, that is 4.6-fold greater than in adult 
animals (Kimpton, Washington et al. 1995; Cahill, Kimpton et al. 1997). The lack of 
tissue-specific homing in the fetus, along with the high rate of recirculation, ensures that 
there is effective surveillance of the periphery despite the low number of lymphocytes 
and limited immunological repertoire relative to the adult. With respect to in utero oral 
immunization, the high level of peripheral T cell migration may also enhance local 
induction of antigen-specific T cells.  
 It has also been hypothesized that the longevity and high rate of peripheral 
recirculation of naïve T cells in the fetus is required for the induction of self-tolerance to  
antigens not expressed in the thymus (Cahill, Kimpton et al. 1999). Using the Danger 
Hypothesis as a model (Matzinger 2002), the absence of inflammation and pro-
inflammatory cytokines in fetal tissues and LNs would ensure that lymphocytes are 
tolerized to peripheral self-antigens. One observation that supports this hypothesis is the 
2-fold decrease in the ratio of CD4+ to CD8+ T cells in afferent lymph relative to high 
endothelial venule input, which suggests a potential deletion or down-regulation of self-
reactive T cells in the periphery (Cahill, Kimpton et al. 1999). The Danger Hypothesis 
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does leave room for the potential induction of autoimmunity in the event of 
transplacental infection or events resulting in the upregulation of endogenous danger 
signals, such as stress proteins.  
 Within the first week of postnatal life to approximately 3 months of age, there is 
a second wave of thymic lymphopoiesis that replaces 80% of the fetal lymphocyte pool 
and increases the size of the RLP by 2 to 3-fold (Table 1.3). These “adult” T cells have a 
phenotype that is distinct from their fetal counterparts. They have a half-life of less than 
8 days, only activated (i.e., effector or memory) cells can enter the afferent lymphatics 
and there is a distinct subpopulation of lymphocytes that circulate through the gut-
associated lymphoid tissues (GALT) (Cunningham, Cahill et al. 1999; Cunningham, 
Kimpton et al. 2001). Activated lymphocytes from adult animals are also resistant to 
cortisol-induced cell death (Munroe 1971; Anderson, Flint et al. 1975; Inaba, Kurasawa 
et al. 1999). One can hypothesize that activated fetal lymphocytes are also capable of 
escaping the cortisol-induced apoptosis that accompanies birth; this hypothesis is 
consistent with observations that immune memory induced in the fetus can persist in the 
neonate (Otsyula, Miller et al. 1996; Gerdts, Snider et al. 2002).  
 
1.4.3. Development of the Immune Repertoire  
 The size of the immune repertoire determines the diversity of antigens against 
which the immune system can react. The repertoire consists of variations in the MHC, 
TCR and immunoglobulin (Ig) molecules and is developed through Ig-chain 
combination, gene conversion, gene rearrangement (also known as somatic 
recombination or VDJ recombination) and somatic mutation. Very little information is 
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available about the size of the immune repertoire in the second trimester fetus; however 
the low numbers of lymphocytes, limited variable region (V) gene usage and low levels 
of somatic hypermutation all suggest that the fetal immune repertoire is severely 
restricted relative to the neonate. 
 The basic antibody molecule consists of two heavy chains and two light chains. 
The following heavy chains have been described in sheep: , 1, 2, 1, 2,  and . 
Each heavy chain has a constant, V, D and J region. In the sheep, there are nine germline 
heavy chain V gene segments (Defour and Nau 1997). All nine gene segments are 
closely related with an overall nucleotide homology of approximately 70%, six are 
expressed in the adult and three are pseudogenes. Pseudogenes are hypothesized to 
donate nucleotide sequences in a process referred to as gene conversion (Reynaud, 
Mackay et al. 1991; Gontier, Ayrault et al. 2005). The ovine heavy chain V gene 
segment contains two complementarity determining regions (CDRs): CDR1 (codons 27-
34) and CDR2 (codons 56-62). CDR3 is formed by the VDJ rearrangement, is 21 codons 
in length and (unlike the mouse CDR3) has the least somatic variability. There are also 
six heavy chain J segments of which two are functional and four are pseudogenes. 
 Sheep, similar to mice and humans, have two different light chains:  and . 
Light chains are composed of constant, V and J chains.  is the major light chain isotype 
and is expressed by 75-90% of B cells in the adult sheep (Griebel and Ferrari 1994). The 
exact number of V gene segments is still under debate, but the large number λV gene 
segments that have been identified to date suggest that repertoire diversity in sheep is 
primarily due to  chain variability. According to Reynaud’s group (Reynaud, Mackay 
et al. 1991; Reynaud, Garcia et al. 1995) there are 60 to 90 V  genes that are organized 
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into 6 families of which there is preferential utilization of 20 segments. Due to the 
limited V  gene usage, Reynaud’s group hypothesized that the majority of diversity in 
the repertoire resulted from antigen-independent somatic hypermutation. A more recent 
model of repertoire expansion has been proposed by Reynolds’ group and is based on 
the identification of a minimum of 120 V  gene segments in sheep (Jenne, Kennedy et 
al. 2003). According to this model, combinatorial gene rearrangement is more important 
than antigen-independent somatic hypermutation in generation of the immune repertoire.  
 All data suggest that the immune repertoire is severely restricted in the fetus 
relative to the young lamb. In the 144 dg fetus, only four of the six heavy chain V gene 
segments are expressed and of these, two are used almost exclusively (Gontier, Ayrault 
et al. 2005). Between 61-146 dg, 12 distinct V  gene segments and six to ten V  gene 
segments are preferentially expressed (Hein and Dudler 1999). As a result of the small 
number and close relatedness of the available germline genes (Reynaud, Mackay et al. 
1991), the combinatorial diversity of the fetal lamb is inherently low relative to the 
adult. In addition, there is no evidence in the literature as to whether gene conversion 
occurs in the fetal lamb.  
 Unlike combinatorial rearrangement, which remains constant with age, the 
frequency of somatic hypermutation increases with age. The age at which somatic 
hypermutation first occurs is uncertain. According to Gontier et al. (2005), there is little 
to no hypermutation in the fetal lamb. This conclusion was based on PCR analysis and 
gene sequencing of the rearranged heavy chain V gene in 3 lambs between 144 dg and 
3-months of age. According to their study, there were no age-dependent changes in the 
rate of mutational variability between 144 dg and 3 months of age. The rate observed 
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was 2.8% (0 to 11%), which contrasted with 18.6% in the adult (>6 months of age). This 
agreed somewhat with a previous report by Hein and Dudler (1999), who characterized 
mRNA from B cells of fetal lambs between 61-146 dg and identified germline sequences 
in all heavy chain V transcripts. In this study, V  transcripts were also present as 
germline sequences; however, there was limited diversity in the V  segment. Overall, 
these data suggest that the diversity in the fetal immune repertoire is primarily dependent 
upon rearrangement of a limited number of V  and V  genes, and Ig chain 
recombination and, therefore, is fairly restricted when compared to the full repertoire in 
adult sheep. The size of the immune repertoire in the fetal lamb has implications with 
respect to the ability of the fetus to respond to a wide variety of antigens. In the study by 
Silverstein et al. (1963), fetal lambs between 60 and 130 dg did not respond to 
immunization with Mycobacteria, BCG, Salmonella or diphtheria toxoid, all of which 
are highly immunogenic.   
 The above studies were conducted in normal, immunologically naïve fetuses and 
there is no data available on somatic hypermutation in activated fetal B cells. Yasuda et 
al. (2006) mentioned that a study is soon to be published which describes activation-
induced cytidine deaminase, which mediates somatic mutation, at different stages in 
fetal lamb development. The presence of activation-induced cytidine deaminase in the 
fetus may allow for affinity maturation in activated fetal B cells.  
 
1.4.4. Development of Antigen-Specific Immune Responses 
 Since the end of the first trimester occurs at 50 dg, tolerance in the first trimester 
fetal lamb must be regulated at the level of the thymus, i.e., central tolerance. This 
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period of development, prior to migration of lymphocytes into the periphery, has been 
referred to as the “preimmune” period and may extend to 55-60 dg (Flake, Harrison et 
al. 1986). It has been hypothesized that the preimmune fetus is immunologically 
incompetent as a result of the immaturity of the immune system and antigens to which 
the fetus is exposed are perceived as self. Therefore, the preimmune fetus corresponds 
with Billingham’s immunological null period (1953) and the fetal lamb does not acquire 
the ability to respond to peripheral antigens until the early second trimester. The end of 
the preimmune period should be concomitant with the population of the spleen and LNs 
by T and B cells (Hein, Dudler et al. 1990; Berek, Berger et al. 1991).  
 The components of the immune system become functional at different stages of 
ontogeny. Natural antibodies first appear in normal fetal lamb serum at approximately 
66 dg (Silverstein, Thorbecke et al. 1963). GCs are not normally present in the naïve 
fetal lamb (Silverstein, Thorbecke et al. 1963; Silverstein, Uhr et al. 1963; Pearson, 
Simpson-Morgan et al. 1976) and do not form unless there is primary B cell activation 
and clonal expansion (Jacob, Kelsoe et al. 1991). Antigen-specific antibody responses 
have been induced as early as 60-66 dg (Silverstein, Uhr et al. 1963). In contrast, CTL 
and DTH responses were not detected prior to 77-85 dg (Silverstein and Prendergast 
1964); however, this may be an artifact of using skin graft rejection as a read-out for 
CTL responses, as 77-85 dg is also the time when naïve T cells and DCs first appear in 
fetal skin (Kimpton, Washington et al. 1995). There have been reports of skin graft 
rejection as early as 53-55 dg, but rejection was mediated by innate immune 
mechanisms, specifically complement (McCullagh 1989; Chen, Shelton et al. 1995). 
Based on the available literature, the earliest reported time for detection of a fetal 
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immune response following immunization is 66 dg (Silverstein, Uhr et al. 1963). In 
studies in which fetal lambs were exposed to infectious virus prior to 60 dg (Table 1.4),  
virus-specific fetal antibodies were not detectable before 70 dg, suggesting that there 
may have been a period after infection during which the immune system was unable to  
respond to the virus. Therefore, the ability of the fetal lamb to respond to a specific 
antigen is limited by the age of the fetus, the low number of lymphocytes and a limited 
immunological repertoire (Sections 1.4.2 and 1.4.3).  
 In the seminal paper on the immunological competence of the fetal lamb 
(Silverstein, Uhr et al. 1963) (Table 1.4), lambs were administered a single 
intramuscular (IM) injection of a combined vaccine composed of ovalbumin, horse 
spleen ferritin, killed Salmonella typhus, phage X174, live Bacillus Calmette-Guerin 
(BCG), diphtheria toxoid and Mycobacteria (in the form of CFA). The earliest elicited 
antibody response was to X174, which appeared between 60-70 dg. A serum antibody 
titer of 1/50 was reported for the one fetus immunized at 60 dg, but there was no 
comparison to titers from age-matched controls and titers were significantly below that 
of naïve fetuses at 110 dg. Significant titers to ferritin and ovalbumin could only be 
detected starting from 70-80 dg and 120-125 dg, respectively. This ordered acquisition 
of specific reactivities over time was referred to as an “antigenic hierarchy”. This 
antigenic hierarchy is likely a reflection of the low number of lymphocytes and restricted 
immune repertoire discussed in Sections 1.4.2 and 1.4.3. Characterization of the order of 
antigens within this hierarchy would significantly advance the field of fetal and neonatal 
immunization research. 
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Table 1.4. Fetal lamb immunization experiments 
Age of fetus 
at time of 
immunization  
(dg) 
Immunizing agent Route Outcome Reference 
14-28 Bovine viral diarrhea 
virus (pestivirus) 
NS Tolerance (Swasdipan, 
McGowan et al. 
2002) 
37-70
1
 Akabane virus  Trans-
placental 
Virus neutralizing 
antibodies at 70 dg; 
LPR at 80 dg. 
(Hashiguchi, 
Nanba et al. 
1979) 
45  Neospora caninum NS No response (Buxton, Maley 
et al. 1998) 
45-90
1
 T. gondii Trans-
placental 
Fetal antibody titers 
detected at 35 dpi. 
(Dubey, Emond 
et al. 1987) 
55-60
2
 -gal 
(MuLV vector)
 
IP Postnatal tolerance 
(humoral and cytolytic 
responses) 
(Tran, Porada et 
al. 2001) 
55-62
2
 Neomycin 
phosphotransferase 
(MuLV vector) 
IP Potential tolerance
3
  (Porada, Tran et 
al. 1998) 
58-65
2 
 Bovine leukemia virus Trans-
placental 
Precolostrum antibody 
titers  
(Onuma, 
Baumgartener 
et al. 1977) 
60-130dg  Combined vaccine: 
ovalbumin, ferritin (1 
mg), Salmonella typhus, 
phage X174 live BCG, 
diphtheria toxoid, 
Mycobacterium (CFA)  
IM Anti-phage titer: 
immunization at 60-66 
dg (n=1) resulted in 
titers less than that in 
naïve 110-130 dg 
fetuses; anti-ferritin 
titers (70-80 dg)
2
; anti-
ovalbumin titers (120-
125 dg)
2
.  
No responses at any 
time to Salmonella, 
BCG, Mycobacterium 
(CFA) or diphtheria 
toxoid. 
(Silverstein, Uhr 
et al. 1963) 
65 or 90 N. caninum NS Fetal antibodies in 1/8 
lambs immunized at 
65 dg; 2/8 lambs 
immunized at 90 dg.  
(Buxton, Maley 
et al. 1998) 
70  Chlamydia abortus  Trans-
placental 
Antibodies in fetal 
serum and thoracic 
fluid. Also antigen-
specific CD8+ and -
T cells. 
(Kennedy, 
McCullough et 
al. 2001) 
(Buxton, 
Anderson et al. 
2002) 
(Continued…)
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(Table 1.4 continued) 
 
80-110
2
 -gal 
(adenoviral 
vector) 
Intratracheal  Potential tolerance (up to 38 
dpi)
3 
(Peebles, 
Gregory et al. 
2004) 
85-100
2
 or  
115-125
2
 
Brucella 
abortus 
Intracardiac Predominantly IgM (low IgG 
titers) peaked about 3 wpi. 
6/9 immunized at 85-100dg. 
Memory persisted at least 40 
d. 12/14 immunized at 115-
125 dg. 
(Richardson, 
Conner et al. 
1971) 
95-140
2
 B. abortus Oral via 
amniotic fluid 
Fetal agglutination titers 
(8/12)
4 
(Richardson and 
Connor 1972) 
112-134
2
  -gal 
(adenoviral 
vector) 
Intra-tracheal 
 
CMI (Vincent, 
Trapnell et al. 
1995) 
120-125
2 
 Bovine 
herpesvirus 
glycoprotein D 
(DNA vaccine) 
Oral cavity  Fetal IgG1, neutralizing 
antibodies and proliferative 
responses. Neonatal immune 
memory. Activation of 
retropharyngeal, but not 
mesenteric LNs. 
(Gerdts, Babiuk 
et al. 2000; 
Gerdts, Snider 
et al. 2002) 
135-142
2
  Horse spleen 
ferritin, 500 mg 
Amniotic fluid Precolostrum serum IgM 
(2/5)
4
; intestinal IgA and IgM 
(4/5)
4
; plasma cells in 
lymphoid tissues (6/6)
4
. Bulk 
of antigen deposited in the 
jejunum. 
(Husband and 
McDowell 1975) 
140 Human Factor 
IX (adenoviral 
vector) 
Umbilical 
vein 
Antibodies to Factor IX and 
adenovirus starting at 7 days 
post-injection 
(Themis, 
Schneider et al. 
1999) 
 
CFA = complete Freund’s adjuvant; dg = days gestation; dpi = days post-immunization; 
IM = intramuscular; IP = intraperitoneal; LNs = lymph nodes; MuLV = Moloney murine 
leukemia retroviral vector for gene therapy; NS = not specified; wpi = weeks post-
immunization. 
 
1 Pregnant dams were first exposed to virus at the earlier date. The infective source was 
removed at the latter date.  
 
2 Where a range is indicated, fetal lambs with differing gestational ages were grouped 
together. 
 
3 No tests for suppression of immune responses were conducted. Tolerance was 
inferred from the presence of antigen in thymic tissues and lack of inflammation in 
transduced tissues.  
 
4 Number of responders/total number of treated animals.  
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 Studies of autoimmune thyroiditis in the fetal lamb model suggest that an 
antigenic hierarchy might also apply to the induction of tolerance to self-antigens. 
Thyroidectomy at 51-54 dg resulted in the rejection of autologous thyroid tissues upon 
reimplantation at 110-115 dg, thus suggesting that the immune system had not become 
tolerized to thyroid antigens during the first trimester and that reactivity to thyroid 
antigens was acquired at some point in the intervening 60 days (King, Hagan et al. 
1998). Autologous thyroid tissues reintroduced between 82-93 dg were tolerized (Belin, 
Hollingsworth et al. 1976). Taken together, these studies suggest that there might be a 
critical period, between 93-110 dg, during which the TCR gene undergoes 
rearrangement to produce T cells specific for thyroid antigens.  
 It is now apparent that the lack of responsiveness to specific antigens is due to 
the limited immunological repertoire in the fetus, and the temporal acquisition of 
reactivity to specific antigens reflects the preferential usage of certain heavy and light 
chain gene segments at different stages of development. The antigenic hierarchy might 
also reflect the low number of lymphoctes in the fetus, which would restrict the number 
of clones with any specific TCR- or Ig-gene rearrangement. Without a minimum number 
of lymphocytes specific for a corresponding antigen, the chances of inducing an immune 
response are limited. As a result, the antigenic repertoire against which the immune 
system can respond should increase proportionally to the number of cells in the 
peripheral lymphocyte pool. In fact, there is a 5-fold increase in the number of 
recirculating peripheral T cells between 135 dg and 2 weeks of age (Cunningham, Cahill 
et al. 1999). An expansion in the repertoire at this time would allow the neonatal lamb to 
respond to the onslaught of new antigens that accompanies birth.  
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1.4.5. Self-Non-Self Discrimination in the Fetal Lamb 
 The fetal lamb is a desirable model for the study of fetal immunization because 
of its immunological naïvety and the absence of maternal antibodies. Studies of immune 
induction in the fetal lamb model are summarized in Table 1.4. A large number of fetal 
transplantation and gene replacement studies have also been conducted in the fetal lamb 
model and these are summarized in Table 1.5. Together, these studies give insight into  
mechanisms of induction of tolerance and immune protection in the fetal lamb model. It 
should be noted, however, that most studies reported a high degree of variability in 
responses within an experimental group. Therefore, the trends described below are based 
on the majority response.  
 A review of the transplantation studies shown in Table 1.5 suggests that a 
number of factors, including the type of graft, its location within the host, and the age of 
the fetus at the time of transplantation, may contribute to determining whether a graft is 
accepted or rejected. The Zanjani-Porada group hypothesized that tolerance to a graft 
could be achieved by introducing the graft while the immune system was immature  
(Flake, Harrison et al. 1986; Zanjani, Ascensao et al. 1992; Zanjani, Pallavicini et al. 
1992; Rice, Flake et al. 1993; Zanjani and Anderson 1999; Almeida-Porada, Porada et 
al. 2004; Porada, Park et al. 2004). This hypothesis was based on the stable 
incorporation of allogeneic stem cells into preimmune fetal hosts. Other groups, 
however, have shown that tolerance to foreign stem cells can also be achieved when 
transplantion occurs after the preimmune period (i.e., at 65-79, 85 and 95 dg) (Miyasaka 
and McCullagh 1982; Liechty, MacKenzie et al. 2000; Sasaki, Nagao et al. 2005). The 
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Table 1.5. Fetal lamb transplantation studies  
Age of fetus 
at time of 
transplant
1 
Graft Route/ 
Location 
Outcome Reference 
40-45 dg Human CD3-
depleted cord 
blood 
hematopoietic 
stem cells 
IP Tolerance (4/12)
2 
(Young, Holzgreve et 
al. 2003) 
45-60 dg Maternal cells IP No effect (Miyasaka and 
McCullagh 1982) 
48-54 dg Human fetal liver 
hematopoietic 
stem cells 
IP Tolerance (13/33)
 
(Zanjani, Pallavicini et 
al. 1992) 
48-64 dg Ovine liver-
derived 
mesenchymal 
cells 
IP Tolerance (McCullagh 1989; 
Schoeberlein, 
Holzgreve et al. 2004; 
Sasaki, Nagao et al. 
2005; Schoeberlein, 
Holzgreve et al. 2005) 
53-55 dg Fetal or adult 
ovine skin 
allografts 
Skin graft Fetal grafts were 
rejected by 
hyperacute 
mechanisms; adult 
grafts were 
tolerized 
(McCullagh 1989) 
55-73 dg Monkey stem 
cells 
Intrahepatic Tolerance (4/4) (Sasaki, Nagao et al. 
2005) 
64-67 dg Fetal ovine skin  Skin graft Tolerance (Silverstein and 
Prendergast 1964) 
65, 85 or 95 
dg 
Human 
mesenchymal 
stem cells 
IP Tolerance; 
detection of donor 
cells in the thymus.  
(Liechty, MacKenzie et 
al. 2000) 
77-139 dg Ovine skin  Skin graft Rejection (13/13)
2 
(Silverstein and 
Prendergast 1964) 
110-133 dg Maternal cells 
(non-inherited 
maternal antigen) 
IP Tolerance; 
suppression of 
neonatal CTL 
responses. 
(Miyasaka and 
McCullagh 1982) 
120-139 dg Fetal ovine skin  Skin graft Rejection (Silverstein, 
Prendergast et al. 
1963) 
 
dg = days gestation; IP = intraperitoneal. 
 
1 Where a range is indicated, fetal lambs with differing gestational ages were grouped 
together. 
 
2 Number of responders/total number of treated animals.  
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 importance of the age of the fetus at the time of transplantation may depend on the  
specific type of graft, e.g., skin grafts introduced prior to 77 dg (when the fetus becomes 
DTH-competent) were consistently tolerized, while skin grafts introduced after the onset 
of DTH-competence were rejected (Silverstein, Prendergast et al. 1963; Silverstein and 
Prendergast 1964; McCullagh 1989). 
 In all of the above studies in which stem cell grafts were accepted, cells were 
delivered via the intraperitoneal (IP) or intrahepatic routes, both of which result in the 
establishment of transplant-derived hematopoietic stem cell populations in the bone 
marrow. The percentage of chimerism obtained by intrahepatic injection of monkey 
stem cells was 1-2% of the hematopoietic bone marrow populaton in 4 of 4 lambs 
(Sasaki, Nagao et al. 2005). Hematopoietic stem cells in the fetus have the potential to 
differentiate into cells of any lineage, including granulocytes, lymphocytes and MTECs 
(Liechty, MacKenzie et al. 2000; Almeida-Porada, Porada et al. 2004). The migration of 
transplant-derived cells to the thymus would allow the foreign MHC to be regarded as 
self. In Tran et al. (2001) and Porada et al.(1998), IP delivery of either lacZ or neoPT, 
the gene for neomycin phophotransferase (NeoPT), in the context of retroviral vectors at 
55-60 dg resulted in the expression of both -galactosidase and NeoPT in hematopoietic 
cells and the thymus. The stable expression of NeoPT at 14 months after gene delivery 
suggested that tolerance had been induced. In a study by Peebles et al. (2004), delivery 
of lacZ to the tracheal epithelium of 80-110 dg fetuses using adenovirus vectors also 
resulted in the induction of specific tolerance. The authors hypothesized that tolerance 
was the result of transduction of stem cell populations in the immature tracheal 
epithelium at 80-110 dg. In contrast, when lacZ in the context of an adenoviral vector 
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was delivered to the tracheal epithelium at 112-134 dg (when stem cells are no longer 
present), CMI was induced (Vincent, Trapnell et al. 1995). Taken together, the above 
studies suggest that tolerance can be induced by targeting genes that encode specific 
antigens to stem cells, or by immunizing with multipotent stem cells expressing a 
specific antigen. In this context, the age of the fetus at the time of immunization does 
determine whether or not stem cells are present at specific anatomical locations and, by 
extension, the preferred route of delivery.  
 A review of the studies presented in Table 1.4 also suggested that the fetal lamb 
might be described as having three stages of immune responsiveness. (i) The pre-thymic 
stage occurs prior to 31 dg and introduction of a foreign antigen during this period is 
likely to result in the induction of tolerance. For example, infection with bovine 
pestivirus during this period resulted in chronic infection (Swasdipan, McGowan et al. 
2002). (ii) The preimmmune stage, as described by the Zanjani-Porada group, occurs 
between 31 and 55-60 dg. Neither tolerance nor protective immunity appears to be 
induced to foreign antigens present in peripheral tissues for the duration of this period. 
(iii) The immune-competent stage starts at approximately 60-66 dg, which is the age 
when the humoral arm of the immune system becomes functional (Silverstein, Uhr et al. 
1963). During the immune-competent stage, the immune system acquires the ability to 
respond to specific antigens according to an antigenic hierarchy. This is consistent with 
the findings in a number of studies (Silverstein, Uhr et al. 1963; Hashiguchi, Nanba et al. 
1979; Dubey, Emond et al. 1987) in which the introduction of an antigen to the 
peripheral immune system prior to its being represented in the immune repertoire did not 
result in the induction of tolerance; however, once the antigen is included in the immune 
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repertoire, the induction of either tolerance or protective immunity depends upon the 
context in which the antigen is delivered (Section 1.2.1). 
 The fetal immune system can respond to an assortment of antigens, including 
live virus, purified protein, soluble protein, phage, bacteria, and antigens delivered in 
genetic form in the context of either bacterial plasmid or adenovirus. Fetal immune 
responses can be induced to small or large antigens as demonstrated by the induction of 
antibodies to both bovine herpesvirus-1 (BHV-1) truncated glycoprotein D (tgD) and 
HBsAg (Gerdts, Babiuk et al. 2000). TgD is a secreted, soluble 61-kDa glycoprotein 
(Tikoo, Campos et al. 1995) while HBsAg is a non-soluble VLP with a diameter of 
approximately 20nm (Petit, Maillard et al. 1986; Aberle, Aberle et al. 1999). Of the 
studies summarized in Table 1.4, fetal immune responses were only detected in those 
studies in which antigen was delivered accompanied by an adjuvant (e.g., bacterial 
DNA, CFA) or danger signal (e.g., infection). The exception is the study by Husband 
and McDowell (1975) in which fetal immune responses were detected following the 
injection of horse spleen ferritin into the amniotic cavity in the absence of any adjuvant; 
however, the induction of an immune response may have been influenced by the dose of 
antigen, which was 500-fold larger than the dose previously shown to induce ferritin-
specific fetal antibodies (Silverstein, Uhr et al. 1963).  
  Overall, the literature supports the hypothesis that the fetal lamb is immune 
competent beyond 60 dg and can mount an antigen-specific protective immune response 
provided the antigen is not targeted to the thymus. Furthermore, the literature supports 
the existence of an immunological “null period” during which foreign antigens 
introduced to the thymus are regarded as self and antigens introduced into the periphery 
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do not appear to have any effect on the functionally immature immune system; however, 
this null period does not extend for the duration of prenatal development as was 
originally suggested by Billingham et al. (1953). The null period for a specific antigen 
ends when it is represented in the immune repertoire and can occur as early as 55-60dg. 
At this time, the antigen is either tolerogenic or immunogenic depending on the route of 
delivery and the presence or absence of co-stimulatory signals.  
  
1.4.6. In Utero Gene Delivery in the Fetal Lamb Model 
 Successful methods of in utero gene delivery have been reported in the fetal 
lamb model and the gene expression data from these studies are summarized in Table 
1.6. The immunological outcome of studies by Gerdts et al. (2000; 2002), Peebles et al. 
(2004), Tran et al. (2001), Porada et al. (1998) and Vincent et al. (1995) were 
summarized in Table 1.4. In most cases, the method of gene delivery resulted in the 
induction of tolerance and, therefore, is appropriate for gene therapy but not fetal 
vaccination. 
 In Tran et al. (2001) and Porada et al. (1998), IP delivery of genes in the context 
of the Moloney murine leukemia virus (MuLV) vector resulted in the transduction of 
hematopoietic stem cells and detection of plasmid-encoded protein in a range of tissues 
and cell types for a prolonged duration. This method of gene delivery is inappropriate 
for fetal immunization as genes delivered to the thymus consistently resulted in the 
induction of tolerance. Intratracheal injection of adenovirus-vectored genes resulted in 
consistently high levels of gene expression in the airway and respiratory epithelium. The 
induction of either tolerance or protective immune responses depended upon the time of  
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Table 1.6. In utero gene delivery in the fetal lamb 
Vector Route of 
delivery  
Reporter 
gene/ 
protein 
Gene distribution/ 
localization of 
antigen  
Duration of 
expression 
Reference 
DNA plasmid Oral cavity BHV-1 
tgD 
NS NS (Gerdts, 
Babiuk et al. 
2000; 
Gerdts, 
Snider et al. 
2002) 
Japan 
hemagglutin-
ating retrovirus 
Ductus 
arteriosus 
CAT Subendothelial and 
smooth muscle of 
ductus arteriosis 
40 d (Mason, 
Bigras et al. 
1999) 
MuLV IP NeoPT Most tissues/organs 
including bone 
marrow, thymus 
(epithelial cells). 
Not germline cells. 
5+ y (Porada, 
Tran et al. 
1998) 
MuLV IP lacZ, 
NeoPT  
Hematopoietic cells 
in blood and bone 
marrow, thymus. 
Not tested 
elsewhere 
40 mo  (Tran, 
Porada et al. 
2001) 
Adenovirus (E1 
and E3 
vectors) 
Umbilical vein lacZ Fetal liver, lung, 
gonads, adrenals, 
kidneys, brain, 
heart. Maternal liver 
and placenta.  
NS (Themis, 
Schneider et 
al. 1999) 
Adenovirus (E1 
and E3 
vectors) 
Umbilical vein Factor IX Inconsistent. 
Systemic in 2/5 
fetuses.
 
Up to 15d (Themis, 
Schneider et 
al. 1999) 
Adenovirus  
(formulated 
with or without 
Na-caprate
1
 
and DEAE) 
Intratracheal 
(ultrasound- 
guided) 
lacZ  Tracheal epithelium 
and bronchi.  
38 d
 
(Peebles, 
Gregory et 
al. 2004) 
 
BHV-1 tgD = bovine herpes virus-1 truncated glycoprotein D; CAT = chloramphenicol 
acetyl transferase; IP = intraperitoneal; MuLV = Moloney’s murine leukemia virus; 
NeoPT = neomycin phosphotransferase; NS = not specified. 
 
1 Na-caprate is a fatty acid that opens tight junctions to enhance viral access to the 
basolateral surface of respiratory epithelial cells; increases gene expression by 90-fold 
relative to adenovirus alone.  
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 injection and tolerance was induced up to 110 dg (Vincent, Trapnell et al. 1995; 
Peebles, Gregory et al. 2004). Direct injection of a foreign gene in the context of a 
retroviral vector into the ductus arteriosus resulted in high levels of localized 
transfection and expression (Mason, Bigras et al. 1999). Unfortunately, the 
immunological outcome and potential negative reffects of direct retroviral injection were 
not reported as part of this study.  
 Injection of an adenovirus vector into the umbilical vein was the least effective 
method of in utero gene delivery in the fetal lamb (Themis, Schneider et al. 1999). 
Adenoviral vectors containing either lacZ or the gene for Factor IX were delivered to 
four and five fetuses, respectively. The small number of animals per experimental group, 
the range of dose, the utilization of more than one gene, the range of fetal age at the time 
of injection (102 – 140 dg) and assaying for gene expression at different times post-
injection limited any conclusions with regards to the efficacy of umbilical vein injection 
as a route of gene delivery. Furthermore, adenovirus at a dose of 2.4 x 10
12
 was lethal, 
while doses between 1 x 10
11
 to 4.8 x 10
11
 gave inconsistent results ranging from no 
detectable gene delivery to widespread, non-specific transfection of most fetal tissues, 
the placenta and the maternal liver.  
Of the different methods of in utero gene delivery described in the fetal lamb 
model, oral delivery of naked DNA plasmid (Gerdts, Babiuk et al. 2000; Gerdts, Snider 
et al. 2002) appears to be best suited for the specific purpose of fetal immunization. The 
other gene delivery methods described in Table 1.6 rely upon delivery in the context of 
viral or retroviral vectors which have potential toxic effects, especially in the developing 
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fetus, and theoretically, can only be used once due to the potential induction of immune 
responses to the vector itself.  
 
1.5.  DNA Vaccination at Mucosal Surfaces 
A fetal vaccine should be designed to maximize both systemic and mucosal 
immunity, since mucosal surfaces are the major site of entry for numerous neonatal 
pathogens. In general, most vaccines are administered via the IM or subcutaneous routes 
despite experiments which have shown that parenteral immunization is not an effective  
means of stimulating mucosal immunity (Brokstad, Eriksson et al. 2002; Cox, Brokstad 
et al. 2004). Induction of mucosal immunity requires that antigen be targeted to mucosal 
surfaces or, more specifically, to mucosal-associated lymphoid tissues (MALTs).   
 Unfortunately, there are a number of obstacles to mucosal vaccination. Low pH, 
proteases and other enzymes decrease the stability of traditional vaccines delivered via 
the vaginal surface or digestive tract. The mucociliary escalator that lines the trachea, 
bronchi and bronchioles impedes delivery of particulate matter to the respiratory 
epithelium and the potential induction of oral tolerance limits targeting of antigens to the 
PPs or mesenteric LNs. Furthermore, mucosal immunity is characterized by Th2-
mediated responses (i.e., IgA) which may be less effective than CMI at protecting 
against intracellular pathogens, such as bovine respiratory syncytial virus (Mapletoft, 
Oumouna et al., 2008). DNA vaccination might overcome many of the obstacles to 
effective mucosal immunization; the continual expression of antigen could potentially 
counter degradation and clearance by innate immune mechanisms and the inherent 
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adjuvanticity of the bacterial DNA might stimulate a Th1-component within the mucosal 
immune response.  
 
1.5.1. DNA Vaccines 
DNA vaccines are the latest technology for inducing long-term immunity and an 
alternative to either virus or bacteria as a gene delivery vehicle. The primary component 
of a DNA vaccine is purified plasmid DNA containing a gene encoding a specific 
antigen under control of an eucaryotic promoter. Plasmid DNA is easy to produce in 
large quantities at a low cost and remains stable upon production. Furthermore, advances 
in cloning technology have allowed the easy adaptation of DNA vaccine technology to a 
number of different antigens/pathogens. 
 The ability to transfect cells in vivo with DNA plasmid was first demonstrated in 
1990 (Wolff, Malone et al.) and led to the hypothesis that expression of a foreign gene in 
vivo would result in the induction of an immune response (Tang, DeVit et al. 1992; 
Ulmer, Donnelly et al. 1993). DNA vaccination studies have since been carried out in a 
number of different species, using genes encoding different antigens, with variable  
success. For example, a DNA vaccine containing the gene for equine herpesvirus-1 
(EHV-1) glycoprotein D (gD) induced both antibody and lymphoproliferative responses 
in mice and protected mice against a subsequent challenge with EHV-1 (Ruitenberg, 
Walker et al. 1999). Cattle immunized with either gD- or tgD-plasmid delivered via the 
intradermal (ID), but not IM, route were protected against challenge with BHV-1 (van 
Drunen Littel-van den Hurk, Braun et al. 1998) and sheep immunized with tgD-plasmid 
delivered by gene gun induced long-term CMI and moderate antibody titers (Braun, 
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Babiuk et al. 1998). A number of DNA vaccine studies have also been carried out in the 
neonate. Among these studies, a plasmid encoding the circumsporozoite protein of P. 
yoelii was the only DNA vaccine found to induce immune tolerance (Ichino, Mor et al. 
1999).  
The effectiveness of DNA vaccination has been attributed to the inherent 
immunogenicity of the bacterial DNA backbone, which contains large numbers of CpG 
and polyG motifs. The former are hexameric sequences consisting of unmethylated 
cytosine and guanosine dimers flanked on either side by two purines (Krieg, Yi et al. 
1995). This contrasts with vertebrate genomes, where CpG motifs are under-represented 
and heavily methylated (Cardon, Burge et al. 1994). As a result of these differences, the 
vertebrate immune system has evolved to recognize CpG motifs as pathogen-associated 
molecular patterns and generates strong innate and CMI responses when confronted with 
CpGs (Krieg, Yi et al. 1995; Yi, Klinman et al. 1996; Schnare, Barton et al. 2001).  
The immunostimulatory activity of CpGs is mediated by TLR-9 which is 
expressed in endosomes of B cells, macrophages and DCs (reviewed by Mutwiri, 
Pontarollo et al. 2003). Upon binding of TLR-9, the MyD88/TRAF6 signaling pathway 
is activated, resulting in production of type-1 cytokines (IFN , IL-1, -6, -10 and -12), up-
regulation of MHC class-II and B7 co-stimulatory molecules, cellular proliferation and 
inhibition of B cell apoptosis. Furthermore, the inherent adjuvanticity of bacterial DNA 
translates into a lowered risk of inflammatory damage and lesions when compared with 
the use of conventional adjuvants such as alum and CFA (Gupta, Relyveld et al. 1993). 
 In addition to their immunostimulatory effect, DNA vaccines may also enhance 
the duration of immune memory. Transfection of host cells and plasmid expression by 
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the host-cell machinery results in the presentation of antigen on MHC-class I molecules 
and the preferential induction of CD8+ T cell-mediated responses. The prolonged 
survival of mCTLs was reviewed in Section 1.2.1. Transfected host cells also become 
factories for the continual production of antigen and as long as these cells remain 
transcriptionally active, there is antigen available for the stimulation of memory 
lymphocytes. This differs from traditional, subunit or killed vaccines, which are rapidly 
degraded or cleared.  
 Although DNA vaccination studies in mice have been successful, that success 
has not translated into large animal models largely as a result of low rates of transfection 
and/or expression. Numerous methods for enhancing plasmid transfection have been 
reported. Electroporation (Babiuk, Baca-Estrada et al. 2004) and low frequency 
ultrasound (Kim, Greeleaf et al. 1996) enhanced transfection efficiency but resulted in 
significant inflammatory damage and cell lysis, respectively. In one simple, yet 
successful study, increasing the hydrostatic pressure at the time of IM injection, e.g., by 
injecting an equal volume of plasmid over a 5 second period as opposed to a 20 second 
period, increased gene expression by 1000-fold (Liang, Nishikawa et al. 2004).  
 The basic principle of using a lipid carrier to transfect cells in vitro has also been 
applied to DNA vaccination. E.g., formulation of plasmid with the cationic lipid carrier 
(N-(1-(2,3-dimyristyloxypropyl)-N,N-dimethyl-(2-hydroxyethyl) ammonium 
bromide/dieoyl phosphatidylethanolamine (DMRIE/DOPE) resulted in a 7-fold increase 
in plasmid expression relative to unformulated plasmid (Talsma, Babensee et al. 2006). 
Complexing with lipids has many effects. These include (i) enlarging the positive 
surface potential, which has been shown to directly correlate with increases in 
 60 
transfection efficiency, and (ii) increasing the efficiency of plasmid translocation across 
the nuclear membrane. The conjugation of lipid carriers to sigma-1 attachment protein 
from recombinant reovirus type-3 resulted in a 7-fold increase in translocation of 
plasmid to the nucleus of fibroblasts in vitro and a 16-fold increase in transgene 
expression (Talsma, Babensee et al. 2006). Nuclear translocation was also enhanced by 
complexing plasmid to M9, which is a modified mRNA transporter derived from 
ribonucleoprotein-A1 (Byrnes, Nass et al. 2002), or by incorporation of the SV40 
enhancer into the plasmid (Young, Benoit et al. 2003).  
 In the study by Gerdts et al. (2000), oral delivery of DNA plasmid to fetal lambs 
resulted in levels of antigen expression sufficient to induce an immune response. This 
indicated that high rates of transfection and expression were achieved in fetuses despite 
the absence of formulation or the use of mechanical means, such as electroporation, to 
increase transfection efficiency.   
 
1.5.2. Induction of Immunity or Tolerance in the Mucosal Immune System  
 Oral delivery of an antigen is associated with the risk of inducing tolerance. 
Induction of a type-1 or type-2 response or oral tolerance depends on a number of 
factors, including the specific antigen and where the primary inductive event takes place. 
In mice, peroral administration of a soluble antigen, OVA, resulted in oral tolerance 
(Spahn, Weiner et al. 2002). Induction of tolerance required that OVA reach both the 
PPs and mesenteric LNs and was characterized by suppression of IFN  and decreases in 
both Th1- and Th2-mediated responses. In contrast, peroral immunization with a soluble 
cholera vaccine in humans resulted in the induction IgG and IgA titers in both serum and 
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saliva (Czerkinsky, Svennerholm et al. 1991). These studies show that oral delivery does 
not necessarily equate with oral tolerance.  
 The term “oral delivery” in the context of vaccine delivery has been used to refer 
to feeding/ingestion, intubation, gastric lavage, injection into the amniotic fluid or 
application to the oral cavity (without swallowing). The induction of oral tolerance 
requires that antigen reach the GALT where it is taken into intestinal M cells and 
translocated to underlying lymphoid follicles, which contain large numbers of B cells 
that are committed to only producing IgA (Cebra, Gearhart et al. 1976). If induction 
occurs in both the mesenteric LNs and PPs, oral tolerance occurs. Alternately, if 
induction is restricted to the PPs, there is preferential induction of type-2 immune 
responses (Spahn, Weiner et al. 2002). Following induction, B cells can migrate to distal 
mucosal sites or enter the circulation. IgA-secreting B cells preferentially home to 
MALTs, including the salivary glands and tonsils (Cebra, Gearhart et al. 1976; 
Kubagawa, Bertoli et al. 1987).  
 The salivary glands are specialized and do not take part in primary immune 
induction. They do, however, contain large numbers of primed B cells. Environmental 
antigens that enter the oral cavity can directly stimulate B cells in the salivary glands to 
produce antibody upon secondary or subsequent exposure to antigen (Nair and 
Schroeder 1983). The sublingual and submandibular salivary glands contribute over 
50% of total IgA in gastric juices, gastric mucus and feces. They also make a small, but 
significant, contribution to serum IgG (Shirai, Wakatsuki et al. 2000). The salivary 
glands also play a role in deviation towards Th2 immune responses. When H. pylori 
sonicate was administered to sialoadenectomized mice (i.e., mice from which sublingual 
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and submandibular salivary glands had been excised), Th2 responses decreased and Th1 
responses increased (Shirai, Wakatsuki et al. 2000). The restoration of Th2 responses by 
the addition of salivary gland extract to the bacterial sonicate suggested that the salivary 
glands produce large amounts of type-2 cytokine (Mbow, Bleyenberg et al. 1998). 
Unlike in salivary glands, primary B cell activation does occur in the tonsils of the oral 
cavity (Brandtzaeg 1989; Inoue, Fukuizumi et al. 1999). 
 In utero oral DNA immunization studies showed that delivery of antigen (in the 
form of DNA plasmid) to the oral mucosal epithelium also induced CMI (Gerdts, 
Babiuk et al. 2000). Antigen delivered to epithelial surfaces may be presented by 
Langerhans cells, which preferentially activate CD8+ T cells, or delivered to draining 
LNs where the type of immune response is dictated by the nature of the antigen and the 
cytokine environment.  
 
1.5.3.  DNA Vaccine Delivery to the Oral Epithelium  
 There are advantages to delivering vaccines to the oral epithelium, such as 
targeting of antigen to MALT, avoiding degradation of antigen in the digestive tract, and 
an increased surface area relative to the nasal cavity. The oral cavity in humans is 
divided into three major areas with respect to drug delivery (Shojaei 1998). (i) The 
buccal cavity is lined by mucosal epithelium, has a rich blood supply, is relatively 
permeable and is the traditional, preferred site for drug delivery. (ii) The sublingual 
mucosa lines the bottom of the mouth and lower palate and also consists of mucosal 
epithelium. (iii) The tongue and lips are covered by cutaneous epithelium. The buccal, 
sublingual and cutaneous epithelium differ in their rates of epithelial cell turnover, 
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vascular supply, lymphocyte subpopulations and permeability. In humans, the buccal 
mucosa is stratified and made up of 40-50 layers of squamous cells. There are fewer cell 
layers in the sublingual mucosa and more in the cutaneous regions. The superficial-most 
layers of the tongue and lips are also keratinized. The main barrier to aqueous solutions 
is provided by the secretion of keratohyalin into the intercellular spaces in the upper 
one-third layers of the cutaneous epithelium. In the absence of keratohyalin, fibrous  
keratin by itself is not a significant barrier to aqueous solutions and keratinized and non-
keratinized epithelium have similar permeabilities (Squier and Hall 1984).  
 In order of increasing permeability are: skin, cutaneous epithelium, palatal 
mucosa, buccal mucosa and sublingual mucosa (Galey, Lonsdale et al. 1976; Harris and 
Robinson 1992; Hengge, Pfutzner et al. 1998). Using beagles as an animal model, it was 
found that injection of equivalent doses of lacZ-plasmid into either the oral mucosa or 
epidermis resulted in 35-fold higher levels of -galactosidase expression in the oral 
mucosa (Hengge, Pfutzner et al. 1998). Although the mucosal epithelium had a higher 
transfection efficiency, gene expression was more transient. At 3 hours post-injection, 
plasmid was present in the basal and supra-basal layers of the mucosal epithelium, but 
was only detectable in the superficial-most layer by 24 hours. Therefore, both the 
permeability and the rate of epithelial turnover must be considered for a specific surface 
as the maximum level of expression is related to the number of plasmid copies able to 
reach nucleated cells and plasmid is only expressed until the transfected cells are 
sloughed off. One method for prolonging the duration of DNA vaccines at mucosal 
surfaces is to deliver into the fetus, which has a lower rate of mucosal epithelial cell 
turnover (Smeaton and Simpson-Morgan 1985).  
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 Epithelial cells in the cutaneous epithelium (e.g., the tongue and lips) can 
produce IL-1, -3 and -6, GM-CSF and TNF and, therefore, can augment local 
inflammation and lymphocyte activation. Human keratinocytes can also up-regulate 
MHC class-II in vitro upon stimulation with IFN  (Wittmann, Purwar et al. 2005). 
Langerhans cells are present in cutaneous, but not mucosal, epithelium superficial to the 
basal cell layer (Bodde, DeVries et al. 1990; Ratzinger, Gaggers et al. 2005). 
Langerhans cells can express MHC class-I, class-II and B7, however, antigen 
presentation by Langerhans cells usually results in the induction of CTL responses. The 
mucosal epithelium contains low numbers of cells that stain for mucosal leukocyte 
antigen (a marker for homing to mucosal tissues), CD8 and TCR, but the majority of 
macrophages and lymphocytes are located in the lamina propria (Ratzinger, Gaggers et 
al. 2005).  
 A number of delivery systems and formulations have been reported to enhance 
drug delivery to the buccal mucosa. These include delivery via mucoadhesive hydrogels 
and buccal patches, and formulation with sodium glycocholate, sodium ethylenediamine 
tetraacetic acid (EDTA) or aprotinin (Veillard, Longer et al. 1987; Bodde, DeVries et al. 
1990; Shojaei 1998). Normally, the oral mucosa is coated by saliva which contains 
mucus. At physiological pH, the mucus network carries a negative charge, which may 
repel naked DNA plasmid (Tabak, Levine et al. 1982). The efficiency of plasmid 
delivery to the oral mucosa may be enhanced in the fetus, in which these surfaces are 
bathed in amniotic fluid. The fetus also has a lower rate of epithelial cell turnover 
relative to the adult (Smeaton and Simpson-Morgan 1985) which may prolong the 
duration of antigen expression. 
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1.5.4. In Utero Oral DNA Immunization 
In utero oral DNA immunization was originally described in Gerdts et al.(2000; 
2002). In brief, DNA plasmid containing the gene for BHV-1 tgD was injected into the 
oral cavity of fetal lambs at 120-125 dg. The uterus was accessed via an abdominal 
incision and the uterus was manipulated such that the head of the fetus, still within the 
uterus, was exteriorized through the incision. A needle was then inserted through the 
uterine wall into the oral cavity and a DNA solution was deposited into the fetal oral 
cavity. To assess the efficacy of in utero immunization, antibody and CMI responses 
against authentic (i.e., virus-derived, non-truncated) BHV-1 gD were assessed in the 
preparturient fetus (140-145 dg). Oral immunization induced titers of gD-specific serum 
IgG that were 100- to 500-fold greater than in age-matched, naïve lambs. Ig-secreting B 
cells and gD-specific lymphoproliferative responses were also detected in the 
retropharyngeal LNs, suggesting that the bulk of the transfection and expression had 
occurred in either the oral cavity or LNs draining the oral cavity. The lack of detectable 
gD-specific responses in mesenteric LNs suggested that oral delivery did not result in 
plasmid or plasmid-encoded protein reaching the gut. The effectiveness of the in utero 
oral delivery method was further demonstrated by the induction of neutralizing 
antibodies to BHV-1, decreased viral shedding following intranasal challenge and tgD-
specific anamnestic responses in the neonate with both systemic and mucosal elements. 
Similar results obtained with a DNA vaccine encoding HBsAg, demonstrated the 
relevance of the in utero oral DNA immunization method to a human pathogen.  
This thesis also makes use of BHV-1 tgD as a model antigen. BHV-1 is an 
important pathogen in cattle that causes a number of clinical diseases, including upper 
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respiratory disease (shipping fever), infectious bovine rhinotracheitis, infectious pustular 
vulvovaginitis, conjunctivitis and abortion (Gibbs and Rweyemamu 1977). BHV-1 
encodes several surface glycoproteins, including gD and glycoprotein B (gB), which 
have been shown to consistently induce immune responses in both cattle and sheep when 
used as vaccinating antigens (van Drunen Littel-van den Hurk, Gifford et al. 1990; van 
Drunen Littel-van den Hurk, van Donkersgoed et al. 1994) (also see references in Table 
3.1). Unfortunately, there is no reliable virus-challenge model available for BHV-1 
infection in sheep. 
 
1.6 Concluding remarks 
 The scientific literature supports the effective design of fetal vaccines, provided 
that factors such as the age of the fetus, the route and method of antigen delivery, the 
provision of co-stimulatory signals and the specific antigen for which an immune 
response is desired are taken into account. With recent advances in genetic research, it 
will be possible to identify antigens that are represented in the fetal immune repertoire, 
and use of these antigens may allow us to identify factors which determine whether the 
outcome of fetal immunization is tolerance or immune protection. Given the evidence in 
support of fetal immune competence, it is interesting that developmental tolerance 
remains an immunological dogma. Challenges to this dogma may result in the effective 
design of fetal vaccines against vertically transmitted pathogens.  
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CHAPTER 2 
 
OBJECTIVES AND HYPOTHESES 
 
 A number of problems have been identified that limit the effectiveness of fetal 
and neonatal vaccination. These include (i) maternal antibodies, which interfere with 
subunit and killed vaccines before they can be properly presented to the fetal immune 
system (Reynolds and Griffin 1990; van Maanen, Bruin et al. 1992; Blasco, Lambot et 
al. 2001); (ii) immune deviation towards type-2 responses (Liu, Tu et al. 2001; Liu, Tu 
et al. 2001), which in some cases are ineffective and in many cases pathological; (iii) 
low numbers of B cells and immature memory, requiring repeated boosting (Siegrist 
2001); (iv) immunosuppression due to high cortisol levels (Munroe 1971; Berdusco, 
Hammond et al. 1993); and (v) the induction of tolerance as a result of the immaturity of 
the immune system and its inability to deliver adequate co-stimulatory signals (Liu, Tu 
et al. 2001; Liu, Tu et al. 2001; Tschernig, Debertin et al. 2001). In 2000 and 2002, our 
laboratory reported a new method of generating specific immunity in the fetus and 
neonate - in utero oral DNA immunization - that appeared to circumvent many of the 
problems listed above (Gerdts, Babiuk et al. 2000; Gerdts, Snider et al. 2002). Using the 
fetal lamb model, Gerdts et al. demonstrated that oral delivery of a DNA vaccine to the 
125 dg fetus induced antigen-specific, long-term immunity with both systemic and 
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mucosal components. This thesis is a continuation of the study of oral DNA 
immunization in the fetal lamb model. 
 Two hypotheses were tested in this thesis: 
 
1) Hypothesis #1: The mucosal epithelium of the oral cavity is the primary 
site of plasmid transfection and expression following in utero oral 
delivery of DNA plasmid. Injection of tgD-plasmid into the fetal oral cavity 
induced strong mucosal and systemic gD-specific immune responses in the 
fetus (Gerdts, Babiuk et al. 2000), thus confirming that transfection and 
expression of the plasmid had occurred. The detection of antigen-specific 
lymphocyte proliferation in the retropharyngeal LNs of immunized fetuses 
suggested that transfection likely occurred in the oral cavity or LNs draining 
the oral cavity. Localization of plasmid transfection to the oral mucosal 
epithelium has consequences with respect to tolerance induction and the 
ability to extend oral DNA delivery to younger or older developmental ages. 
The oral epithelium undergoes major histological changes during 
development. If plasmid transfection is restricted to the oral epithelium, 
increases in (i) the thickness of the epithelium, (ii) the rate of epithelial cell 
turnover, and (iii) effectiveness with respect to its barrier function that 
accompany suckling may limit the ability to extend oral DNA delivery to the 
neonatal period. On the other hand, the decreased rate of epithelium cell 
turnover and decreased barrier function in the younger fetus may allow for 
prolonged antigen expression and increased drainage of plasmid and/or 
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antigen to regional LNs, respectively. Failure to restrict plasmid transfection 
and expression to the oral epithelium increases the risk of systemic antigen 
distribution and induction of tolerance.   
 
2) Hypothesis #2: Oral DNA immunization in the second trimester (49-98 
dg) is an effective method of inducing a fetal immune response with a 
memory component capable of persisting into the neonate. The earliest 
report of immune competence in the fetal lamb is 60-66 dg following IM 
immunization with crystallized horse spleen ferritin in the presence of 
adjuvant (Silverstein, Uhr et al. 1963). Others have reported that injection of 
fetal lambs prior to 60-62 dg with either allogeneic stem cells (McCullagh 
1989; Zanjani, Pallavicini et al. 1992; Schoeberlein, Holzgreve et al. 2004; 
Sasaki, Nagao et al. 2005; Schoeberlein, Holzgreve et al. 2005) or retroviral 
vectors expressing foreign antigens (Porada, Tran et al. 1998; Tran, Porada et 
al. 2001) induced long-term tolerance in fetal lambs. In contrast, oral delivery 
of DNA plasmid encoding a specific antigen should not result in the 
induction of tolerance if transfection is restricted to the oral cavity and does 
not reach the thymus. The presence of CpGs in the bacterial backbone should 
also stimulate local APCs to up-regulate MHC class II and pro-inflammatory 
cytokines, thus overcoming the inherent lymphopenia and inhibiting 
peripheral tolerance mechanisms. Furthermore, the low rate of epithelial cell 
turnover and the continued expression of antigen should ensure that antigen 
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persists and, therefore, is able to support the development and maintenance of 
immune memory.  
 
 The following six experimental objectives were defined in order to test the above 
hypotheses:  
 
1) Objective #1: To identify the location and duration of plasmid 
expression following oral DNA delivery. The successful transfection and 
expression of plasmid DNA following in utero oral delivery has been 
indirectly shown by the induction of immune responses specific to the 
plasmid-encoded antigen (Gerdts, Babiuk et al. 2000). Using the same 
delivery protocol as in Gerdts et al. (2000), DNA plasmid containing the 
gene for soluble, non-secreted firefly luciferase was orally delivered into 125 
dg fetal lambs. At specified times following plasmid delivery, fetal tissues 
were collected and examined for the presence of luciferase activity. Using 
this method, the location and duration of transgene expression were 
determined.  
 
2) Objective #2: To identify factors that might influence the level of 
plasmid transfection and expression. Once the primary sites of plasmid 
transfection and expression were identified, those factors that might increase 
the efficiency of in utero plasmid transfection and/or expression were 
determined. Manipulation of these factors to increase the efficiency of oral 
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plasmid delivery in the second trimester fetal lamb ensured that failure to 
detect an immune response following second trimester immunization would 
not be the result of a failure in vaccine delivery. Information gained from this 
objective will also allow us to define the limitations of oral vaccine delivery 
and answer the question, “Is oral DNA vaccine delivery restricted to the 
fetus?” 
 
3) Objective #3: To determine the earliest possible time for induction of 
immune responses using a single oral DNA vaccination. Increasing the 
duration of fetal immunity in utero might provide additional protection 
against infectious agents that are transmitted prior to or during birth. Intrinsic 
factors influencing the earliest potential age of immunization are maturity of 
the immune system, the potential induction of tolerance and the ability of the 
fetal immune system to process, present and recognize a specific antigen. 
Success might also be limited by toxic effects of the plasmid at earlier 
gestational ages. In utero oral DNA immunization studies were conducted 
using BHV-1 tgD, which has previously been shown to be represented in the 
ovine fetal immune repertoire (Gerdts, Babiuk et al. 2000). The age of the 
fetus at the time of immunization was gradually decreased from 125 dg (the 
age at which fetal responses to BHV-1 tgD were reported by Gerdts et al. 
(2000)) to 55 dg (when T and B lymphocytes first appear in peripheral 
lymphoid tissues).  
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4) Objective #4: To determine if a single oral DNA vaccination in the 2nd 
trimester can induce detectable immune responses and immune memory 
that persist into the neonatal period.  According to the WHO (2003), the 
highest prevalence of vertical transmission of persistent viral pathogens, such 
as HIV, occurs during the neonatal period, which in humans is less than 28 
days of age. Therefore, the immune response induced by fetal vaccination 
must be able to persist until the time of birth in order to provide adequate 
protection. Protection is most effective if both primary effector functions and 
immune memory are present at birth. The duration of immune memory is 
influenced by a number of factors including antigen persistence and exposure 
to cross-reactive environmental antigens, both of which can boost waning 
immune memory; however, the placenta acts as a barrier that prevents the 
fetal immune system from being exposed to numerous environmental 
antigens. Therefore, the duration of immune memory following in utero 
immunization is largely dependent upon the primary immunization event. 
Lambs that were immunized in the second trimester were examined at birth 
for the presence of primary antibody and CMI responses. To test for survival 
of immune memory into the neonatal period, in utero-immunized lambs were 
administered a second DNA immunization at 2 weeks of age. The presence 
of anamnestic responses was used as an indicator of survival of immune 
memory.  
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5) Objective #5: To determine if failure to detect primary immune 
responses following second trimester oral DNA immunization might be 
due to the induction of tolerance.  Secondary immunization in the neonate 
also provided an opportunity to determine if lack of detectable primary 
immune responses might be due to the induction of tolerance. By decreasing 
the age of the fetus at the time of DNA immunization, the risk of inducing 
tolerance to the immunizing antigen is enhanced. Due to the individual 
variability that is expected when conducting experiments in an outbred 
population, it was expected that second trimester immunization might fail to 
induce detectable immune responses in some lambs; therefore, secondary 
immunization in the neonate was also used to determine if there was antigen-
specific immune suppression in non-responders. In the event that tolerance 
was induced in some lambs, in utero oral DNA delivery might be proposed 
as a method for gene replacement therapy or treatment of autoimmunity, 
allergy or asthma.  
 
6)  Objective #6: To evaluate the magnitude and duration of fetal immune 
responses and immune memory. The ovine syndesmochorial placenta 
maintains the fetal lamb in a state of true immunological naïvety, and 
therefore, allows us to determine the duration of fetal primary immune 
responses and immune memory achieved by a single immunization. In order 
to assess the quality of immune responses achieved in the ovine fetus, a 
relevant comparison was required; therefore, a study (Chapter 3) was 
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conducted in which young lambs, aged 2-3 months, were immunized with 
the same BHV-1 tgD plasmid used for the fetal vaccination studies described 
in Objectives #3 through #5. Delivery of the DNA vaccine was optimized to 
obtain the maximal magnitude and duration of primary immune responses. 
The duration of immune memory following a single DNA immunization was 
also determined. The parameters obtained from this study were then used as 
an appropriate comparison to assess the magnitude and duration of immune 
responses obtained by second trimester oral DNA immunization. This study 
also examined the influence of the primary immune response on immune 
memory.  
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CHAPTER 3 
 
A SINGLE DNA IMMUNIZATION IN COMBINATION WITH 
ELECTROPORATION PROLONGS THE PRIMARY IMMUNE RESPONSE 
AND MAINTAINS IMMUNE MEMORY FOR SIX MONTHS
1
 
 
3.1. Abstract 
 Recombinant protein vaccines and vaccines using killed or inactivated pathogens 
frequently require multiple vaccinations to induce protective immune responses which 
may be of relatively short duration. There is also increasing concern regarding adverse 
local and systemic reactions to injected vaccines and this concern is driving the quest for 
vaccine formulations capable of inducing protective immunity following a single 
administration. Vaccine studies frequently evaluate immune responses and disease 
protection within a relatively short interval following primary and secondary 
immunizations and, therefore, fail to address the duration of immunological memory or 
protection. DNA vaccines offer a unique opportunity to enhance the duration of immune 
responses through their capacity for prolonged antigen expression. The route of DNA 
vaccination and the method of plasmid delivery are critical factors which can determine 
transfection efficiency and the duration of vaccine antigen production. Studies were 
completed which demonstrated that a single IM DNA vaccination, when combined with 
                                                 
1
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electroporation significantly enhanced the onset and duration, but not the magnitude, of 
the primary antibody response. A secondary protein vaccination was performed 6 
months after the primary DNA immunization. A significant (p < 0.0001) correlation was 
observed between both the magnitude (r
2
 = 0.40) and duration (r
2
 = 0.74) of the primary 
antibody response and the occurrence of a secondary antibody response. Therefore, an 
effective primary DNA vaccination has the potential to significantly prolong the 
duration of an antibody response and possibly reduce the frequency of revaccination.  
 
3.2. Introduction 
 Vaccines are an important tool in the prevention and control of infectious 
disease. Effective vaccines have been developed for a wide variety of viral and bacterial 
diseases and as new pathogens, such as West Nile virus, emerge there is an increasingly 
rapid development of vaccines (Chang, Kuno et al. 2004). Thus, humans and domestic 
animals are subjected to an increasing number and frequency of vaccinations. This has 
led to increased concern regarding the risks and adverse reactions associated with 
vaccination (Moylett and Hanson 2004) and renewed interest in developing vaccines that 
require fewer booster shots to induce and maintain protection against infectious disease. 
These objectives differ from the more traditional goals of vaccine development, which 
included the identification of immunogenic antigens and evaluation of immune-mediated 
protection. For example, numerous vaccine trials were performed to demonstrate that a 
truncated form of glycoprotein D (tgD) was a protective antigen for BHV-1. The basic 
design of these experimental trials involved primary, secondary and tertiary 
immunizations within 3-6 week intervals and viral challenge within 2-5 weeks after the 
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last immunization (Table 3.1). These trials did not, however, address critical questions 
such as the onset or duration of immune-mediated protection following single or 
multiple vaccinations. 
 A single vaccination with a modified-live BHV-1 vaccine can induce immune 
memory and reduce clinical disease when animals are infected 25 weeks after 
vaccination (Platt, Burdett et al. 2006); however, the use of modified live virus (MLV) 
vaccines is associated with a number of safety concerns, including reactivation and 
shedding of both latent and vaccine virus, and the possible reversion of the vaccinating 
strain to virulence (Strube, Abar et al. 1995). These safety concerns are not an issue with 
DNA vaccines; however, there is no evidence that a single DNA vaccination can induce 
long-term protective immunity despite reports that transfected genes can be expressed 
over a prolonged period (Muramatsu, Arakawa et al. 2001).  
 DNA vaccines remain an attractive vaccine technology due their safety, stability, 
and the relatively low cost of DNA vaccine production. Furthermore, the 
immunostimulatory properties of plasmid DNA (Uwiera, Gerdts et al. 2001; Uwiera, 
Rankin et al. 2001) eliminate the need to formulate DNA vaccines with adjuvants, which 
often induce a marked local inflammatory response and tissue pathology (Nichani, 
Kaushik et al. 2004). Unfortunately, commercial development of this technology has 
been limited by difficulties with achieving efficient DNA plasmid delivery and high 
levels of plasmid gene expression in target species (Babiuk, Pontarollo et al. 2003).  
 Numerous vaccination methods have been evaluated for their capacity to 
enhance DNA plasmid delivery and the induction of immune responses. These 
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Table 3.1. Vaccine trial protocols with recombinant tgD protein and DNA vaccines 
 
1 Vaccine antigen and species immunized in parenthesis. 
 
2 Vaccine antigen and interval between 1o and 2 o immunization in parenthesis. 
 
3 Vaccine antigen and interval between 2o and 3 o immunization in parenthesis.  
 
4 Method of BHV-1 infection and interval between final immunization and viral infection 
in parenthesis. 
 
5 Immunization with recombinant, BHV-1 tgD protein. 
 
6 Immunization with various DNA plasmid (p) constructs encoding BHV-1 glycoprotein D 
(tgD, gIV, or gD). 
Primary1 
(Species) 
Secondary2 
(Interval) 
Tertiary3 
(Interval) 
Challenge4 
(Interval) 
Reference 
25 μg tgD5 
(Bovine) 
25 μg tgD 
(3 weeks) 
--- 
BHV-1 aerosol 
(4 weeks) 
(Aberle, Aberle et 
al. 1999) 
50 μg tgD 
(Bovine) 
50 μg tgD 
(5.6 weeks) 
--- 
BHV-1 aerosol 
(2 weeks) 
(van Drunen Littel-
van den Hurk, 
Braun et al. 1998) 
500 μg 
pRSVgIV6 
(Bovine) 
500 μg 
pRSVgIV 
(4 weeks) 
500 μg 
pRSVgIV 
(8 weeks) 
BHV-1 aerosol 
(4 weeks) 
(Lewis, van 
Drunen Littel-van 
den Hurk et al. 
1999) 
500 μg 
pSLIAtgD 
(Bovine) 
500μg 
pSLIAtgD 
(3 weeks) 
--- 
BHV-1 aerosol 
(3 weeks) 
(Gerdts, Snider et 
al. 2002) 
500 μg 
pSLIAtgD 
(Ovine) 
500 μg 
pSLIAtgD 
(15 weeks) 
--- 
Immune response 
following secondary 
immunization 
(Widera, Austin et 
al. 2000) 
500 μg 
pMASIA-tgD 
(Bovine) 
500 μg 
pMASIA-tgD 
(4 weeks) 
--- 
BHV-1 aerosol 
(3 weeks) 
(Braun, Babiuk et 
al. 1999) 
500 μg 
pSLIAtgD 
(Ovine) 
500 μg 
pSLIAtgD 
(7 weeks) 
--- 
Antibody titers 
monitored for 8 
weeks 
(van Drunen Littel-
van den Hurk, 
Tikoo et al. 1997) 
500 μg 
pSLKIAtgD 
(Bovine) 
500 μg 
pSLKIAtgD 
(5 weeks) 
--- 
BHV-1 aerosol 
(3 weeks) 
(Cox, Zamb et al. 
1993) 
500 μg 
pCItgD 
(Bovine) 
500 μg 
pCItgD 
(4 weeks) 
500 μg 
pCItgD ID 
(4 weeks) 
Intranasal BHV-1 
(4 weeks) 
(Pontarollo, 
Babiuk et al. 2002) 
250 μg 
pCIgD and 
pCItgD 
(Bovine) 
250 μg pCIgD 
and pCItgD 
(4 weeks) 
Killed 
BHV-1 
vaccine 
(4 weeks) 
Intranasal BHV-1 
(5 weeks) 
(Pontarollo, 
Babiuk et al. 2002) 
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technologies include formulation with polymers and liposomes (Gregoriadis, Saffie et al. 
1997), biolistic or gene gun delivery (Fynan, Webster et al. 1993), and electroporation 
(Dupuis, Denis-Mize et al. 2000). Currently, electroporation appears to be the most 
effective method of delivering plasmid DNA and has been reported to increase gene 
expression 10- to 100-fold in tissues such as skin and muscle (Mir, Moller et al. 2005). 
Electroporation enhances DNA transfection by creating temporary pores in cell 
membranes and increasing plasmid distribution throughout the tissues (Zaharoff, Barr et 
al. 2002). Electroporation may also enhance the immunogenicity of DNA vaccines 
through the induction of an acute, localized infiltration of immune cells (McMahon, 
Signori et al. 2001; Babiuk, Baca-Estrada et al. 2004) and the up-regulation of cytokines, 
heat shock proteins, and other co-stimulatory molecules (Pazmany, Murphy et al. 1995). 
The acute inflammatory response induced by electroporation probably works in concert 
with increased gene expression to enhance immune responses to plasmid-encoded 
antigens. Enhanced immune responses as a result of electroporation have been reported 
in mice (Widera, Austin et al. 2000), pigs (Babiuk, Baca-Estrada et al. 2002) and sheep 
(Scheerlinck, Karlis et al. 2004). Thus, electroporation appears to be the best available 
technology with which to analyze immune responses following a single DNA 
immunization. 
 The duration of immune memory following a single DNA immunization has 
rarely been investigated. We previously reported that a single ID immunization of 
newborn lambs with plasmid expressing tgD induced a detectable primary immune 
response and an anamnestic immune response was observed following secondary 
immunization 15 weeks later (van Drunen Littel-van den Hurk, Braun et al. 1999). 
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Furthermore, a single injection of DNA plasmid encoding tgD into the oral cavity of 
third trimester fetal lambs was able to support anamnestic responses in the neonate 
(Gerdts, Snider et al. 2002). Thus, there is evidence that a single DNA immunization, in 
the absence of formulations to enhance delivery or transfection efficiency, can induce 
protective immunity and immune memory which persist much longer than expected 
based upon previous investigations with recombinant protein vaccines (Table 3.1). 
Therefore, we hypothesized that enhancing DNA transfection and expression would 
significantly enhance the onset, magnitude and possibly the duration of a primary 
immune response. It has also been suggested that immune memory is dependent upon 
both the magnitude of the primary immune response (Ahmed and Gray 1996) and 
continued exposure to antigen (Gray and Skarvall 1988). Thus, increasing both the 
magnitude and duration of a primary immune response should not only prolong the 
duration of immune-mediated protection against infection but may also provide an 
approach to prolong immune memory and reduce the frequency of revaccination.  
 
3.3 Materials and Methods 
 
3.3.1.  Animals 
 Experiments were performed with 2-3 month old, female and castrated male 
Suffolk-cross lambs housed in a single outdoor pen. Lambs were randomly assigned to 
six treatment groups (Table 3.2; n =7/group) and all experimental procedures were 
approved by the local animal care committee under the guidelines of the Canadian 
Council on Animal Care. 
 81 
 
Table 3.2. Experimental design and vaccination protocol 
 
 
Group 
 
n1 
Primary Immunization 
(Day 0) 
Secondary Immunization 
(Week 25) 
Route          Vaccine Route         Vaccine 
 Control 6 - No vaccine SC 20μg recombinant tgD2 
 Protein 7 SC 20 μg recombinant tgD SC 20μg recombinant tgD 
 DNA-ID 7 ID3 500 g pSLIA-tgD4 SC
 20μg recombinant tgD 
 DNA-IM 7 IM5 500 g pSLIA-tgD SC
 20μg recombinant tgD 
DNA+Electro 7 IM 500 g pSLIA-tgD  
+ electroporation 
SC 20μg recombinant tgD 
DNA(2X)+ 
Electro 
6 IM 1 mg pSLIA-tgD  
+ electroporation 
SC 20μg recombinant tgD 
SC = subcutaneous; ID = intradermal; IM = intramuscular 
1 Number of lambs per group at the time of primary immunization. Lambs were removed 
from the trial upon development of detectable gB-specific antibody titers. 
 
2 Purified recombinant truncated glycoprotein D (tgD) protein of BHV-1.  
 
3 Intradermal injection of DNA plasmid on the convex side of the left ear. 
 
4 DNA plasmid (pSLIA) encoding truncated glycoprotein D (tgD) protein of BHV-1. 
 
5 Intramuscular injection of DNA plasmid into the semimembranosus muscle.  
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 The 42 lambs were screened for the presence of serum antibodies specific to or 
cross-reactive with BHV-1 glycoprotein B (gB) and gD prior to the first vaccination. 
Animals with gD and gB titers less than 100 were considered naïve and all animals were 
monitored at monthly intervals throughout the trial for possible development of gB-
specific antibodies. Development of a gB-specific titer was used as evidence of possible 
exposure to a natural BHV-1 infection or infection with a cross-reactive ovine 
herpesvirus. One animal was removed from each of the Control and DNA(2X)+Electro 
groups (Table 3.2; n = 6) at the beginning of the trial due to the presence of both gD-
specific titers (>40,000) and gB-specific titers (>970). Three other sheep developed 
detectable gB-specific titers at week 17 (one each from the Control, Protein, and DNA-
IM groups) and two animals (one each from the Protein and DNA+Electro groups) 
developed detectable gB-specific titers at week 26. Only data up to and including the 
time that gB titers still tested negative were included in data analyses.  
 
3.3.2. Preparation of the DNA Vaccine and tgD Protein Vaccine 
 The pSLIA-tgD plasmid encodes the gene for a secreted 61-kDa truncated form 
of glycoprotein D from BHV-1 (tgD) expressed under control of the human 
cytomegalovirus immediate early promoter/1A-region (van Drunen Littel-van den Hurk, 
Braun et al. 1998). Plasmid was grown in E. coli DH5  (New England Biolabs, 
Mississauga, ON) and purified using the EndoFree  Plasmid Giga Kit (Qiagen, 
Mississauga, ON). Purified plasmid was resuspended at 2 mg/ml in endotoxin-free 
Dulbecco’s PBS (Sigma-Aldrich, St. Louis, MO) and stored at -20 °C. The size and 
quality of the plasmid was confirmed by restriction enzyme digest. Endotoxin activity, 
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assessed using the QCL-1000 Limulus Amebocyte Lysate Kit (BioWhittaker Inc., 
Walkersville, MD), was <0.01 EU/ml, which is below the minimal threshold required to 
induce a mitogenic response in ovine leukocytes (Burrells and Wells 1977).  
Each dose of the tgD-protein vaccine was injected subcutaneously and consisted 
of 20 μg of purified, recombinant BHV-1 tgD protein (van Drunen Littel-van den Hurk, 
Gifford et al. 1990) and 100 g CpG ODN 2007 (TCGTCGTTGTCGTTTTGTCGTT) 
formulated in an oil and water emulsion (30% Emulsigen Plus; MVP Laboratories, 
Ralston, NE) in a 2 ml volume. This specific vaccine formulation had previously been 
shown to induce primary and secondary antibody responses of greater magnitude than 
formulation of tgD with Emulsigen alone (Ioannou, Griebel et al. 2002b).  
Detection of an anamnestic response following secondary immunization was 
used as an indicator that immue memory was present. Secondary immunization with a 
protein vaccine is the most effective method to elicit anamnestic responses following 
DNA immunization (Toussaint, Letellier et al. 2005). Therefore, all animals received a 
secondary immunization with recombinant tgD protein at 25 weeks following primary 
immunization (Table 3.2). 
 
3.3.3. DNA Vaccination  
Three different methods of DNA immunization were compared in the present 
study (Table 3.2). Previous experiments had demonstrated that ID DNA immunization 
with pSLIA-tgD plasmid was an effective method to induce both a primary antibody 
response and enhanced secondary antibody responses following revaccination 15 weeks 
later (van Drunen Littel-van den Hurk, Braun et al. 1999). Thus, animals in the DNA-ID 
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group provided a positive control for the DNA vaccine and received 500 g of plasmid, 
which was divided into 100 l aliquots and injected ID into five sites between the 
central ridges on the convex side of one ear. The second method of DNA vaccination 
was IM injection of 500 μg of tgD-plasmid in a 500 μl volume into a single site in the 
left semimembranosus muscle. The third method of DNA vaccination was to combine 
IM plasmid injection with electroporation. For this method of immunization, animals 
were sedated by intravenous injection of 12.5 mg/kg Pentothal (Abbott Labs, Montreal, 
PQ). The DNA vaccine was then injected into two adjacent sites in the left 
semimembranosus muscle. The DNA+Electro group received a total of 500 μg of tgD-
plasmid (i.e., 250 μg of tgD-plasmid in a 500 μl volume per injection site). The 
DNA(2X)+Electro group received a total of 1 mg of tgD-plasmid (i.e., 500 μg of tgD-
plasmid in a 500 μl volume per injection site). For each DNA injection, the needle was 
inserted to a depth of 1-cm in the muscle. Immediately following each DNA injection, 
an electrode with six 23-gauge needles arranged equidistant in a 1-cm diameter circle 
(BTX ECM 830 Pulse Generator; Genetronics, San Diego, CA) was placed directly over 
each injection site and inserted 1-cm into the muscle. Six pulses (200V/20 ms, 5 Hz per 
pulse) were applied to each injection site. Previous studies have shown that this 
electroporation protocol resulted in a significant increase in DNA plasmid gene 
expression relative to DNA immunization alone (Pazmany, Murphy et al. 1995; Mir, 
Moller et al. 2005).   
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3.3.4. Serum Collection and Analysis of Antibody Titers 
Serum was collected from all lambs prior to vaccination, at 10 days following 
primary immunization, and then at weekly intervals for a period of 27 weeks. The last 
two serum collections (weeks 26 and 27) were at one and two weeks following the 
secondary vaccination. All serum samples were stored at -20 °C.  Antibody titers for all 
samples were analyzed within the same assay in order to eliminate inter-assay 
variability.  
To determine BHV-1 gB and tgD-specific antibody titers, sera were serially 
diluted in 0.1 M Tris-buffered saline containing 0.05% Tween-20 (pH 7.5) and added to 
triplicate wells in Immulon-2 96-well plates (Dynex Labs Inc, Franklin, MA) which had 
been coated with 0.5 g/ml of recombinant BHV-1 gB or tgD as previously described 
(van Drunen Littel-van den Hurk, Braun et al. 1998). Bound antibody was detected 
using phosphatase-labeled rabbit anti-sheep IgG (H+L) (Kirkegaard-Perry Labs, 
Gaithersburg, MD) and 100 mg/ml p-nitrophenyl phosphate in 1% diethanolamine, 0.5 
mM MgCl2 (pH 9.8). Titers were expressed as the reciprocal of the highest serum 
dilution to give a positive reaction. To identify individual animals with positive tgD-
titers, the cut-off was defined as the upper 99% confidence interval (CI) for time-
matched serum samples collected from naïve animals (Table 3.2; Control group). The 
serum titer cut-off for an acceptable background level of gB-specific antibody was set at 
the upper 99% CI for the average of titers for all animals (n = 42) when using serum 
samples collected at the beginning of the experiment.  
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3.3.5. Statistical Analysis 
Data for antibody titers were not normally distributed. To compare each 
treatment group against the Control group or to compare responses among selected 
treatment groups at selected time points, data were analyzed using the Kruskal-Wallis 
test for non-parametrically distributed samples followed by Dunn’s comparison of 
selected data sets (GraphPad Prism 4.0, GraphPad Software, San Diego, CA). A positive 
tgD-specific antibody titer was defined as a titer exceeding the 95% CI of titers observed 
in the naïve Control group when measured within the same assay and at the same time 
point. 
Regression analysis was performed to determine if a relationship existed between 
either the magnitude or the duration of the primary antibody response and the magnitude 
of the secondary antibody response at one week following the secondary immunization. 
To explore these possible relationships, each animal receiving a primary immunization 
was first ranked for magnitude of the primary antibody response. This ranking was 
based on the maximal antibody titer measured for an individual animal at any time 
following primary immunization (see Section 3.3.1, Fig. 3.1). Animals were then ranked 
according to the duration of a detectable primary antibody response. The duration of a 
primary antibody response was defined as the interval between primary immunization 
and the time when the tgD-specific antibody titer of each animal returned to a level 
comparable to the Control group. An increase in the magnitude of the secondary 
antibody response was used as one possible indicator of immune memory having 
persisted until the time of secondary immunization. 
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3.4. Results 
 
3.4.1.  Effect of Electroporation and DNA Immunization on the Primary Antibody 
 Response 
A significant increase in tgD-specific antibody responses was first observed in 
the DNA immunization groups. At 10 days post-primary immunization, both groups 
which had received DNA immunization in combination with electroporation, had tgD-
specific serum antibody titers significantly different (p < 0.05) from the Control group 
(Fig. 3.1A). Furthermore, these same two groups had tgD-specific antibody titers that 
were significantly different (p < 0.05) from the group receiving IM DNA immunization. 
There was not, however, a significant difference in antibody titers when comparing 
between the two groups that received DNA immunization in combination with 
electroporation, or when comparing these same two groups with the group that received 
recombinant tgD protein. Thus, electroporation enhanced the onset of a primary immune 
response induced by IM DNA vaccination, but doubling the dose of DNA vaccine did 
not significantly enhance the effectiveness of electroporation (Fig. 3.1A).  
Three weeks after primary immunization, all immunized groups had achieved maximum 
median antibody titers (Fig. 3.1B). At this time, the tgD-specific antibody titers of all IM 
DNA immunized groups were significantly (p < 0.01) different from the Control group, 
but there were no significant differences among the immunized groups.  
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Figure 3.1. Primary tgD-specific antibody titers.  
 
 Comparison of primary antibody responses following immunization with either 
tgD protein or tgD-plasmid showed that DNA vaccination with electroporation resulted 
in the highest tgD-specific antibody titers. TgD-specific serum antibody titers 10 days 
(A), 3 weeks (B), and 5 weeks (C) following primary immunization. The immunization 
protocol for each group is as follows: Control (naïve lambs); Protein (lambs immunized 
with 20 g recombinant tgD protein); DNA-ID (lambs injected intradermally with 500 
g tgD-plasmid); DNA-IM (lambs injected intramuscularly with 500 g tgD-plasmid); 
DNA+Electro (intramuscular injection of 500 g tgD-plasmid was followed by 
electroporation at the plasmid injection site); and DNA(X2)+Electro (IM injection of 1 
mg tgD-plasmid was followed by electroporation at the plasmid injection site). The tgD-
specific antibody titers were determined by ELISA and expressed as the reciprocal of the 
highest serum dilution to give a positive reaction. All samples were analyzed within a 
single assay and the cut-off for positive tgD titers was set at the 99% upper CI of the 
Control group. Data presented are values for individual animals with group medians 
indicated by the horizontal bars. *p < 0.05; **p < 0.01. 
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 90 
 Thus, DNA immunization, in combination with electroporation, did not 
significantly increase peak serum antibody titers. Electroporation did, however, improve 
the consistency with which individual animals responded to vaccination; all 13 animals 
in the two DNA vaccine plus electroporation groups developed antibody titers greater 
than 7000 (Fig. 3.1B). In contrast, only 5 of 7 animals in the DNA-IM group and 2 of 7 
animals in the DNA-ID group developed tgD-specific titers that exceeded 7000. The 
consistency in individual animal responses to DNA immunization plus electroporation 
was maintained at 5 weeks post-immunization (wpi) (12 of 13 animals had titers greater 
than 5000). Furthermore, at 5 wpi, there were significant (p < 0.05) differences between 
the tgD-specific antibody titers of the group immunized IM with DNA and the group 
receiving recombinant tgD protein (Fig. 3.1C). Thus, IM DNA immunization, with or 
without electroporation, induced significantly (p < 0.05) elevated antibody responses 
when compared with the Protein group at 5 wpi. 
The duration of primary antibody responses in individual animals was then 
analyzed throughout the 25 week interval between primary and secondary immunization. 
The duration of a primary antibody response was defined as the interval between 
primary immunization and the time when the tgD-specific antibody titer for an 
individual animal returned to a level comparable to the Control group. This analysis 
revealed that IM DNA immunization, only when combined with electroporation, 
resulted in a significantly (p < 0.05) prolonged primary antibody response when 
compared to immunization with tgD protein (Fig. 3.2). Furthermore, when  
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Figure 3.2. Duration of tgD-specific serum antibody responses following primary 
immunization.  
 
 The longest duration of tgD-specific primary antibody titers was achieved in the 
group that received high-dose DNA vaccination plus electroporation. The immunization 
protocol for each group was as follows: Control (naïve lambs); Protein (lambs 
immunized with 20 g recombinant tgD protein); DNA-ID (lambs injected intradermally 
with 500 g DNA plasmid encoding tgD protein); DNA-IM (lambs injected 
intramuscularly with 500 g DNA plasmid encoding tgD protein); DNA-Electro 
(intramuscular injection of 500 g DNA plasmid encoding tgD protein was followed by 
electroporation at the plasmid injection site); and DNA(X2)-Electro (intramuscular 
injection of 1 mg DNA plasmid encoding tgD protein was followed by electroporation at 
the plasmid injection site). The duration of the primary immune response for each 
animal was defined as the interval between vaccine injection and the time point when 
their tgD-specific antibody titer was no longer positive. The cut-off for a positive tgD 
titer was set at the 99% upper CI of the Control group. TgD-specific antibody titers were 
determined at weekly intervals following primary immunization with all samples 
analyzed within a single assay. Data presented are values for individual animals with 
group medians indicated by the horizontal bars. *p < 0.05; **p < 0.01. 
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(Fig. 3.2)
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electroporation was combined with a 2-fold increase in the dose of DNA vaccine, the 
duration of the tgD-specific antibody response was significantly (p < 0.05) prolonged 
relative to IM DNA immunization. A primary IM immunization with 1 mg of DNA 
plasmid, in combination with electroporation, induced a tgD-specific antibody response 
that was still detectable in 4 of 6 animals at 11 weeks post-immunization. In contrast, IM 
immunization with 20 g of recombinant tgD protein induced a tgD-specific antibody 
response that was detectable for only 4 weeks post-immunization in 4 of 6 animals.  
 
3.4.2  Effect of Electroporation and DNA Immunization on the Secondary 
Immune Response  
An interval of 25 weeks between primary and secondary immunization was 
selected. This interval exceeded the 15 week interval used in a previous ID DNA 
immunization study in sheep (van Drunen Littel-van den Hurk, Braun et al. 1999), and  
was equivalent to the interval used to evaluate immune memory and protection against 
BHV-1 infection following a single immunization with a modified-live virus BHV-1 
vaccine (Platt, Burdett et al. 2006). At one week following secondary immunization with 
tgD protein, it was apparent that all previously immunized groups had significantly 
greater tgD-specific antibody responses than the Control group, which received a 
primary immunization (Fig. 3.3A). The detection of anamnestic antibody responses 
provided evidence for the persistence of immune memory for at least 25 weeks 
following primary immunization. At two weeks following secondary immunization, only 
those groups that had received a primary IM DNA immunization, with or without  
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Figure 3.3. The tgD-specific serum antibody titers at one week (A) and two weeks 
(B) following secondary immunization with recombinant tgD protein.  
 
 Anamnestic antibody responses were detected in all groups that had been 
immunized 25 weeks previously. Delivery of DNA vaccine via the IM route , with or 
without electroporation, significantly increased the magnitude of secondary antibody 
titers at 2 weeks post-boost.  Control (lambs receiving a primary immunization with 20 
g recombinant tgD protein while other groups received a secondary immunization with 
recombinant tgD protein); Protein (lambs were immunized with 20 g recombinant tgD 
protein 25 weeks prior to secondary immunization); DNA-ID (lambs were injected 
intradermally with 500 g DNA plasmid encoding tgD protein 25 weeks prior to 
secondary immunization); DNA-IM (lambs were injected intramuscularly with 500 g 
DNA plasmid encoding tgD protein 25 weeks prior to secondary immunization); DNA-
Electro (intramuscular injection of 500 g DNA plasmid encoding tgD protein was 
followed by electroporation at the plasmid injection site 25 weeks prior to secondary 
immunization); and DNA(X2)-Electro (intramuscular injection of 1 mg DNA plasmid 
encoding tgD protein was followed by electroporation at the plasmid injection site 25 
weeks prior to secondary immunization). Data presented are values for individual 
animals with group medians indicated by the horizontal bars. *p < 0.05; **p < 0.01. 
 95 
 
 
C
on
tr
ol
P
ro
te
in
D
N
A
-ID
D
N
A
-IM
D
N
A
-E
le
ct
ro
D
N
A
(X
2)
-E
le
ct
ro
102
103
104
105
106
*
A.
*** *
*
tg
D
-s
p
e
c
if
ic
 A
n
ti
b
o
d
y
 T
it
re
C
on
tr
ol
P
ro
te
in
D
N
A
-ID
D
N
A
-IM
D
N
A
-E
le
ct
ro
D
N
A
(X
2)
-E
le
ct
ro
102
103
104
105
106
B.
*
*
*
tg
D
-s
p
e
c
if
ic
 A
n
ti
b
o
d
y
 T
it
re
 
(Fig. 3.3) 
A. 1 week 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. 2 weeks 
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electroporation, had antibody responses that were significantly greater than the Control 
group (Fig. 3.3B). Thus, the persistence of memory T or B cells in the Protein or ID 
DNA immunized groups may have been sufficient to support a more prompt antibody 
response without significantly altering the magnitude of the secondary immune 
response. 
 The fixed interval between primary and secondary immunization resulted in 
marked differences among individual animals when comparing the interval between 
when primary antibody responses were no longer detectable and secondary 
immunization. For example, the interval during which there was no longer a detectable 
primary antibody response and secondary immunization for most animals in the Protein 
group was 21 weeks, but only 14 weeks for most animals in the DNA(2X)-Electro group 
(Fig. 3.2). Thus, it was possible to ask whether both the magnitude and the duration of 
the primary antibody response had a significant effect on the secondary antibody 
response. The responses of all animals that had received a primary immunization, 
regardless of antigen form or route of delivery, were included in this analysis. All 
animals were ranked based on the peak magnitude of their tgD-specific antibody titers 
during the primary response (without restricting the time required to achieve this 
maximal response). Each animal was then ranked according to the magnitude of the 
antibody response at one week following secondary immunization. This short time 
interval following secondary immunization was selected as the best indicator of a more 
rapid onset of antibody responses, which is one characteristic of an anamnestic response. 
Regression analysis of these two parameters revealed a significant (p < 0.0001) 
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correlation (r
2
 = 0.40) between the magnitude of the primary and secondary immune 
responses (Fig. 3.4A).  
A second regression analysis was then performed to determine if a significant 
correlation existed between the duration of the primary immune response and the 
magnitude of the secondary immune response. All immunized animals were again 
included in this analysis and animals were ranked for duration of the primary immune 
response as shown in Figure 3.2. This analysis revealed a significant (p < 0.0001) and 
greater correlation (r
2
 = 0.74) between duration of the primary immune response and 
magnitude of the secondary immune response (Fig. 3.4B). These regression analyses 
support the conclusion that factors which influence both the magnitude and the duration 
of a primary immune response may also influence immune memory. 
 
3.5. Discussion 
DNA vaccination held great promise as the third generation of vaccine 
technology capable of accelerating the development of new vaccines, simplifying 
vaccine formulation and delivery, and reducing the cost of vaccine production. 
Unfortunately, failure to achieve high levels of DNA transfection and gene expression 
has limited the transfer of this technology from the laboratory to clinical application 
(Babiuk, Pontarollo et al. 2003). Recent investigations have focused on the use of DNA 
vaccines within a prime-boost strategy, which relies on a secondary immunization with 
recombinant protein or vector-delivered antigen to enhance the relatively weak immune 
responses induced by single or multiple DNA vaccinations (Table 3.1). In contrast, 
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Figure 3.4. Correlation between peak magnitude (A) and duration (B) of the 
primary antibody response and the magnitude of the secondary antibody response 
at one week post-immunization. 
 
 Regression analysis revealed a significant correlation between the magnitude of 
primary and secondary antibody titers and a greater correlation between the duration of 
the primary and magnitude of secondary antibody titers. Peak magnitude of the primary 
antibody response for individual animals was determined between 3 to 5 weeks 
following primary immunization. Duration of the primary antibody response was 
determined as the interval between primary immunization and the time point when tgD-
specific titers no longer exceeded the cut-off set at the 99% upper CI of the control 
group. A significant (p < 0.0001) correlation (r
2
 = 0.40) was observed between 
amplitude of the primary and secondary immune responses. A significant (p < 0.0001) 
correlation (r
2
 = 0.74) was also observed between duration of the primary immune 
response and amplitude of the secondary immune response. response equivalent in 
magnitude to that obtained with recombinant protein delivered with an optimized 
adjuvant formulation (Fig. 3.1). Furthermore, electroporation was able to significantly 
enhance both the onset of a primary antibody response and prolong the duration of this 
response approximately three-fold when compared to the recombinant protein vaccine 
(Fig. 3.2). Thus, a single DNA vaccination when combined with electroporation has the 
potential to provide rapid onset of immune-mediated disease protection and prolonged 
protection if antibody mediates this protection.  
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(Fig. 3.4)  
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the present investigation clearly demonstrates that a single DNA vaccination, when 
combined with electroporation, can induce an antibody response equivalent in 
magnitude to that obtained with recombinant protein delivered with an optimized 
adjuvant formulation (Fig. 3.1). Furthermore, electroporation was able to significantly 
enhance both the onset of a primary antibody response and prolong the duration of this 
response approximately 3-fold when compared to the recombinant protein vaccine (Fig. 
3.2). Thus, a single DNA vaccination when combined with electroporation has the 
potential to provide rapid onset of immune-mediated disease protection and prolonged 
protection (if antibody mediates this protection).  
The development of vaccines capable of inducing protective immune responses 
following a single immunization remains a challenge when using vaccine technologies 
other than MLV vaccines. This search for single-shot vaccines is driven by increasing 
concerns regarding vaccine safety (Moylett and Hanson 2004) and a lack of client 
compliance when multiple vaccinations are required to achieve protective immunity. 
These concerns have also been instrumental in raising questions regarding the duration 
of immune-mediated protection and immune memory following vaccination. The 
present investigation was designed to determine if a single DNA immunization, in 
combination with electroporation, could prolong the primary antibody response and 
support an anamnestic antibody response when the secondary immunization was 
performed 6 months later. A previous DNA vaccination study in newborn lambs 
indicated that a single ID DNA immunization could induce immune memory, detectable 
in the form of an anamnestic antibody response, up to 15 weeks after primary 
immunization (van Drunen Littel-van den Hurk, Braun et al. 1999). In this study, a 
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secondary protein immunization at 6 months after primary DNA immunization resulted 
in the induction of an anamnestic antibody response (Fig. 3.3). The secondary antibody 
response observed following DNA immunization, with or without electroporation, was 
not significantly different, however, from the secondary antibody response observed 
following a primary protein immunization. Regression analysis of ranked data for (i) the 
duration of the primary antibody response and (ii) the magnitude of the secondary 
antibody response revealed a relatively high correlation between these two parameters 
(Fig. 3.4B). Since DNA immunization with electroporation had the greatest impact on 
the duration of the primary antibody response (Fig. 3.2), it could be implied that this 
vaccination strategy may be a more effective approach to enhance the duration of 
immune memory. This conclusion would be consistent with reports that antigen 
persistence is a major factor in the maintenance of immune memory (Gray and Skarvall 
1988). Therefore, achieving efficient DNA transfection and sustained antigen expression 
may be a key factor when attempting to reduce immunization frequency without 
compromising the duration of immune-mediated protection against an infectious disease.  
The present data are also consistent with previous observations that a single 
injection of plasmid DNA into the oral cavity of fetal lambs induced both immune 
memory and protection against infection (Gerdts, Snider et al. 2002). More specifically, 
a single administration of plasmid encoding HBsAg into the oral cavity of fetal lambs 
induced protective levels of serum antibody that persisted for over 15 weeks. The long-
term persistence of HBsAg-specific antibodies following a single DNA immunization 
may reflect, in part, the unique nature of this vaccine antigen. Recombinant HBsAg 
protein self-assembles into virus-like particles (VLP) that are very stable and the 
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prolonged immune response to HBsAg observed following a single DNA immunization 
is consistent with antigen persistence (Zi, Yao et al. 2006). These observations suggest 
another strategy that may be useful when attempting to design DNA vaccines with 
prolonged duration of primary immune responses and immune memory following a 
single vaccination: it may be possible to engineer recombinant proteins to enhance their 
stability and persistence through the incorporation of protein domains which support 
protein aggregation or assembly into stable multimeric complexes, such as VLPs 
(Aberle, Aberle et al. 1999). “Single-shot” vaccines which produce stable and persistent 
forms of antigen may, however, raise unique safety issues arising from the prolonged 
induction of an immune response (Zi, Yao et al. 2006). 
Electroporation significantly enhanced the onset (Fig. 3.1) and duration (Fig. 3.2) 
of the primary antibody response in the present investigation. Previous studies have 
demonstrated that electroporation significantly enhances the level of DNA transfection 
(Mir, Moller et al. 2005) and may also enhance antigen presentation through recruitment 
of APCs to the site of immunization (Babiuk, Baca-Estrada et al. 2004). The rapid onset 
and prolonged duration of the primary antibody response observed in the present 
investigation are consistent with both enhanced antigen expression and antigen 
presentation. Of interest, however, was the observation that electroporation did not 
enhance the magnitude of the primary antibody response relative to either IM injection 
of plasmid alone or other forms of immunization (Fig. 3.1). This may reflect a paucity of 
lymphocyte trafficking through muscle. Previous investigations have also demonstrated 
that the form of gD expressed in transfected myocytes can significantly alter the onset 
and duration of an immune response (Lewis, van Drunen Littel-van den Hurk et al. 
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1999) and this may be related to the rate of tgD release. The prolonged duration of the 
tgD-specific primary antibody response, however, suggests that electroporation achieved 
a sufficient level of tgD expression to ensure prolonged antigenic stimulation. The 
duration of plasmid expression is a major factor limiting vaccine efficacy when DNA is 
targeted to skin where the high rate of cell turn-over rapidly eliminates transfected cells 
(Braun, Babiuk et al. 1999). The short duration of the primary antibody response and 
high inter-animal variation in antibody responses observed following ID DNA 
immunization (Fig. 3.1) supports the conclusion that IM delivery may be the optimal 
route for immunization when prolonged DNA transfection and expression is required.  
The present investigation also revealed the importance of ensuring that animals 
are not exposed to cross-reactive or homologous antigen during the period between 
immunization and analysis of antibody responses. This is of particular concern when 
assessing the duration of immune responses to pathogens, such as BHV-1, which may be 
endemic and establish latent infections.The development of BHV-1 gB-specific antibody 
titers was used as a criterion to exclude animals which may have been exposed to either 
ovine or bovine herpesviruses. It was not possible, however, to directly monitor 
inadvertent exposure to antigens that may have re-stimulated gD-specific T or B cells. 
Therefore, controlling environmental exposure will be critical when conducting 
experiments to analyze the duration of immune responses following vaccination. 
In conclusion, the present investigation clearly demonstrated that electroporation 
accelerated the onset and prolonged the duration of the primary antibody response 
induced by IM DNA vaccination. Similar effects may be achieved by the use of much 
larger quantities of protein antigen or improved adjuvants; however, these approaches to 
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changing protein vaccine formulation may be limited by cost and an increased risk of 
adverse reactions at the injection site. The use of electroporation remains an 
experimental procedure at this time and further development of the technology is 
required before it can become a practical method for DNA vaccine delivery. The present 
observations indicate, however, that increasing the efficiency of DNA vaccine delivery 
can have potential benefits for both the duration of a primary antibody response and 
possibly for the duration of immune memory following a single vaccination. Designing 
DNA vaccine trials to address these aspects of immune responses will be critical if we 
are to achieve the goal of a “single shot” vaccine that optimizes vaccine safety and 
minimizes the risk of adverse reactions while still providing both a rapid onset of 
protection against infection and the prolonged immune-mediated protection observed 
with a MLV vaccine (Platt, Burdett et al. 2006).  
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CHAPTER 4 
 
TRANSFECTION AND EXPRESSION FOLLOWING ORAL DELIVERY  
OF NAKED DNA PLASMID IN THE OVINE FETUS
1
 
 
4.1.  Abstract 
 We previously demonstrated that in utero oral DNA vaccination may be an 
effective strategy to prevent vertical disease transmission. The detection of antigen-
specific immune responses in LNs draining the oral cavity of fetal lambs suggested that 
DNA plasmid had penetrated the oral mucosa. Experiments were performed to identify 
the sites of DNA transfection following oral injection of plasmid during the third 
trimester of gestation. Luciferase was used as a reporter gene and the analysis of 
luciferase activity revealed that oral injection of naked DNA plasmid resulted in a 
detectable level of protein expression in 14 of 15 fetuses (93%). The primary site of 
plasmid expression was the anterior aspect of the oral cavity, specifically the tongue and 
lips. At 11 dpi, the level of luciferase activity was still increasing and could be detected 
in all areas of the oral cavity, lymphoid tissues draining the oral cavity, as well as the 
liver and lungs of some fetuses. In contrast, oral delivery of plasmid DNA in newborn 
lambs did not induce a detectable immune response. Observed differences in the 
histology of the oral mucosa of fetuses at varying ages, supported the conclusion that 
                                                 
1 Manuscript accepted with revisions. Tsang C, Kaushik RS, Mirakhur KK, Gerdts V, Babiuk LA, Griebel 
PJ. 2007. Dev Comp Immunol. 
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DNA transfection in the oral cavity of fetal lambs was due to a lack of mucosal 
epithelial cell differentiation. Therefore, the fetal oral cavity may provide a unique site 
where delivery of a naked DNA vaccine can achieve sufficient protein expression to 
induce an immune response.  
 
4.2. Introduction 
 DNA vaccines have many potential applications, including induction of immune 
protection against pathogens, induction of tolerance to autoantigens and allergens, or 
replacement of a genetic deficiency. For a DNA vaccine to be of therapeutic value, it 
must transfect the appropriate cells and sufficient protein must be produced to induce an 
immune response. For example, enhancing DNA plasmid transfection efficiency and 
changing the site of DNA transfection significantly alters both the duration of a primary 
immune response and the persistence of immune memory (Tsang, Babiuk et al. 2007). 
Finding methods to deliver DNA vaccines to appropriate target cells, while obtaining 
high levels of transfection and expression, remain major barriers to the clinical 
application of DNA vaccine technology.  
Current methods of DNA vaccine delivery can be divided into either vectored or 
non-vectored delivery systems. Viral vectors (Sharpe, Fooks et al. 2002; Xin, Ooki et al. 
2002; Zhang, Mei et al. 2003; Pinto, Fitzgerald et al. 2004; Liu, Yang et al. 2005) and 
bacterial vectors (Paglia, Terrazzini et al. 2000; Bauer, Darji et al. 2005) have been used 
to target genes to specific cell types. Although these vectors provide efficient gene 
delivery, they can also induce inflammation, toxic responses, and disease (Lehrman 
1999; Bessis, GarciaCozar et al. 2004). Viral vectors also carry a risk of integration into 
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the host genome (Miller, Rutledge et al. 2002) and the size of the transgene being 
packaged may be limited (Dong, Fan et al. 1996). Non-vectored delivery systems 
include the encapsulation of plasmid DNA in reagents, such as polyethylene glycol 
(Kaul and Amiji 2005) and cationic lipids (Clark, Stpoeck et al. 2000; Byrnes, Nass et 
al. 2002). Encapsulation enhances transfection efficiency and strategies have been 
reported for increasing the rate of plasmid transport across the nuclear membrane. 
Conjugation of a lipid carrier to a modified mRNA transporter (Byrnes, Nass et al. 2002) 
or sigma-1 attachment protein from recombinant reovirus (Talsma, Babensee et al. 2006) 
enhanced gene expression, while incorporation of the SV40 enhancer downstream of the 
transgene was shown to enhance nuclear translocation (Young, Benoit et al. 2003); 
however, disadvantages of encapsulation include cytotoxic effects (Kiefer, Clement et 
al. 2004) and failure to target appropriate cells.  
Delivering therapeutic genes in the form of naked plasmid offers a number of 
important advantages. Plasmid can be administered repeatedly without risk of inducing 
specific immunity against the delivery vehicle. Purified plasmid can be produced in 
large quantities at a relatively low cost, is very stable and unlikely to have toxic effects. 
These potential advantages continue to drive the search for more efficient methods of 
DNA delivery. Electroporation (Babiuk, Baca-Estrada et al. 2004) and low frequency 
ultrasound (Talsma, Babensee et al. 2006) have been used to enhance plasmid 
transfection efficiency but induce significant inflammation and cell lysis, respectively. 
Although there is no limit to the size of the gene being inserted into the DNA plasmid, 
larger plasmids have a reduced transfection efficiency. This is especially true when 
compared to the relative high transfection efficiency of minicircles (Darquet, Cameron 
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et al. 1997). The presence of immunostimulatory CpGs in the bacterial DNA backbone 
may oppose stable gene expression, however, plasmids can be engineered such that 
immunostimulatory CpGs are removed or suppressed (Yamada, Gursel et al. 2002). 
Thus, genes delivered in the context of DNA plasmids have the potential to function as 
effective vaccines if an adequate level of plasmid transfection can be achieved. 
Our laboratory has previously reported the successful induction of immune 
responses following injection of plasmid in saline solution into the oral cavity of third 
trimester fetal lambs (Gerdts, Babiuk et al. 2000; Gerdts, Snider et al. 2002). Immune 
responses specific to the plasmid-encoded viral glycoprotein were detected in 19 of 23 
(83%) injected fetuses. The induction of these responses occurred following a single 
plasmid injection and in the absence of any delivery vehicle or mechanical treatment to 
enhance transfection efficiency. The analysis of immune responses in fetal lambs 
indicated that the site of immune induction was restricted to LNs draining the oral 
cavity. Furthermore, incubation of plasmid DNA with fetal fluid revealed that the 
plasmid was rapidly degraded. These observations were interpreted as evidence that 
DNA plasmid either transfected the oral mucosal epithelium or penetrated the mucosal 
barrier and transfected cells in the draining LN. Plasmid transfection of mucosal 
epithelium would raise questions regarding the duration of gene expression, since 
previous studies determined that DNA transfection of skin and mucosal epithelium 
resulted in gene expression for less than 72 hours due to the rapid loss of epithelial cells 
(van Drunen Littel-van den Hurk, Braun et al. 1998; Loehr, Willson. et al. 2000). 
Furthermore, plasmid expression in epithelial cells was only observed in these studies 
following ballistic delivery of the DNA into epithelial cells.  
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In this study, we examined the site of plasmid transfection and the duration of 
gene expression following a single injection of luciferase-encoding plasmid into the oral 
cavity of 120-125 dg fetal lambs. Specifically, we examined the mucosal epithelium of 
the oral cavity for plasmid expression, since this was suggested to be the primary site of 
plasmid transfection (Gerdts, Babiuk et al. 2000). We also demonstrated proof of 
principle that fetal oral tissues can be transfected in the absence of either tissue 
manipulation or formulation of plasmid with transfecting agents. To determine if naked 
DNA transfection of the oral mucosa was unique to the fetus, a DNA vaccine was 
applied to the oral cavity of newborn lambs to determine if DNA transfection was 
sufficient to induce an immune response. Histological studies were also completed to 
determine if structural changes in the mucosal epithelium might be one factor limiting 
DNA transfection.  
 
4.3. Materials and Methods 
 
4.3.1. Animals  
 The estrus of Suffolk ewes were synchronized by insertion of vaginal sponges 
containing 60 mg medroxyprogesterone acetate (Veramix®, Pharmacia & Upjohn, 
Orangeville, ON). Upon removal of sponges, ewes were exposed to rams for a period of 
5 days. Thus, the gestational age of fetuses was defined with a variance of +2.5 days and 
all pregnancies were confirmed by rectal ultrasound at 45 dg (gestational length in sheep 
is approximately 148 days). All experiments were conducted following the guidelines of 
the Canadian Council on Animal Care. 
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4.3.2. In utero and Post-Partum DNA Injection 
 Fetal surgeries and in utero oral injections were carried out as described in 
Gerdts et al. (2000). Briefly, ewes were placed under general anaesthetia and a ventral 
midline incision was made along the linea alba. The uterus was manipulated such that a 
portion containing the head of the fetus was exteriorized (Fig. 4.1A). The lips of the 
fetus were parted by applying pressure at the commissures of the mouth and a 22-gauge 
needle or 28-gauge catheter was placed into the oral cavity. Oral deliveries were initially 
performed with a 22-gauge needle, and later replaced with a 28-gauge catheter as a 
precaution against possible disruption of the oral mucosal epithelium. The following 
criteria were used to ensure that the oral epithelium was not penetrated: (i) following 
insertion of the catheter into the oral cavity, the plunger on the syringe was withdrawn to 
ensure aspiration of amniotic fluid and (ii) there was no resistance noted upon 
depression of the plunger. After injection, the uterus was returned to the abdominal 
cavity and the abdominal incision was closed. At specified times post-injection (pi), 
ewes were euthanized and fetal tissues collected. Age-matched control fetuses were 
either injected orally with endotoxin-free saline or did not undergo surgical 
manipulation. 
 For post-partum immunizations, four groups of newborn lambs (n = 5 per group), 
between 0-3 days of age, received either saline containing plasmid DNA or saline alone. 
Solutions were injected ID (5 x 100 μl aliquots) between the central ridges on the 
convex side of the ear or injected into the oral cavity.  
 All animals were randomly assigned to experimental groups. 
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Figure 4.1. Delivery of plasmid at 125 days gestation and tissue collection.  
(A) The head of the fetus within the uterus was exteriorized through an abdominal 
incision. DNA plasmid was injected through the uterine wall and into the opened oral 
cavity. (B) Anatomical map for the collection of mucosal epithelium from the fetal oral 
cavity. The mucosa and attached submucosa of the oral cavity, tongue and oropharynx 
were harvested in approximately 1-cm
2
 sections. Samples 26 and 27 refer to tissue deep 
to the frenulum and sample 40 includes the palatine tonsils. The retropharyngeal and 
superficial cervical lymph nodes, lung, liver and tip of the left ear were also collected.  
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4.3.3. Plasmid Preparation 
 The plasmid pMASIA-luc contains the gene for firefly luciferase, which is a non-
secreted, soluble protein (Uwiera, Rankin et al. 2001), and pSLIA-tgD contains the gene 
for BHV-1 tgD (Braun, Babiuk et al. 1997). Plasmids were amplified in E. coli DH5  
(New England Biolabs, Mississauga, ON) and purified using the EndoFree  Plasmid 
Giga Kit (Qiagen, Mississauga, ON). Purified plasmid was reconstituted at 0.5-2 mg/ml 
in endotoxin-free Dulbecco’s PBS (Sigma-Aldrich, St. Louis, MO) and stored at -20 C. 
DNA quality was confirmed by electrophoresis and sterility was confirmed by plating 
plasmid solution on 2x YT in the absence of antibiotic. Endotoxin levels were measured 
using the QCL-1000 Limulus Amebocyte Lysate Kit (BioWhittaker Inc., Walkersville, 
MD) and ranged between 0.01-0.7 EU/ml of plasmid solution. These levels were below 
the minimal threshold required to induce non-specific stimulation of ovine leukocytes 
(Messina, Gilkeson et al. 1991).  
 
4.3.4. In Vitro Transfection Assay 
 All media and transfection reagents unless otherwise noted were obtained from 
InVitrogen (Burlington, ON). Madin-Darby bovine kidney (MDBK) cells (ATCC, 
Manassas, VA) were cultured in Modified Eagle’s Medium (MEM) with 10% FBS and 
grown in Nunclon 6-well tissue culture plates (Nalge-Nunc, Rochester, NY). Upon 
reaching 80% confluence, triplicate cultures were transfected with Opti-MEM 
containing pMASIA-luc, Lipofectamine Plus™ and Lipofectamine™ at a ratio of 
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1:10:2.5 (w/v/v) according to manufacturer’s directions. Cultures were harvested at 24 
hour intervals, lysed and analysed for luciferase activity.  
 
4.3.5. Luciferase Assay 
 Cultured cells were prepared according to manufacturer’s directions (Luciferase 
Assay System, Promega, Madison, WI). The mucosal epithelium and submucosa were 
collected from the oral cavity and oropharynx in 1-cm
2
 samples mapped to specific 
anatomical loci (Fig. 4.1B). Samples were snap frozen in liquid nitrogen and stored at -
70 °C. Tissues were minced in liquid nitrogen, homogenized and then assayed for 
luciferase activity using the Luciferase Assay System. The lower detection limit of the 
assay using the Packard Picolite  Luminometer (United Technologies Packard, Palo 
Alto, CA) was 100 pg as determined from a standard curve constructed using 
QuantiLum® Recombinant Luciferase (Promega, Madison, WI). Luciferase activity was 
expressed as units of luciferase activity per mg of protein (ULA). Total protein per 
sample of homogenized tissue or cultured cells was determined using the Bradford assay 
(BioRad, Hercules, CA). The cut-off for non-specific luciferase activity (i.e., non-
specific luminescence) in a specific tissue or tissue group was calculated as the upper 
95% CI from age-matched, control fetuses.  
 
4.3.6. Ex Vivo Transfection Assay 
 The dorsum of the tongue was removed from three fetal lambs between 129-134 
dg and each tongue was cut into ten pieces with an approximate mucosal surface area of 
7.5 mm
2
 and tissue thickness of 3-5 mm. Sections were placed in individual wells of a 
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Nunclon 6-well tissue culture plate containing 37 °C AIM-V media (InVitrogen) and 
positioned such that the epithelial surface was above the meniscus of the media. The 
epithelial surface was then overlaid with 50 μg of pMASIA-luc in saline for 15, 30 or 60 
minutes (n = 3 tissue samples per fetus per time point). Transfection was terminated by 
repeated flushing of each tissue fragment with sterile saline to remove non-adhered 
plasmid and explants were then submerged in fresh AIM-V with 2% FBS and antibiotic-
antimycotic (Sigma-Aldrich) and incubated for 24 hours at 37 °C with 5% CO2. 
Luciferase activity was measured as described previously. Control tissue sections (one 
per fetus) were treated with a 50 μg of an irrelevant plasmid (pCAN-GFP (Uwiera, 
Gerdts et al. 2001)). The cut-off for non-specific luciferase activity was calculated as the 
upper 99% CI from tissues transfected with an irrelevant plasmid.  
        
4.3.7. BHV-1 tgD-Specific Serum IgG Titers 
 ELISAs were carried out as described previously (Gerdts, Babiuk et al. 2000). 
Immunolon-2 plates (Dynatech Laboratories, Gaithersburg, Maryland) were coated with 
0.5 μg/ml purified BHV-1 tgD per well and incubated with serial dilutions of serum. 
Alkaline-phosphate-conjugated rabbit-anti-sheep IgG (H+L) (1:6000 dilution; 
Kirkegaard and Perry Laboratories, Gaithersburg, MD) was used to detect sheep Igs 
captured by tgD protein. The reaction was visualized with 100 mg/ml p-nitrophenyl 
phosphate (Sigma-Aldrich). Antibody titers were expressed as the reciprocal of the 
highest serum dilution to give a positive reaction. A positive reaction was defined as an 
OD value which was two times greater than the average value for serum collected from a 
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naïve fetus. Each serum sample was analyzed in triplicate and the average value used to 
calculate serum antibody titers.  
 
4.3.8. Histology 
 Tissue samples taken from the tongue and lips of fetuses and newborn lambs  
were fixed in 10% buffered formalin and submitted to Prairie Diagnostic Services 
(Saskatoon, SK) for hematoxylin and eosin staining and immunohistochemical staining 
for Ki67 nuclear antigen (clone MIB-1; InVitrogen).  
  
4.3.9. Statistical Analysis 
 All analyses were carried out before logarithmic transformation of data. The 
upper 95 or 99% CI was used as the cut-off for non-specificity in all assays. The 
Kruskal-Wallis test, followed by Dunn’s comparison, was used to compare data between 
groups. All statistical analyses were conducted using GraphPad Prism 4.0 (GraphPad 
Software, San Diego, CA). 
 
4.4. Results 
 
4.4.1. Validation of Luciferase Plasmid 
 In vitro and in vivo experiments were conducted to verify the activity of the 
luciferase protein encoded in pMASIA-luc and to identify the interval between plasmid 
transfection and the expression of a detectable level of luciferase activity. MDBK cells 
were transfected in vitro with 0.1, 1, 2 or 5 μg of pMASIA-luc. At 24 and 48 hours, a 
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significant relationship between plasmid dose and luciferase activity was observed for 
0.1 and 5 μg of plasmid (p<0.05) (Fig. 4.2A). Plasmid dose had no effect on either the 
time of peak luciferase expression or the duration of luciferase expression. Luciferase 
activity reached peak levels at 24 hours for all groups.  
 To validate the assay for detection of luciferase activity in tissue samples, 100 μg 
of pMASIA-luc in 100 μl saline was injected subcutaneously at each of two sites on 
either side of the midline of the dorsal and ventral lips, and at three sites along the 
midline of the tongue of a single, six-month old lamb. At 24 hours, each injection site 
(contained in a 1-cm
2
 piece of tissue) was tested for luciferase activity. Luciferase 
activity was detected in each tongue sample that contained an injection site as well as 
both the left and right retropharyngeal LNs. No luciferase activity was detected in the 
palatine tonsils or samples of tongue taken from areas adjacent to the sites of injection 
(data not shown). Thus, the functional activity of the pMASIA-luc plasmid as well as the 
capacity of the luciferase assay to detect gene expression in tissues was confirmed. 
 
4.4.2. Ex vivo transcutaneous transfection of fetal oral tissues with naked plasmid 
DNA 
 An ex vivo transfection experiment was conducted to determine if naked plasmid 
could transfect fetal oral mucosa. Fragments of fetal tongue (129-135 dg) were overlaid 
with 50 μg of pMASIA-luc in saline for 15, 30 or 60 minutes. At 24 hours post-
transfection, luciferase activity was detected in 7 of 27 treated tongue fragments (Fig. 
4.2B). Increasing the duration of plasmid contact did not increase the level of detectable  
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Figure 4.2.  Expression of luciferase-plasmid following in vitro transfection of 
MDBK cells and ex vivo transfection of fetal tongue. 
 
 Experiments were conducted to validate the biological activity of the luciferase-
plasmid and to demonstrate proof of principle that fetal mucosal epithelium can be 
transfected with DNA plasmid in the absence of either tissue manipulation or plasmid 
formulation. (A) Luciferase activity in transfected MDBK cells. Luciferase levels were 
compared using the Kruskal-Wallis test followed by Dunn’s comparison. (B) Luciferase 
activity in 1-cm
2
 sections of fetal tongue following overlay with 50 μg of luciferase-
plasmid in saline. Plasmid was in contact with the epithelial surface for 15, 30 or 60 
minutes. Luciferase activity was measured 24 hours after removal of plasmid. The cut-
off (---) for luciferase activity was set at the 99% CI of three samples treated with 
control plasmid. 
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luciferase activity. Low amounts of transfected plasmid DNA may have limited the 
detection of positive samples. Regardless, this experiment provided evidence for  
transfection of mucosal epithelium within 15 minutes, which was consistent with 
previous evidence that DNA plasmid is rapidly degraded after in utero oral injection 
(Gerdts, Snider et al. 2002). 
 
4.4.3. Optimizing Plasmid Dose for Oral Transfection  
 In previous oral injection studies, the arbitrary use of 0.5 mg of plasmid 
delivered in a 5 ml volume of saline resulted in gene expression in 80% of injected 
fetuses (Gerdts, Babiuk et al. 2000; Gerdts, Snider et al. 2002). Therefore, we 
investigated the effect of plasmid dose on oral transfection efficiency. A dose response 
study was performed with oral injection of 0.5, 1 or 2 mg of pMASIA-luc in 1 ml of 
saline (n = 3 fetuses/group). At 72 hours post-injection (hpi), the fetal oral epithelium 
was harvested in 1-cm
2 
sections mapped to specific anatomical loci (Fig. 4.1B) and 
luciferase activity was measured for each tissue section. Considerable non-specific 
luciferase activity was noted in all animals and all tissues. To differentiate between non-
specific luciferase activity and luciferase activity resulting from expression of luciferase-
plasmid, luciferase activity was measured in tissue samples from 4 age-matched control 
fetuses (Fig. 4.3A): fetuses 103a and 336a were non-surgical controls and 114a and 115b 
were orally injected with saline. Tissues related by function and anatomical loci were 
grouped and the cut-off value for each tissue group was set at the upper 95% CI of 
values established with samples collected from control animals. Only tissue samples 
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Figure 4.3.  Dose titration of orally-injected luciferase plasmid.  
 
 A 1 mg dose of luciferase-plasmid resulted in the highest levels of luciferase 
activity.  Considerable variation in transfection and expression efficiency was also noted 
between individual animals and between different tissue groups. Each symbol represents 
the luciferase activity in a 1-cm
2
 tissue sample mapped to a specific anatomical location 
(Fig. 4.2B). The identity of individual fetuses is given and small case designations (“a” 
and “b”) refer to twin fetuses. (A) The level of non-specific luciferase activity detected 
in tissues from control fetuses (n = 4) at 120-125 dg. The cut-off for non-specific 
luciferase activity in each related tissue grouping was defined as the upper 95% CI for 
grouped tissue samples ( ). Fetuses (n = 3) between 120-125 dg were orally injected 
with 0.5 mg (B), 1 mg (C), or 2 mg (D) of luciferase-plasmid in a 1 ml volume of sterile 
saline. The oral mucosa was collected at 72 h post-injection and each sample was 
assayed for luciferase activity. Only those tissue samples with luciferase activity above 
the cut-off ( ) were considered positive for the expression of luciferase protein. 
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with luciferase activity above the cut-off were considered positive. Due to the high 
threshold, the number of samples that tested positive provided a minimum estimate of 
transfection efficiency. Eight of the 9 orally-injected fetuses had between 1 and 5 tissue 
samples that tested positive for luciferase activity (Figs. 4.3B-D) and the dorsal surface 
of the tongue appeared to be the primary site of transfection. A 4-fold increase in 
plasmid dose from 0.5 to 2 mg did not significantly alter transfection efficiency or gene 
expression levels at 72 hpi. Therefore, 1 mg of pMASIA-luc in a 1 ml volume of saline 
was selected as the dose for subsequent transfection experiments.  
 
4.4.4. Duration and Localization of Luciferase Expression 
 Studies were then conducted to determine the location and duration of plasmid 
expression following oral injection of 1 mg of pMASIA-luc into 120-125 dg fetuses. 
Tissues were harvested at 2, 3, 5, 7 and 11 dpi and tested for luciferase activity. 
Luciferase activity was detected on all days assayed (Table 4.1). To determine if there 
was an overall increase in luciferase expression with time, the total ULA was calculated 
for each fetus and expressed as a value relative to the mean total ULA of the 4 control 
fetuses: ∑injected fetus (ULA1,…,ULA48) / meann=4 [∑control #1(ULA1,...,ULA48),…,∑control 
#4(ULA1,…,ULAn)]. At 2 and 3 dpi, there was a median 2.1-fold increase in luciferase 
activity relative to control fetuses (Fig. 4.4). This increased to 6.2-fold between 5 and 11 
dpi. To determine if there was a significant increase in luciferase activity over time, a 
regression analysis was performed and a significant correlation (p<0.05, r
2 
= 0.44) was 
observed between duration of transfection and luciferase levels. These observations 
support the conclusion that there was sustained luciferase expression following oral 
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 Table 4.1. Localization of luciferase expression in fetal tissues following oral 
injection with 1 mg of luciferase-plasmid at 120-125 days gestation. 
 
1
 Fetuses with the same numerical designation followed by “a” or “b” refer to twins.  
2
 Tissues were sampled in 1-cm
2
 sections mapped to specific anatomical loci (Fig. 4.2B). 
3
 Background was defined as luciferase activity below the upper  95% CI as determined by 
grouped tissues from age-matched control fetuses (n=4). 
4
 The total number of 1-cm
2
 sections comprising a tissue group. 
5
 Lymphoid tissues with luciferase activity are indicated: retropharyngeal lymph nodes (RPh), 
superficial cervical lymph node (SCv), palatine tonsils (T). 
6
 The presence of luciferase activity was tested for in tissues that were not specifically targeted 
by oral delivery: liver (Lv), lung (Lg), ear (E). Ear samples were tested from fetuses 112b, 119 
and 120. 
Days 
post-
injection 
Fetus
1
 
Number of tissues sections
2 
with luciferase activity > background
3 
Tongue 
(10)
4
 
Lips 
(14) 
Upper 
palate 
(5) 
Lower 
palate (6) 
Lymph 
tissues
5 
(3) 
Subcut. 
Oral 
(2) 
Control
6
 
(3) 
2 
116 1 3 0 0 0 0 0 
117a 4 0 0 0 0 1 0 
117b 0 0 0 0 0 0 0 
3 
102a 1 0 1 0 0 0 E 
102b 1 1 1 0 0 0 0 
103b 0 1 0 0 0 0 0 
113 3 4 3 2 SCv 0 0 
5 
112a 10 6 2 2 SCv 2 Lv, E 
112b 2 2 3 2 RPh 1 0 
5
 
 
7 
118 2 4 3 1 T, SCv 1 Lg 
121 2 8 3 4 T, SCv 0 0 
122 5 6 3 3 
T, SCv, 
RPh 
1 Lv, Lg 
11 
119 4 5 4 1 
T, SCv, 
RPh 
1 Lv, Lg 
5
 
120 3 8 2 2 - 0 Lv, Lg 
5
 
123 9 13 5 1 RPh 0 Lv, Lg, E 
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Figure 4.4. Total luciferase activity in individual fetuses at various times 
following a single oral injection of plasmid. 
 The total luciferase activity in an individual fetus increased with time for a 
minimum of 11 days. Fetuses were orally injected with 1 mg of luciferase-plasmid in 1 
ml of saline at 120-125 dg. Data shown is the sum of luciferase activity in all tissue 
sections collected from individual fetuses expressed as a value relative to the mean total 
luciferase from four age-matched controls. 
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injection of plasmid; however, the number of samples falling outside the 95% CI (5/15) 
suggested a significant variation in transfection efficiency among individual fetuses. 
 Localization of plasmid expression was determined by assaying luciferase 
activity in individual tissue samples collected from the oral cavity and adjacent tissues. 
On 2 and 3 dpi, 27 of the 29 samples with detectable luciferase activity localized to the 
anterior aspects of the oral cavity, specifically the lower lip and anterior regions of the 
tongue (Table 4.1). These data were consistent with the previous data collected at 72 hpi 
(Fig. 4.3). Throughout all experiments, the tongue and lips were consistently the tissues 
with the highest levels of luciferase expression with respect to both total ULA per cm
2
 
section and the percentage of tissue samples testing positive. By 5 dpi, luciferase activity 
was detectable in all tissues and tissue groups tested, including the upper and lower 
palate, lymphoid tissues and liver or lung in some fetuses. At 7 dpi, luciferase activity 
was detected in the palatine tonsils (4/15 fetuses), which sample material in the oral 
cavity. Luciferase activity was also detected in the SCv (6/15) and medial 
retropharyngeal (4/15) LNs, which drain the oral cavity (Schwartz-Cornil, Epardaud et 
al. 2005), starting at 3 and 5 dpi, respectively. Luciferase activity in these LNs may 
reflect drainage of either plasmid or protein via lymphatics from the sites of transfection. 
Detection of luciferase activity in tissues not directly exposed to plasmid or lymph, such 
as the liver (5/15) and oral tissues deep to the frenulum (5/15), may be more consistent 
with a systemic distribution of luciferase protein.  
A total of 14 of 15 fetuses (93%) had detectable levels of luciferase in sampled 
tissues. Only fetus 117b, which had the lowest level of total luciferase activity (1.5 times 
control; Fig. 4.4), lacked tissue samples with luciferase activity above threshold. 
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Possible explanations for this lack of detection include a failure in plasmid delivery or 
insufficient time between plasmid injection and tissue collection at 48 hours. During in 
utero oral injection studies, we observed through the amniotic membrane that fluid 
streamed out of the oral cavity in a dorso-caudal direction (data not shown). This 
dispersion of plasmid, immediately following delivery, may explain the apparent failure 
of delivery in fetus 117b and also the detection of luciferase activity in tissue collected 
from the ears of fetuses 102a, 112a and 123. 
   
4.4.5. Oral Delivery of Plasmid in Newborn Lambs 
 The mucosal delivery of DNA vaccines or DNA plasmid has required the use of 
a variety of delivery vehicles (Roy, Mao et al. 1999; Loehr, Willson. et al. 2000; Chen, 
Yang et al. 2004). Therefore, the effective delivery of naked DNA plasmid to the fetal 
oral mucosa (Gerdts, Babiuk et al. 2000; Gerdts, Snider et al. 2002) suggests that the 
fetus may represent a unique opportunity for the delivery of DNA vaccines. To test this 
hypothesis, newborn lambs were orally injected with naked DNA plasmid encoding the 
gene for BHV-1 tgD. This plasmid had previously been used to induce detectable 
immune responses following oral injection in fetuses (Gerdts, Babiuk et al. 2000; 
Gerdts, Snider et al. 2002) and detectable immune responses and immune memory in 
newborn lambs following ID injection (van Drunen Littel-van den Hurk, Braun et al. 
1999). Newborn lambs between 0-3 days of age (n=5 per group) were immunized as 
shown in Table 4.2. 
 Only lambs that were immunized ID had a significant increase in tgD-specific 
antibody titers on 21 dpi (Fig. 4.5A). On day 28, all lambs were administered a second  
 125 
 
 
 
 
Table 4.2. Oral DNA injection in neonatal lambs aged 0-3 days. 
Group 
n 
 
Day 0 Day 28 
Treatment Route Treatment Route 
1 - negative control 5 Saline ID1 Saline ID1 
2 – positive control 5 0.5 mg pSLIA-tgD ID1 0.5 mg pSLIA-tgD ID1 
3 5 0.5 mg pSLIA-tgD Oral 0.5 mg pSLIA-tgD ID1 
4 5 2.5 mg pSLIA-tgD Oral 0.5 mg pSLIA-tgD ID1 
5 - negative control 5 Saline ID1 0.5 mg pSLIA-tgD ID1 
  
1 Intradermal injection was in the left ear. 
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Figure 4.5. Oral immunization of newborn lambs with tgD-plasmid.  
 
 Oral DNA immunization with tgD-plasmid did not result in the induction of 
detectable tgD-specific antibody titers, suggesting that plasmid transfection and 
expression may not have occurred. A positive correlation between age and magnitude of 
primary antibody titers was also noted. (A) Oral DNA immunization failed to induce a 
detectable immune response in newborn lambs. All lambs were immunized as shown in 
Table 4.2. Antibody titers for each group were compared with the age-matched 
PBS/PBS control group. (B) The primary tgD-specific antibody response induced by 
tgD-plasmid was significantly lower in newborn lambs (0-3 d of age) than lambs 
immunized at 28 d of age. Newborn (n = 5) and 28-day old lambs (n = 10) were 
immunized by injecting 0.5 mg of tgD-plasmid ID in the ear. Age-matched control 
lambs (n = 5) received an ID injection of 500 μl of saline. Peak tgD-specific serum 
antibody titers were detected at 3 weeks post-immunization. p<0.001 (***). 
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(Fig. 4.5)
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ID DNA immunization to determine if the lack of detectable antibody responses in the 
orally-immunized group was the result of tolerance to the antigen. All lambs that had 
received a primary oral-immunization (Groups 3 and 4) responded to the secondary ID 
immunization with a significant increase in tgD-specific antibody titers. The delayed  
kinetics of this response was characteristic of a primary antibody response, suggesting 
that primary oral immunization had induced neither immune tolerance nor sufficient 
immune memory to support an anamnestic response. 
 On days 35 and 49, there were no significant differences in tgD-specific titers 
between groups that had received either one or two ID immunizations (Fig. 4.5A). The 
apparent lack of anamnestic responses in the ID/ID group suggested that either immune 
memory was lacking, or that the magnitude of the primary immune response may 
increase with age. To differentiate between these possibilities, newborn (1-3 day old) 
and 28 day old lambs were administered identical primary ID DNA immunizations and 
tgD-specific immune responses were monitored weekly. Lambs immunized at 28 days 
of age achieved significantly greater tgD-specific IgG titers than lambs immunized at 
birth (Fig. 4.5B).  
 Overall, these data show that oral DNA delivery failed in the neonate. As these 
data also showed the capacity of newborn lambs to respond to DNA immunization, it is 
likely that transfection failed or that the level of protein expression in the newborn lamb 
was insufficient to induce a detectable immune response.  
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4.4.6. Structural Differences in Fetal Versus Newborn Oral Epithelium  
 The failure of oral DNA immunization in the neonate (Fig. 4.5A) suggested that 
oral transfection with naked DNA might be limited by developmental changes in the 
mucosal epithelium. The histological structure of the oral mucosal epithelium was 
examined in 100 dg fetuses, 140 dg fetuses and 3 day old lambs. All tissue sections were 
obtained from the dorso-rostral surface of the tongue, which corresponded to the region 
with the highest rate of DNA transfection in utero (Table 4.1). At 100 dg, the mucosal 
epithelium consisted of stratified squamous epithelium with nucleated cells present in 
the superficial-most layers (Fig. 4.6A). At 140 dg, there was an increase in keratinization 
and localized areas of cornification were noted (Fig. 4.6B). By 3 days post-partum, the 
stratum corneum was continuous, with sloughing of superficial layers and the presence 
of filiform papillae (Fig. 4.6C). Thus, there were marked structural changes in the 
mucosal epithelium following birth that might create a barrier between nucleated 
epithelial cells and the oral cavity.  
 The prolonged detection of luciferase activity in the oral mucosa (Fig. 4.4) also 
suggested that the rate of epithelial cell turnover might have a major impact on the 
duration of gene expression. Therefore, tissue sections from the dorso-rostral surface of 
the fetal and newborn tongue were stained for the Ki67 antigen as a measure of 
epithelial cell proliferation. Immunohistochemical staining revealed that fewer than 7% 
of basal epithelial cells had entered the S- to M-phase of the cell cycle in 100 dg (Fig. 
4.6D) and 140 dg fetuses (Fig. 4.6E). Less than 1% of basal epithelial cells were visibly 
stained with Ki67 in newborn lambs (Fig. 4.6F). The low level of Ki67 staining was 
consistent with previous reports of a much lower rate of epithelial cell turnover in the 
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Figure 4.6. Histological comparison of oral mucosal epithelium in fetal and 
newborn lambs.  
 
 The oral mucosal epithelium at 100 dg is characterized by a large number of 
nucleated cells located in the upper-most strata, a lack of desquamation and moderate 
staining for nuclear proliferating antigen (Ki67). With increasing age, there is a decrease 
in the number of nucleated cell at the superficial most strata, an increase in 
desquamation and a decrease in cellular proliferation. The dorso-rostral surface of the 
tongue was collected from 100 dg fetuses (A,D), 140 dg fetuses (B,E) and 3 day old 
lambs (C,F). Tissues were formalin-fixed and stained with either hematoxylin and eosin 
(A-C) or monoclonal antibody specific for the Ki67 antigen (D-F). Examples of Ki67
+
 
cells () and melanocytes () are indicated. 
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fetal lamb when compared to adult animals (Smeaton and Simpson-Morgan 1985) and 
was also consistent with the persistent expression of luciferase in mucosal epithelium 
collected from the surface of the tongue and lips (Table 4.1). 
 
4.5 Discussion 
 Successful fetal vaccination has been reported following IM injection of naked 
DNA plasmid into porcine fetuses (Fazio, Ria et al. 2004) and oral delivery of naked 
DNA plasmid into fetal lambs (Gerdts, Babiuk et al. 2000; Gerdts, Snider et al. 2002). 
There are also reports of naked plasmid delivery by a variety of methods to mucosal 
surfaces in adult animals, but in most cases plasmid delivery failed or resulted in low 
levels of transfection and/or expression and failure to induce detectable immune 
responses (Roy, Mao et al. 1999; Chen, Yang et al. 2004). In contrast, the present study 
confirmed that delivery of naked DNA plasmid to the fetal oral cavity resulted in 
transfection of the mucosal epithelium. Furthermore, recombinant protein could be 
detected in a wide variety of tissues that were not directly exposed to DNA plasmid 
(Table 4.1). This observation indicates that oral delivery of DNA plasmid may provide 
an effective method for both mucosal and systemic delivery of a recombinant protein. 
The current study indicates, however, that effective DNA transfection of the oral mucosa 
is restricted to the fetus.  
Properties unique to the fetal oral mucosa appear to be critical for transfection by 
naked DNA plasmid. This was revealed by the ex vivo transfection of oral mucosa with 
naked luciferase-plasmid formulated in saline (Fig. 4.1) and the failure to induce a 
detectable immune response to the plasmid encoded protein following oral delivery of 
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naked DNA plasmid in newborn lambs (Fig. 4.5). Histological examination of the 
mucosa on the dorsum of the tongue revealed major structural changes during fetal 
maturation and immediately following birth (Fig. 4.6). The stratum corneum is the 
principal barrier of the oral mucosa (Smeaton and Simpson-Morgan 1985), and its 
thickness is inversely proportional to its permeability (Loehr, Willson. et al. 2000). 
Thus, we hypothesize that efficient DNA transfection was attributed to the presence of 
nucleated cells in the superficial layer of oral mucosal epithelium, lesser keratinization 
and a lower rate of epithelial cell turnover. The low frequency of Ki67-positive basal 
epithelial cells in the fetal oral mucosa (Fig. 4.6) is consistent with a low rate of 
epithelial cell turnover (Smeaton and Simpson-Morgan 1985), and this may be a critical 
factor contributing to the sustained expression of plasmid DNA in the fetus (Fig. 4.4). If 
the immature structure of the mucosal epithelium is critical for DNA transfection 
competence, then it may be possible to extend DNA delivery to much earlier periods of 
fetal development without compromising the efficiency of vaccine delivery. 
 We were unable to directly demonstrate DNA transfection of mucosal epithelial 
cells with either PCR or immunohistochemical staining for luciferase (data not shown). 
Other plasmid delivery studies, using either hypotonic shock (Lemoine, Farley et al. 
2005) or gene gun-mediated delivery (Loehr, Willson. et al. 2000), have suggested that 
the basement membrane is an effective barrier to DNA plasmid and that transfection is 
limited to epithelial cells. Previous studies have also found that DNA plasmid is rapidly 
degraded in fetal fluid so there is a limited time for plasmid uptake in the oral cavity 
(Gerdts, Snider et al. 2002). Also, luciferase has a short half-life of 3-4 hours in 
mammalian cells (Leclerc, Boockfor et al. 2000). Thus, the persistent detection of 
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luciferase activity in the oral mucosa (Fig. 4.4) is consistent with sustained protein 
expression at this site. Lymphatic drainage from the mucosal epithelium may then 
account for the detection of luciferase activity in a wide variety of tissues, such as LNs 
and liver, which are not directly exposed to plasmid (Table 4.1). Future studies should 
also include a survey of the thymus, since the presence of a foreign protein in this tissue 
may have important implications for the possible induction of immune tolerance.  
 Although the luciferase assay had a relatively low sensitivity due to high tissue-
specific thresholds, successful plasmid delivery was detected in 14 of 15 (93%) treated 
fetuses. This exceeded the 80% success rate that had been reported by Gerdts et al. 
(2000, 2002) in which immune responses were used to monitor plasmid delivery. The 
difference between luciferase expression and the induction of an immune response may 
be explained by a level of gene expression which is insufficient to induce a detectable 
immune response. Marked variation in transfection efficiency among individual fetuses 
was observed throughout ex vivo (Fig. 4.1) and in vivo experiments (Fig. 4.3). The 
absence of a detectable immune response following oral immunization of the neonate 
(Fig. 4.5) may, therefore, be explained by either a failure in plasmid transfection of the 
oral mucosa or limited plasmid expression due to increased shedding of mucosal 
epithelial cells (Fig. 4.6). The current study also demonstrated that the neonate had a 
reduced capacity to respond to DNA vaccination (Fig. 5B) and this reduced immune 
competence may also apply to the fetus. The risks associated with fetal oral DNA 
vaccination will dictate that very efficient and consistent delivery methodologies be 
identified before considering this procedure for clinical application.  
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4.6. Conclusions 
 Oral transfection and expression by naked plasmid DNA appears to be specific to 
the fetus. The majority of gene expression was localized to the oral mucosal epithelium 
but luciferase assays provided evidence that foreign protein could be detected in a wide 
variety of anatomical sites, including LNs draining the oral cavity. A comparison of fetal 
and neonatal oral mucosal histology supports the conclusion that prolonged plasmid 
expression may be dependent upon both a lack of epithelial cell differentiation and a low 
rate of basal cell proliferation in the fetus. Furthermore, a combination of high levels of 
transgene expression with prolonged plasmid expression may be critical to ensure the 
induction of an immune response by the immature fetal immune system.  
 
4.7 Acknowledgements 
 We wish to thank the VIDO Animal care staff for assisting with all aspects of 
animal care and experimentation and special thanks goes to Sherry Tetland for 
overseeing animal experiments. We also thank Andy Hanson and Real Lepage for 
breeding of ewes, Dr. Colin Palmer for ultrasound diagnosis of pregnancy, Dr. Shawn 
Babiuk for laboratory assistance and Juliane Deubner for preparing the illustrations. This 
work was funded by a grant from the Canadian Institutes of Health Research and the 
Canada Research Chair in Vaccinology awarded to Dr. L.A. Babiuk. This manuscript is 
published with the permission of the director of VIDO as manuscript no. 443.   
 135 
 
 
CHAPTER 5 
 
ORAL DNA IMMUNIZATION IN THE SECOND TRIMESTER FETAL LAMB 
AND SECONDARY IMMUNE RESPONSES IN THE NEONATE
1
 
 
5.1. Abstract  
 We previously demonstrated that oral DNA vaccination of the third trimester 
fetus may be an effective strategy to prevent vertical disease transmission despite an 
immature immune system and the possibility of developing tolerance. The present 
investigation examined oral DNA vaccine delivery and immunogenicity in the second 
trimester fetal lamb (50-100 dg). First, we examined the efficiency of oral delivery of 
DNA plasmid in the second trimester. Histological examination revealed the presence of 
nucleated cells in the superficial layers of the oral mucosa. Luciferase-encoding DNA 
plasmid was then injected into the oral cavity of 65-70 dg fetuses to monitor plasmid 
expression. Luciferase activity was detected in the oral mucosa of all fetuses, but the 
level of luciferase activity varied among individual fetuses. Luciferase activity was also 
detected within the tonsils and LNs draining the oral cavity. Oral DNA immunizations 
were then conducted in fetuses between 55 and 83 dg. Immunization with a tgD-
encoding plasmid induced GCs in draining LNs and detectable tgD-specific serum 
antibody titers and/or IFN -secreting cell responses in 16 of 24 (67%) fetuses. TgD-
                                                 
1
 Published as: Tsang C, Mirakhur KK, Babiuk LA, Griebel PJ. 2007. Vaccine 25: 8469-8479.  
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specific antibody and IFN -responses persisted until birth in some fetuses but the 
magnitude of antibody titers in second trimester fetuses was low relative to antibody 
titers induced following oral DNA immunization in the third trimester. Lambs 
immunized during the second trimester of gestation responded to neonatal DNA 
immunization and anamnestic responses were detected in some lambs immunized as 
early as 67–72 dg. These observations confirmed that oral DNA immunization of the 
early second trimester fetus induced antigen-specific immune responses with no 
evidence of tolerance induction. 
 
5.2. Introduction 
 Fetal vaccination is a potential method of preventing vertical transmission of 
diseases, such as HIV or hepatitis B, and the immune protection afforded by fetal 
immunization might be further enhanced if carried out at the earliest possible fetal age; 
however, advances in the field of fetal immunization have been hindered by the dogma 
that exposure of the fetal immune system to antigen results in the induction of immune 
tolerance (Billingham, Brent et al. 1953). This is despite studies in large animal models 
which document the induction of primary immune responses in fetuses following 
immunization or infection in the second (Silverstein, Uhr et al. 1963; Otsyula, Miller et 
al. 1996; Buxton, Maley et al. 1998; Kennedy, McCullough et al. 2001; Buxton, 
Anderson et al. 2002) and third trimesters of gestation (Fennestad and Borg-Petersen 
1957; Richardson and Connor 1972; Watts, Stanley et al. 1999; Gerdts, Babiuk et al. 
2000). Gerdts et al. (2000; 2002) confirmed that fetal lambs during the mid-third 
trimester of gestation could be orally immunized with a single injection of naked DNA 
 137 
plasmid encoding BHV-1 tgD. This oral DNA immunization induced both humoral and 
CMI responses and immune memory which persisted in the neonate.  
 Many fetal immunization studies have been conducted using the fetal lamb 
model due to developmental similarities between the ovine and human immune systems. 
In both species, thymic colonization and T cell development occur in the first trimester 
of gestation and this is followed by T and B cell population of peripheral lymphoid 
tissues, such as the spleen and LNs (Ohama and Kaji 1974; Anderson, Bird et al. 1981; 
Griebel 1998; Riley 1998; Al Salami and Filippich 1999; Cahill, Kimpton et al. 1999; 
Hein and Griebel 2003). In a series of seminal studies on immune competence in the 
fetal lamb, 67-70 dg (gestational length is 148 days) was identified as the earliest time at 
which the fetus generated a specific immune response to a foreign antigen (Silverstein, 
Uhr et al. 1963; Silverstein and Prendergast 1964). The concept of a pre-immune period 
during fetal development is also supported by experiments which showed that allogeneic 
cells were tolerogenic in the fetal lamb prior to 60-65 dg (reviewed by Almeida-Porada, 
Porada et al. 2004). The pre-immune fetal period has been defined on the basis of studies 
conducted with allogeneic stem cells and antigens expressed by retroviral vectors that 
can infect the thymus (Porada, Tran et al. 1998; Tran, Porada et al. 2001). These studies 
may not, however, reflect immune responses induced by oral immunization, which 
delivers antigen to peripheral lymphoid tissue. 
 In this study, we hypothesized that in utero oral DNA immunization could 
induce an antigen-specific immune response as early as 55-60 dg. At this age, T and B 
cells have recently appeared in the spleen and peripheral LNs (Symons and Binns 1975; 
Griebel 1998). A previous study has also suggested that plasmid delivered to the fetus 
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per os results in transgene expression primarily in the oral cavity (Gerdts, Babiuk et al. 
2000). Furthermore, the immunostimulatory effects of bacterial DNA in the plasmid 
backbone (reviewed in Mutwiri, Pontarollo et al. 2003) might overcome developmental 
tolerance. Since the ovine placenta effectively blocks transfer of maternal antibodies to 
the fetus (Needham 1931), there should be no pre-existing antibodies to interfere with 
the induction of an immune response. Thus, the duration and magnitude of the primary 
immune response and immune memory in the fetus should be influenced only by the 
primary immunization event.   
 
5.3. Materials and Methods 
 
5.3.1. Animals 
 Vaginal progesterone sponges (Veramix , Pharmacia & Upjohn, Orangeville, 
ON) were used to synchronize estrus in Suffolk ewes. Rams were then introduced into 
the flock for a period of 5 days, thus allowing determination of the gestational age of the 
fetus within +2.5 days. Pregnancies were confirmed by assays for serum progesterone 
levels (Prairie Diagnostic Services, Saskatoon, SK) and rectal ultrasound at 42 dg. Blood 
was collected from ewes at the time of fetal surgery and also at parturition, and serum 
was tested for the presence of tgD-specific antibody titers.  Ewes did not have tgD-
specific serum antibody titers at any time.  All animals were randomly assigned to 
experimental groups.  All experiments were conducted in accordance to the Canadian 
Council on Animal Care Guidelines. 
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5.3.2. DNA plasmid preparation 
 The plasmid pSLIA-tgD contains the gene for BHV-1 tgD which is a 61-kDa, 
secreted glycoprotein (van Drunen Littel-van den Hurk, Braun et al. 1999). The empty 
pSLIA vector was used as a control plasmid for fetal immunization experiments. 
pMASIA-luc contains the gene for firefly luciferase (Uwiera, Rankin et al. 2001). The 
immediate early promoter/1A-region from human cytomegalovirus was located 
upstream of both the tgD and luciferase genes. Plasmids were grown in E. coli DH5α 
and purified using the Endo-Free™ Plasmid Giga Kit (Qiagen, Mississauga, ON). 
Purified plasmids were resuspended in endotoxin-free Dulbecco’s phosphate buffered 
saline (Sigma-Aldrich, St. Louis, MO) and the endotoxin activity in each plasmid 
preparation was assessed using the QCL-1000 Limulus Amebocyte Lysate Kit 
(BioWhittaker Inc. Walkersville, MD). Endotoxin activity was <0.01 EU/ml in all 
samples, which is below the minimum threshold required to induce mitogenic 
stimulation of ovine leukocytes (Burrells and Wells 1977). 
 
5.3.3. Fetal immunization 
 Fetal surgeries were performed at defined gestational periods during the second 
trimester. Briefly, ewes were pre-medicated with acepromazine and butorphanol and 
anaesthesia was induced using sodium Pentothal (Abbott Labs, Guelph, ON) and then 
maintained with isoflurane in oxygen. Ewes were maintained on IV fluid therapy and 
assisted ventilation throughout anesthesia and positioned in dorsal recumbency. Access 
to the fetus was achieved by exposing the uterus through a midline abdominal incision. 
The myometrium and chorion were incised, which made it possible to view the fetus 
 140 
through the intact amniotic membrane. The head of the fetus was manipulated into the 
amniotic bubble (Fig. 5.1A), a 22-gauge catheter was inserted through the amniotic 
membrane into the oral cavity of the fetus (Fig. 5.1B), and sterile saline solution 
containing DNA plasmid was injected into the oral cavity. See Table 5.1 for fetal  
immunization groups. The uterine and abdominal incisions were closed and pregnancy 
allowed to proceed until the time of fetal tissue collection or birth.  
 
5.3.4. Neonatal Immunization 
 IM DNA immunization was performed by injecting 325 μg of pSLIA-tgD 
plasmid into each semimembranous muscle. Where indicated, IM plasmid injection was 
followed immediately by electroporation which was performed as described previously 
(Babiuk, Baca-Estrada et al. 2002). Briefly, lambs were sedated with Pentothal, injected 
IM with plasmid, and then an electrode, with six 23-gauge needles arranged equidistant 
in a 1-cm diameter circle (Genetronics, San Diego, CA), was inserted to a 1-cm depth 
into the muscle such that the electrodes surrounded the DNA injection site. 
Electroporation was performed by delivering 6 pulses of 200 V/ms (5 Hz per pulse). 
 
5.3.5. Antibody Detection 
 Fetal blood was collected by intracardiac puncture and postnatal blood was 
collected from the jugular vein. Blood was collected from newborn lambs prior to 
suckling to avoid possible transfer of maternal antibodies through the colostrum. Blood 
was collected into SST Vacutainer tubes (BD, Oakville, ON) and tubes were centrifuged 
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Figure 5.1. In utero oral DNA immunization in the second trimester fetal lamb at 
55-60 days gestation.  
 
Head of the fetus visualized within the amniotic bubble (A). Insertion of a catheter 
through the amniotic membrane, into the oral cavity (B).  
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Table 5.1. Immunization groups. 
  
Exp 
Age of fetus at 
time of in utero 
immunization 
Group n 
Fetal 
immunization 
Neonatal 
immunization 
(2 weeks of age) 
1 65-70 dg Immunized 10 0.5 mg pMASIA-
luc 
 
Control 3 No treatment  
2 55-60 dg Immunized 13 1 mg pSLIA-tgD  
Control 8 1 mg pSLIA-null  
120-125 dg Immunized 2 1 mg pSLIA-tgD  
Control 3 1 mg pSLIA-null  
3 67-72 dg Immunized 4 1 mg pSLIA-tgD 650 μg pSLIA-tgD 
(IM) 
+ electroporation 
Control 4 No treatment 650 μg pSLIA-tgD 
(IM) 
+ electroporation 
78-83 dg In-Utero 7 1 mg pSLIA-tgD 1 mg pSLIA-tgD (IM) 
Primary 5 1 mg pSLIA-null 1 mg pSLIA-tgD (IM) 
Naïve 4 No treatment No treatment 
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 to isolate serum. The ELISA for the detection of tgD-specific antibodies has been 
previously described (van Drunen Littel-van den Hurk, Gifford et al. 1990). Briefly, 
serum was diluted using a 2-fold dilution series, starting with neat serum, and applied to 
Immulon-2 96-well plates (Dynex Labs Inc, Franklin, MA) that had been coated with 
0.5 g/ml of purified recombinant tgD. Bound antibodies were detected using 
phosphatase-labeled rabbit anti-sheep IgG (H+L) (Kirkegaard-Perry Labs, Gaithersburg, 
MD) and 100 mg/ml p-nitrophenyl phosphate in 1% diethanolamine, 0.5 mM MgCl2 
(pH 9.8). All titers were expressed as the reciprocal of the highest serum dilution to give 
a positive reaction. The threshold for a positive response was defined as the mean titer 
plus 2 SD of age-matched control fetuses. The biological relevance of this cut-off with 
respect to BHV-1 protection has been previously established (van Drunen Littel-van den 
Hurk, Gifford et al. 1990). All tgD-specific antibody titers were determined within the 
same assay with the exception of data presented in Figure 5.3A, which was obtained 
using a different lot of recombinant tgD protein to coat wells in the ELISA plates.  
 
5.3.6. Detection of Interferon (IFN)- -responses 
 Peripheral blood mononuclear cells and splenocytes were purified as previously 
described (Ioannou, Griebel et al. 2002b). The number of tgD-specific IFN -secreting 
cells was assayed using a modified enzyme-linked immunospot assay. Microtiter 
nitrocellulose filtration plates (Polyfiltronics, Rockland, MS) were coated with 2.5 
g/ml of anti-bovine IFN  monoclonal antibody (clone 2.2.1A; IgG1 isotype). One 
million cells were added to triplicate wells in a final volume of 200 l of media alone 
(AIM-V media plus 2% heat inactivated FBS (InVitrogen, Burlington, ON)), media with 
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5 g/ml tgD or media with 20 g/ml concanavalin A (Sigma-Aldrich, Oakville, ON). 
Captured IFN  was visualized with rabbit anti-bovine IFN  antisera and biotinylated-
goat anti-rabbit IgG (H+L) (Zymed Laboratories, San Francisco, CA). The number of 
tgD-specific IFNγ-secreting cells was expressed as the difference between the mean 
number of spots per 10
6
 cells from triplicate tgD-stimulated cultures minus the mean 
number of spots per 10
6
 cells from triplicate cultures in medium alone. The threshold for 
determining tgD-specific IFN -responses was calculated as the mean number of spots 
plus 2 SD for age-matched naïve animals.  
 
5.3.7. Luciferase Assay 
 The mucosal epithelium and submucosa were collected from the oral cavity and 
oropharynx in 1-cm
2
 samples mapped to specific anatomical loci. Samples were also 
collected from the liver, lungs, ears and LNs draining the oral cavity. Frozen tissues 
were minced in liquid nitrogen, homogenized, and then assayed for luciferase activity 
using the Luciferase Assay System (Promega, Madison, WI). The lower detection limit 
of the assay using the Packard Picolite  Luminometer (United Technologies Packard, 
Palo Alto, CA) was 100 pg as determined from a standard curve constructed using 
QuantiLum® Recombinant Luciferase (Promega). The luciferase activity in each 1-cm
2 
tissue sample was expressed as units of luciferase activity per mg of protein (ULA). 
Total protein per sample was determined using the Bradford assay (BioRad, Hercules, 
CA). The cut-off for non-specific luciferase activity in a specific tissue or tissue group 
was calculated as the upper 95% CI for the corresponding tissue samples collected from 
three age-matched, control fetuses.  
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5.3.8. Histology 
 Tissues were fixed in 10% buffered formalin and submitted to Prairie Diagnostic 
Services for staining with hematoxylin and eosin and immunohistochemical staining 
with monoclonal antibody for the detection of Ki67 nuclear antigen (clone MIB-1; 
InVitrogen).  
 
5.4. Results 
 
5.4.1.  Plasmid Transfection and Expression in the 65-70 dg Ovine Fetus 
 Transfection studies were conducted to confirm that oral injection would be an 
effective method for delivering naked DNA plasmid in the second trimester fetus. 
Luciferase-plasmid was injected into the oral cavity of fetuses between 65-70 dg and the 
sites of plasmid expression and expression levels were determined. This age of fetal 
gestation was selected since it has been reported that this is the interval during which the 
ovine fetus acquires immunological competence (Silverstein, Uhr et al. 1963). 
Luciferase plasmid was injected into the oral cavities of 10 fetuses. The cut-off for non-
specific luciferase activity in the fetal oral cavity was determined from 3 untreated, age-
matched fetuses.  
 At 24, 48 and 72 hours post-injection (hpi), luciferase activity was detected in the 
oral cavity of fetuses injected with pMASIA-luc (Fig. 5.2). There was considerable 
variation among individual fetuses with respect to the number of tissue samples with 
positive luciferase activity and the level of luciferase activity at specific anatomical 
locations. The tongue was, however, the primary site of luciferase expression with the  
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Figure 5.2.  Luciferase expression in the oral cavity of the second trimester fetus.  
 
 Transgene activity was detected in all fetuses and localized primarily to the 
mucosal epithelium of the tongue and rostral-most aspects of the oral cavity. Fetuses 
(65-70 dg; n=10) were orally-injected with 0.5 mg of luciferase-plasmid. Tissues were 
then collected in 1 cm
2 
samples, with each sample corresponding to a specific 
anatomical locus, and the luciferase activity measured. The distribution and level of 
luciferase activity in the oral cavities and lymph nodes of injected fetuses at 24 (n=3; A), 
48 (n=4; B) and 72 (n=3; C) hours post-injection. Each data point represents the 
luciferase activity/mg of total protein in an individual 1 cm
2
 tissue sample. The identities 
of fetuses are shown in the legends. The horizontal bar ( ) indicates the upper 95% CI 
of luciferase activity in all samples comprising the same anatomical grouping in 3 age-
matched control fetuses. Abbreviations: retropharyngeal lymph nodes (RPh LNs), 
superficial cervical lymph nodes (SCv LNs). 
 147 
 
                                              
  
 
(Fig. 5.2) 
A. 24h 
 
 
 
 
 
 
 
 
B. 48 h 
 
 
 
 
 
 
 
 
C. 72 h 
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highest frequency of positive samples and the highest levels of luciferase activity within 
individual samples. Furthermore, a significant level of luciferase activity was detected in 
a minimum of one tissue sample/tongue from all injected fetuses. The total luciferase 
activity in the tongue of each fetus was determined and linear regression analysis was 
used to determine if there was a change in the amount of luciferase expression over time.  
Due to variation among individual animals within each group, there was no significant 
increase or decrease in luciferase activity between 24 to 72 hpi.  
  Luciferase activity was also detected in the lips, upper palate and lower palate. 
The detection of luciferase activity in samples of chin (6/10 fetuses) and ear (3/10 
fetuses) was consistent with the observation that fluid frequently streamed out of the oral 
cavity immediately following plasmid injection. Luciferase activity was also detected in 
the tonsils, LNs draining the oral cavity and liver of four fetuses.  
 At all times examined, there was considerable variation among fetuses in the 
number of oral mucosal samples with detectable luciferase activity, and the level of 
luciferase activity per tissue sample. When the total luciferase activity (i.e., sum of 
luciferase activity in 29 tissues samples) was calculated for each injected fetus (n=10) 
and expressed as an increase in total luciferase activity relative to control fetuses (n=3), 
there was a 2.5- to 100-fold increase in luciferase activity in three fetuses, and a 100- to 
450-fold increase in luciferase activity in four fetuses. In the remaining 3 of 10 fetuses, 
luciferase expression was restricted to very few sites and did not contribute to a 
significant overall increase in total luciferase activity.  
 For transfection to occur, the plasmid must transfect the oral mucosal epithelium 
or bypass this barrier by being ingested or inhaled. Histological examination of the oral 
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mucosa at 65-70 dg revealed that the mucosal epithelium on the dorsal aspect of the 
tongue consisted of 2-3 layers of nucleated cells with a developing stratum corneum 
(Fig. 5.3A). Neither desquamation nor papillae were observed. In contrast, the mucosal 
epithelium on the tongue of a 120-125 dg fetus had differentiated with a thick, anuclear 
stratum corneum and desquamation of epithelial cells (Fig. 5.3B). Thus, histology 
revealed that nucleated cells were available for transfection at the surface of the oral 
mucosa of 65-70 dg fetuses.  
 Overall, these experiments confirmed that injection of 0.5 mg of naked DNA 
plasmid into the oral cavity resulted in the expression of luciferase within the oral 
mucosa and protein was also detected in LNs draining the oral cavity.  
  
5.4.2. Fetal immune responses following oral DNA immunization in the early 
second trimester  
 Low levels of plasmid transfection and expression have been identified as major 
factors limiting the efficacy of DNA vaccination in humans and many other species. The 
detection of luciferase activity in 100% of fetuses that received an oral DNA injection 
on 65-70 dg supported the hypothesis that oral DNA immunization might be extended to 
the second trimester (55-60 dg) of gestation when the spleen and peripheral LNs are 
being populated with lymphocytes (Symons and Binns 1975; Griebel 1998). Fetuses 
were immunized between 55-60 dg (Table 5.1) and tgD-specific serum antibody titers 
were measured at 14, 30 and 50 dpi. A tgD-specific antibody response was detected in 9 
of 13 (69%) immunized fetuses (Table 5.2).  
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Figure 5.3. Mucosal epithelium from the dorsal aspect of the tongue.  
 
 In the second trimester fetus, there are nucleated cells ( ) in the superficial-
most layer of the mucosal epithelium. In the third trimester, the epithelium is more 
differentiated and there is a thick stratum corneum (). Fetuses at 65-70 dg (A) and 
120-125 dg (B). Hematoxylin and eosin (x 40). 
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 The fetus examined at 14 dpi had a tgD-specific serum antibody titer of 27, 
which exceeded the threshold determined from sera collected from 30 dpi control 
fetuses. Examination of the SCv and retropharyngeal LNs from this fetus revealed the  
LNs to be small and gelatinous and there was no demarcation of the cortex from 
medulla. Staining of serial tissue sections for Ki67 nuclear proliferating cell antigen 
revealed individual cells and small clusters of stained cells randomly distributed 
throughout the LNs (data not shown). 
 A tgD-specific antibody response was detected in 3 of 5 fetuses at 30 dpi (Fig. 
5.4A) and 5 of 7 fetuses at 50 dpi (Fig. 5.4B). Ki67-staining of serial sections revealed 
large foci of proliferating cells in the cortex of at least one of the parotid, submandibular, 
retropharyngeal or SCv LNs in all fetuses with elevated antibody titers (Fig. 5.5A). In 
contrast, no proliferating cell foci were detected in LNs collected from control fetuses 
(Fig. 5.5B). Examination of hematoxylin and eosin stained serial sections from the same 
LNs revealed that the Ki67
+
 staining foci were lymphoid follicles with an architecture 
similar to GCs (data not shown). For 7 of the 8 responders (Fig. 5.4), the magnitude of 
the tgD-specific antibody titers was relatively low (i.e., <150) when compared within the 
same ELISA to the serum antibody responses of fetuses orally immunized in the third 
trimester (titers of 561 and 597) or tgD-specific antibody responses following DNA 
immunization in the neonate (see Figs. 5.6C, E). Fetus #54 was an exception with an 
antibody titer of 2461 and tgD-specific IFN -secreting cells following in vitro re-
stimulation of peripheral blood mononuclear cells (data not shown). Also, Ki67
+
 GCs 
were detected in all LNs draining the oral cavity (retropharyngeal, mandibular, parotid 
and SCv LNs) of fetus #54 and these LNs were at least 5-fold larger than the 
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Figure 5.4.   TgD-specific serum antibody responses following oral DNA 
immunization in the early second trimester.  
 
 Oral tgD-plasmid immunization at 55-60 dg resulted in significant tgD-specific 
antibody titers in 3 of 5 and 5 of 7 immunized fetuses at 30 dpi and 50 dpi, respectively.  
There was considerable variation in the magnitude of antibody titers and fetus #54 had a 
markedly elevated titer. Fetuses (55-60 dg) were orally immunized with either 1 mg of 
control- or tgD-plasmid. Total tgD-specific serum antibody titers at 30 dpi (A) and 50 
dpi (B) were measured in two separate ELISAs. The horizontal line ( ) represents the 
mean plus 2 SD of cross-reactive antibody titers from 4 age-matched control fetuses and 
indicates the cut-off for tgD-specific fetal antibody responses (p<0.05).  
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Figure 5.5.  Retropharyngeal lymph nodes from 105-110 dg fetuses stained for 
Ki67 nuclear proliferating antigen.  
 
 Oral immunization with tgD-plasmid resulted in the development of germinal 
centers in lymph nodes draining the oral cavity.  Sections of retropharyngeal lymph node 
from a fetus immunized with tgD-plasmid at 55-60 dg (A) and an age-matched naïve 
fetus (B). Section were stained with with antibody specific for Ki67 nuclear proliferating 
antigen ( ). 
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Figure 5.6. Immune responses in newborn lambs following oral DNA immunization 
at 78-84 days gestation.  
 
 Primary tgD-specific antibody titers were detected at birth in 3 of 7 lambs. 
Primary IFN  responses were also detected in 3 of 6 newborn lambs. Based on earlier 
onset and greater magnitude of antibody responses, anamnestic responses were present 
in 3 fetuses (#184, 197 and 192). Fetal lambs were orally immunized at 78-84 dg with 1 
mg of tgD-plasmid (n = 7). TgD-specific fetal serum antibody titers were measured in 
newborn lambs prior to suckling (A) and tgD-specific IFN  responses were measured in 
peripheral blood mononuclear cells isolated from 3 day old lambs (B). One lamb in the 
in utero-immunized group died between birth and 3 days of age. The horizontal line ( ) 
in A and B represent the mean tgD-specific response plus 2 SD from 5 age-matched 
naïve lambs. The identities of lambs that responded to fetal immunization are given. At 
2 weeks of age, lambs that had been orally immunized at 78-84 dg (In-Utero; n = 6) 
were boosted with an intramuscular injection of 650 μg of tgD-plasmid. Age-matched 
lambs were either immunized with the same protocol (Primary; n=5) or did not receive 
any treatment (Naïve; n = 4). TgD-specific immune responses were assayed weekly and 
the following data are shown: serum antibody titers at 1 wpb (C), IFN -responses at 1 
wpb (D), serum antibody titers at 2 wpb (E) and 8 wpb (F). The horizontal line ( ) in C 
through F represents the mean response plus 2 SD for the Naïve group.  
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corresponding LNs collected from the other 4 fetuses with detectable antibody responses 
at 50 dpi. A medial longitudinal cross-section of the retropharyngeal LN from fetus #54 
contained 43 Ki67
+
 foci but only two Ki67
+
 foci were observed in a medial longitudinal 
cross-section of the retropharyngeal LN collected from fetus #28, which had a tgD-
specific antibody titer of 70. 
 Overall, 69% of fetal lambs responded to oral DNA immunization at 55-60 dg. 
These responses included tgD-specific serum antibody responses and foci of Ki67
+
 cells 
within LNs draining the oral cavity. In one fetus, an IFN -secreting cell response was 
also detected. 
 
5.4.3. Secondary tgD-Specific Immune Responses in the Neonate Following Oral 
DNA Immunization During the Second Trimester 
 To optimize immune protection against vertically transmitted diseases, immune 
effector and memory functions must persist until birth when there is the greatest risk of 
infection. We therefore examined the duration of primary immune responses and 
immune memory following second trimester oral DNA immunization. Fetuses were 
orally immunized with tgD-plasmid at 67-72 dg (Table 5.1), which resulted in a 12 week 
interval between primary immunization and birth. This interval is equivalent to the 
longest duration of a primary antibody response reported following a single DNA 
immunization of young lambs with tgD-plasmid (Tsang, Babiuk et al. 2007). A positive 
tgD-specific serum antibody titer was detected in 1 of 4 newborn lambs that had been 
immunized at 67-72 dg (lamb #253, Table 5.2). At 2 weeks of age, lambs received a 
secondary tgD-plasmid immunization and lambs #253 and #249 displayed tgD-specific 
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antibody titers significantly higher (p < 0.05) than titers detected in age-matched 
controls. One interpretation of these data is that tgD-specific antibody responses and 
immune memory may have waned prior to birth.  
 The interval between primary fetal immunization and birth was reduced to 
determine if waning of immune responses was a significant factor contributing to the 
presence of detectable antibody titers at birth. When fetuses were immunized at 78-83 
dg (Table 5.1), which shortened the interval between immunization and birth to 9.5 
weeks, tgD-specific immune responses were detected in 5 of 7 (71%) newborn lambs; 
significant tgD-specific antibody titers were detected in 3 of 7 lambs (Fig. 5.6A) and 
IFN -secreting responses were detected in 3 of 6 lambs (Fig. 5.6B). Lamb #072 died 
within 24 hours of birth and was not tested for an IFN -secreting cell response. Only one 
newborn lamb (#184) had both tgD-specific antibody and IFN  -secreting responses.  
 A secondary IM tgD-plasmid vaccination was then performed at 2 weeks of age 
(Table 5.1) to determine if anamnestic responses or antigen-specific immune tolerance 
was present in newborn lambs. At the time of DNA boost, there was no significant 
difference in tgD-specific antibody titers among the Naïve, Primary or In-Utero groups 
(data not shown). The response to neonatal DNA immunization was evaluated by 
comparing the serum antibody titers of individual immunized lambs against the mean 
plus 2 SD of serum antibody titers from the Naïve group (p < 0.5). Immunization with 
tgD-plasmid induced tgD-specific antibody and IFN  responses in all immunized lambs 
(Fig. 5.6C-F).  
 To determine if anamnestic responses were present, immune responses of 
individual lambs in the In-Utero group were compared to the mean plus 2 SD of 
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responses in the Primary group (n=5). Immune responses exceeding this value were 
significant (p < 0.05) and considered to be an anamnestic response. At 1 week post-
boost (wpb), anamnestic responses were detected in 2 of 6 In-Utero lambs: lamb #197 
had a significantly increased tgD-specific antibody titer (Fig. 5.6C) and lamb #184 had 
both significantly increased antibody and IFN  responses (Fig. 5.6C, D). Between 2 and 
7 wpb, tgD-specific antibody titers in the In-Utero group were indistinguishable from 
titers in the Primary group. At 8 wpi, tgD-specific antibody titers were significantly 
higher in lambs #184 and 192 (Fig. 5.6F). Collectively, these data suggested that an 
anamnestic response had occurred in 3 of 6 (50%) lambs orally immunized in utero 
during the second trimester. In only one lamb (#184) was there evidence of both 
humoral and cellular anamnestic responses. In addition, all lambs in the In-Utero group 
responded to neonatal DNA immunization with induction of both tgD-specific antibody 
and IFN  responses. This indicated that immunization during the second trimester did 
not induce immune tolerance. 
 
5.5. Discussion 
 In this study, oral DNA immunization was extended from the third to second 
trimester of fetal gestation. The feasibility of second trimester oral DNA immunization 
is dependent upon successful delivery of plasmid to the oral mucosa, transfer of 
plasmid-encoded protein to the draining LNs, the presence of a functional immune 
system, and the induction of a protective immune response rather than immune 
tolerance. In the first part of this study, reporter gene studies were completed which 
confirmed that oral delivery of DNA plasmid could overcome the variety of physical and 
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chemical barriers that reduce transfection efficiency at mucosal surfaces (reviewed by 
Hobson, Barnfield et al. 2003). Oral delivery of luciferase-plasmid to second trimester 
fetuses resulted in the consistent detection of luciferase activity in the oral mucosa and 
protein was detected in the LNs draining the oral cavity (Fig. 5.2). Therefore, oral 
delivery of DNA plasmid appeared to be an effective route of delivery to target protein 
to the peripheral immune system.  
 There was marked variation in the level of luciferase activity detected within the 
oral mucosa of individual fetuses, which indicated that the level of plasmid transfection 
varied among fetuses. Plasmid transfection efficiency may vary as a result of either 
inconsistent oral delivery or differences in the degree of epidermopoeisis or 
keratinization of the mucosal epithelium (Fig. 5.3). The detection of luciferase activity in 
LNs draining the oral cavity is consistent with reports that the peripheral lymphatic 
system becomes functional between 60 and 65 dg (Cahill, Kimpton et al. 1999). 
Furthermore, the presence of GC reactions within the draining LNs and detectable serum 
antibody titers following immunization with tgD-plasmid provided direct evidence for 
protein uptake from the oral cavity. The variable level of luciferase activity in the oral 
mucosa may be correlated with the variation observed for both serum antibody 
responses and the numbers of GCs observed within individual LNs. The percentage of 
fetuses with greater than 2.5-fold increases in total luciferase activity (70%) was similar 
to the frequency of fetuses with detectable tgD-specific antibody responses (67%). This 
observation supports the conclusion that increasing the efficiency of oral plasmid 
delivery may be an effective strategy to improve the consistency of immune responses 
during the second trimester of gestation.  
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 To determine the earliest possible age for fetal DNA vaccination, fetuses were 
immunized starting at 55-60 dg when T and B cells first appear in the periphery 
(Symons and Binns 1975; Press, Hein et al. 1993; Griebel 1998). A tgD-specific 
antibody response was first detected within 14 dpi, which is consistent with the earliest 
reported age of antigen-specific antibody responses in the fetal lamb (Silverstein, Uhr et 
al. 1963). Visible GC reactions were not detected in the retropharyngeal or SCv LNs 
until 30 dpi. The presence of GCs at 30 and 50 dpi, in conjunction with tgD-specific 
antibody titers, confirmed that tgD-specific responses had occurred despite the low 
magnitude of serum antibody responses. These results contrast with other studies where 
delivery of a foreign gene at 55-60 dg, in the context of retroviral vectors, resulted in 
protein expression within the thymus and the induction of antigen-specific immune 
suppression/tolerance (Porada, Tran et al. 1998; Tran, Porada et al. 2001). We 
hypothesize that developmental tolerance in 55-60 dg fetuses was overcome by 
delivering a foreign protein via the oral DNA immunization method, which combines a 
peripheral route of antigen delivery with the immune-stimulatory effects of the bacterial 
DNA backbone (Mutwiri, Pontarollo et al. 2003). The bacterial DNA may function as a 
potent danger signal (Matzinger 2002) or adjuvant within an otherwise sterile fetal 
environment.   
 Oral DNA immunization in the second trimester also induced antigen-specific 
IFN -secreting cell responses in 4 of 24 (17%) lambs despite the reported suppression of 
IFN  responses in the ovine fetus (Buxton, Anderson et al. 2002). The presence of both 
antigen-specific humoral and IFN  responses in two fetuses that were assayed pre-
parturtion and in all lambs that received a secondary neonatal DNA immunization 
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indicated that immune deviation had not occurred following fetal immunization (Ahmed 
1991; Otsyula, Miller et al. 1996). The lack of detectable IFN -secreting responses in the 
majority of fetuses at 69-74 dg or 87-92 dg may reflect a delayed development of cell-
mediated immune responses relative to humoral responses in the ovine fetus (Silverstein, 
Prendergast et al. 1963; Silverstein, Uhr et al. 1963). 
 The duration of fetal immune responses was also examined in this study. Data 
obtained in another study (manuscript submitted) suggests that oral DNA delivery in the 
third trimester fetus resulted in prolonged protein expression which may correlate with a 
relatively low rate of mucosal epithelial cell renewal. Prolonged expression of a foreign 
protein should theoretically sustain and possibly amplify fetal immune responses in the 
absence of cross-reactive environmental antigens. DNA immunization in the second 
trimester did not enhance the magnitude of fetal immune responses but may, instead, 
have influenced the duration of immune responses. GCs were clearly visible at 7 wpi, 
which exceeded the expected 3-5 week period reported for GCs following a single 
protein exposure (Kesmir and De Boer 1999). Also, fetal antibody titers were still 
detectable at 10 wpi  (78-84 dg to birth) and possibly up to 11.5 wpi (67 dg to birth), 
which is comparable to the maximum duration of primary tgD-specific antibody 
responses following a single DNA immunization in young lambs (Tsang, Babiuk et al. 
2007).  
 In postnatal animals, the survival of immune memory cells may be aided by 
exposure to cross-reactive environmental antigens (Gray and Matzinger 1991; Selin, 
Nahill et al. 1994); however, the ovine placenta prevents fetal exposure to most 
environmental antigens (Needham 1931). The exclusion of foreign antigen in control 
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fetuses was confirmed by the absence of tgD-specific serum antibodies and lack of GC 
development within the LNs. Despite the absence of environmental antigens or 
commensal microflora in the intestine, a single oral DNA immunization in the second 
trimester induced immune memory that persisted throughout the 11.5 week interval 
between immunization at 67-72 dg to birth. Thus, the duration of fetal immune 
responses and immune memory was similar to that reported following a single IM 
immunization of newborn lambs with the same tgD-plasmid (Tsang, Babiuk et al. 2007). 
The prolonged immune memory observed following IM DNA immunization was 
attributed to sustained antigen expression within myocytes. Therefore, we hypothesize 
that the persistence of immune memory in immunized fetuses may be a consequence of 
prolonged antigen expression in transfected oral mucosal epithelial cells and the 
effective uptake of this protein by the immune system.  
 The low magnitude of fetal immune responses and the absence of detectable 
immune responses in many neonatnal lambs raises the question of whether fetal immune 
responses can prevent vertical disease transmission. The magnitude of immune 
responses during the second trimester may have been limited by the limited diversity of 
the fetal immune repertoire (Hein, Dudler et al. 1990; Reynaud, Mackay et al. 1991), as 
well as the low number of lymphocytes present in the fetus (Pearson, Simpson-Morgan 
et al. 1976; Hein, Dudler et al. 1990), which restricts the frequency of antigen-specific 
lymphocytes at the time of immunization and limits the magnitude of immune responses 
despite prolonged antigen expression by transfected cells. The occasional fetus 
responded to second trimester DNA immunization with a relatively high serum antibody 
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response (Fig. 5.4B) which suggests that genetic variability may be an important factor 
to consider during in utero immunization.  
In conclusion, this study demonstrated that oral DNA immunization during the 
second trimester of gestation resulted in the induction of antigen-specific humoral and 
CMI responses with no evidence for the induction of immune tolerance. Further studies 
will be required, however, to determine if vaccine-induced fetal immune responses have 
the ability to confer immune-mediated protection against vertical disease transmission.  
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CHAPTER 6 
 
GENERAL DISCUSSION AND CONCLUSIONS 
 
 This thesis addressed the feasibility of DNA vaccination in the second trimester 
fetus. Specifically, the hypotheses being tested were that a DNA vaccine introduced into 
the “preimmune” fetus could induce an immune response and that oral DNA injection is 
an effective method to deliver a foreign antigen into the second trimester fetus. Delivery 
of a DNA vaccine as early as possible in gestation would increase the period of time 
during which the developing immune system is exposed to the antigen. This would 
potentially result in the continued induction of fetal immune responses for as long as the 
antigen persisted, thus increasing both the magnitude and duration of the primary 
immune response. The presence of a primary immune response in the fetus may have 
implications for protection from infectious pathogens that are transmitted to the fetus 
during the pre- or periparturient period. Similarly, exposing the fetal immune system to 
an antigen for a prolonged period might enhance immune memory, which is also a 
hallmark of an effective vaccine, thus enhancing neonatal immune protection.  
 In order to test the main hypothesis – that it is possible to immunize the second 
trimester fetus - it was necessary to select a method of antigen delivery that would be 
consistent, that would not induce tolerance, and would not be detrimental to the fetus. In 
Section 1.2.1, mechanisms of self/non-self discrimination were reviewed and the 
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requirement for a pro-inflammatory component, danger signal or adjuvant to induce a 
protective immune response and circumvent tolerance induction, was discussed. The use 
of a traditional killed or subunit vaccine was negated due to studies in other models 
which have demonstrated inactivation by maternal antibodies (van Maanen, Bruin et al. 
1992; Blasco, Lambot et al. 2001), thus preventing its ability to be translated to the 
human model. It is also inadvisable to increase the immunogenicity of traditional or 
subunit vaccines with the addition of potent adjuvants, such as alum or CFA, due to the 
increased risk of abortion. While MLV vaccines are inherently immunogenic and very 
effective at inducing CMI in the older animal (Platt, Burdett et al. 2006; Reber, Tanner 
et al. 2006), the lack of cross-reactive or well-developed innate immune responses in the 
fetus limit the ability to control viral replication, thus increasing the risk of abortion. 
Retroviral vectors, which are a very effective method of antigen delivery in the fetus, 
preferentially induce tolerance (Table 1.5). We selected oral DNA vaccination as our 
method of antigen delivery for two primary reasons: (i) the immunostimulatory 
properties of the bacterial DNA backbone should overcome the lack of danger signals in 
the fetus; and (ii) previous experiments have shown that in utero oral DNA 
immunization is an effective method of immunizing the third trimester ovine fetus 
(Gerdts, Babiuk et al. 2000; Gerdts, Snider et al. 2002).  
 The mechanism of action of DNA vaccines was reviewed in Section 1.5. In order 
for DNA vaccination to be effective in the fetus, host cells must be transfected and 
expression of the plasmid-encoded protein must be at a level exceeding the minimal 
threshold for activation of immune cells (MacGregor, Boyer et al. 1998; Ugen, Nyland 
et al. 1998; van Drunen Littel-van den Hurk, Gerdts et al. 2000; Babiuk, Pontarollo et al. 
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2003). Furthermore, fetal immune cells must express TLR-9, which mediates the 
immunostimulatory activity of CpGs motifs endogenous to the bacterial DNA backbone. 
The ovine fetus undergoes significant developmental changes between the second and 
third trimesters of gestation; and developmental differences in the mucosal epithelium 
and immune surveillance system, specifically the rate of leukocyte trafficking and 
lymphatic drainage of the oral cavity, were identified as potential factors limiting the 
ability to extend oral DNA immunization from the third to second trimester of gestation. 
Prior to testing the immune competence of the second trimester fetus, it was necessary to 
demonstrate the consistency of the oral delivery protocol and ensure that adequate levels 
of plasmid transfection and expression could be achieved in the second trimester fetus.  
 Initial plasmid dose and transfection/expression studies were conducted in the 
third trimester ovine fetus between 120-125 dg, i.e., the age of fetus used by Gerdts et al. 
(2000; 2002) to conduct immunization experiments. A simple dose titration study 
conducted with luciferase-plasmid (Fig. 4.3) confirmed that injection of 1 mg of plasmid 
resulted in higher levels of transgene expression in the oral cavity relative to a 500 μg 
dose of plasmid, which was the arbitrary dose used in the original studies by Gerdts et 
al.. As other studies have shown a correlation between high levels of transgene 
expression and successful DNA vaccination, 1 mg was selected as the preferred dose for 
subsequent transfection/expression and immunization experiments.  
 In vitro experiments conducted with tissue explants collected from 120-125 dg 
fetuses provided proof of principle that transfection of fetal mucosal epithelium can 
occur in the absence of either tissue manipulation or DNA plasmid formulation and 
evidence to suggest that transfection of mucosal epithelium with naked DNA plasmid 
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occurs within 15 minutes of contacting the mucosal epithelium (Section 4.4.2). This 
latter finding was consistent with studies showing that circular plasmid was degraded 
within 4-8 hours in amniotic fluid (Gerdts, Snider et al. 2002). Within 24 hours of oral 
delivery, transgene expression was located primarily in the tongue and lips. Between 24 
and 72 hours, the level of luciferase activity increased slightly and from 5 dpi onward, 
there was a significant increase in both the level and distribution of luciferase activity. 
When compared with the duration of luciferase expression in cultured MDBK cells (72 
hours) and the reported half-life of luciferase in mammalian cells (3-4 hours), the 
continual increase in levels of luciferase activity up to 11 dpi suggested that plasmid 
expression was ongoing in transfected cells. Therefore, in utero oral injection of DNA 
plasmid is followed by persistent transfection of cells and prolonged expression of 
plasmid in the recipient fetus. The oral DNA vaccination method was selected for 
second trimester fetal immunization studies for its potential to provide long-term 
antigenic stimulation to the naïve fetal immune system, as well as to provide long-term 
antigenic support to activated memory cells.  
 Based on the detection of luciferase activity in fetal tissues, oral injection of 
DNA between 120-125 dg resulted in successful transgene expression in 93% of fetuses. 
This corresponded with a greater that 83% immunization rate in fetuses, which was 
obtained using a lower dose of orally delivered DNA plasmid (Gerdts, Babiuk et al. 
2000; 2002). Oral DNA delivery experiments were also conducted in both newborn and 
second trimester fetal lambs. Delivery of plasmid solution to the oral mucosal epithelium 
of newborn lambs (less than 24 hours of age; n=3) did not result in detectable levels of 
luciferase activity in tissues collected  at 24, 48 or 72 hours post-injection (1 lamb per 
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collection time; data not shown). This absence of detectable luciferase activity was 
consistent with failure to immunize newborn lambs with tgD-plasmid using the oral 
delivery method (Section 4.4.5). In contrast, oral delivery of luciferase-plasmid to 
fetuses between the ages of 65-70 dg resulted in luciferase detection in a larger 
percentage area of tissues in the oral cavity and higher levels of luciferase activity per 
sample area relative to fetuses treated at 120-125 dg (Fig. A.1). Furthermore, oral 
delivery of luciferase-plasmid in the second trimester resulted in detectable levels of 
luciferase activity in 100% of treated fetuses (Fig. 5.2). We hypothesized that the 
enhanced transfection and expression of DNA plasmid in the second trimester fetus 
might translate into a higher rate of immune induction following oral DNA 
immunization, provided that the immune system in the second trimester was competent 
at the time of immunization. Significant variation in transfection efficiency was noted 
between individual animals in all transfection/expression experiments and low levels of 
transgene expression might limit the efficiency of in utero oral DNA immunization in 
some fetuses. 
 Variation in levels of transgene expression among individual fetuses may be 
caused by a number of factors, including escape of plasmid solution from the oral cavity 
and differences in transfection competence. The oral delivery protocol was modified for 
all second trimester injection/immunization studies, such that the fetus was clearly 
visible within an amniotic bubble (Fig. 5.1). This modification of the surgical procedure 
had no effect on fetal survival rates, but did allow visualization of the injection process 
and further assurance that oral tissues were neither directly injected nor damaged during 
plasmid delivery. We noted fluid flowing out of the oral cavity from the commissures of 
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the lips during oral injection of some, but not all, fetuses. This loss of plasmid from the 
oral cavity likely contributed to detection of transgene activity in external body tissues, 
such as the ear, as well as lower levels of transfection in certain fetuses. Plasmid solution 
might also have been lost from the oral cavity as a result of diffusion into the upper 
respiratory tract or swallowing. Unfortunately, neither intestinal tissues nor mesenteric 
LNs were analyzed for transgene activity.  
 In Chapter 2 (p. 68), we hypothesized that transfection occurred primarily in the 
mucosal epithelium of the oral cavity. This hypothesis was based on the prior detection 
of tgD-specific lymphocyte proliferative responses in LNs draining the oral cavity, but 
not elsewhere in the body (Gerdts, Babiuk et al. 2000). Luciferase experiments in second 
and third trimester fetuses gave similar localization results; specifically, that transgene 
activity was present at the earliest times examined post-injection and at the highest 
levels in the mucosal epithelium of the oral cavity. We then refined our hypothesis to 
state that transfection and expression occurred primarily in nucleated cells in or 
superficial to the stratum basale as a result of plasmid being unable to permeate the 
basement membrane  (Loehr, Willson. et al. 2000; Lemoine, Farley et al. 2005). Studies 
in human fetuses have shown that the basement membrane of skin has developed by the 
first trimester (Hentula, Peltonen et al. 2001), but no equivalent studies have been 
conducted in sheep. Unsuccessful attempts were made to identify the type and location 
of cell(s) preferentially transfected with plasmid using either immunohistochemical 
staining for luciferase protein or fluorescence microscopy (following oral delivery of 
green-fluorescent protein (GFP)-encoding plasmid). The inability to detect individual 
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cells expressing either luciferase or GFP may reflect a very low frequency of cell 
transfection in the oral mucosa.  
 Our hypothesis that transfection occurred in the epithelial layer was consistent 
with the findings that: (i) oral delivery was not successful in newborn lambs (Section 
4.4.5), and (ii) the level of luciferase activity was higher in fetuses that were orally 
injected at a younger gestational age (Fig. A.1). The different types of epithelium 
present in the oral cavity were discussed in Section 1.5.3. Increased cornification and 
keratinization of cutaneous surfaces, such as the tongue and lips, which were identified 
as primary sites of plasmid transfection and expression, might restrict plasmid uptake 
and transfection in the neonate relative to in the fetus. In addition, the higher rate of 
epithelial cell turnover in neonatal lambs would result in a more rapid loss of transfected 
cells, thus limiting the duration and level of transgene expression. Without adequate 
levels of antigen expression, the minimum threshold for immune activation may not be 
reached. In contrast, reduced cornification and keratinization, the lower rate of epithelial 
cell turnover as shown by low levels of Ki67 staining, and the presence of nucleated 
cells at the superficial surface are all consistent with increased levels and duration of 
transgene activity in fetuses injected at 65-70 dg as compared to fetuses injected at 120-
125 dg. Another factor that may also influence the age-dependence of transfection 
efficiency is the total surface area of the oral cavity at the time of plasmid delivery. 
Between 65 and 120 dg, the surface area of the oral cavity increased by 240% (based on 
dissection of the oral mucosa into 1-cm
2
 tissue sections). Studies have shown that 
increasing the volume of an injection of naked DNA plasmid relative to the surface area 
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(i.e., increasing the hydrostatic pressure at the contact surface) resulted in higher 
transfection efficiency (Hiraoka, Koike et al. 2003).  
 The induction of an immune response requires effective antigen presentation to 
naïve fetal lymphocytes. DNA vaccine studies in adult animals have shown that the 
basement membrane forms an effective barrier against non-specific transport of plasmid 
and protein between the mucosal epithelium and underlying submucosa (Loehr, Willson. 
et al. 2000; Lemoine, Farley et al. 2005); however, the effectiveness of the fetal 
basement membrane at preventing diffusion of plasmid or plasmid-encoded protein to 
the lamina propria has not been determined. According to Bodde et al. (1990), the 
mucosal epithelium does not support Langerhans cells; yet, immunohistochemistry 
revealed the presence of low numbers of MHC class II
+
 cells with a dendritic 
morphology interspersed among epithelial cells in the stratum basale of the oral mucosal 
epithelium in third trimester fetuses (Fig. A.2). Large numbers of cells expressing MHC 
class II were also detected in the fetal lamina propria, which is consistent with reports 
that there is a high rate of lymphocyte recirculation through fetal peripheral tissues 
(Kimpton, Washington et al. 1995; Cahill, Kimpton et al. 1997).  Despite the presence 
of MHC class II
+
 cells in the fetal oral mucosa, the detection of functional luciferase 
activity in the retropharyngeal, mandibular, parotid and SCv LNs strongly suggests that 
protein (and possibly some plasmid) was well distributed throughout tissues of the head 
and neck and arrived at the draining LNs via the lymphatics (Fig 6.1). The use of 
plasmid isolation, followed by either PCR amplification or transformation of bacteria, 
did not result in detection of plasmid in draining LNs (data not shown). The 
development of germinal centers in LNs draining  
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Figure 6.1. Flow of plasmid solution following oral injection and lymphatic 
drainage of the head and neck. 
 
 Plasmid solution injected into the oral cavity could permeate the mucosal 
epithelium, be swallowed, enter the respiratory tract or escape the oral cavity. Lymph 
from the head and anterior cervical region eventually collect at the lateral 
retropharyngeal (RPh) lymph nodes (LNs). Lymph from the pharynx, neck and anterior-
most portions of the thorax collect at the superficial cervical (SCv) LNs. Both the SCv 
and RPh LNs drain into the jugular vein via the thoracic duct.  1. Parotid LN; 2. medial 
RPh LN; 3.lateral RPh LN, 4. mandibular LN, 5. SCv LN; 6. entry of the thoracic duct 
into the jugular vein; a. drainage area corresponding to the parotid LN; b. drainage area 
corresponding to the medial RPh LN; c. drainage area corresponding to the lateral RPh 
LN; d. drainage area corresponding to the mandibular LNs; e. drainage area 
corresponding to the SCvLN; f. arrow showing direction of lymph flow in the tracheal 
duct, i.e., from the head region to the thoracic duct; A. arrow indicating primary flow 
pattern of plasmid solution upon oral injection; B. arrow indicating flow of plasmid 
solution from the oral cavity to the external ear. (Sisson and Grossman 1953; Dyce, Sack 
et al. 2002). 
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the oral cavity does, however, support the conclusion that protein and/or plasmid was 
transported via the lymphatics. According to the literature, the lymphatic system 
becomes fully functional in the fetal lamb at 78 dg (Pearson, Simpson-Morgan et al. 
1976). Our data suggest that portions of the lymphatic network, including those in the 
head and neck, are functional as early as 69 dg. The localization of plasmid-encoded 
protein to the SCv LNs may be a significant factor contributing to the success of in utero 
oral DNA immunization as these are the dominant LNs in the ovine fetus up to 140 dg 
(Bryden 1969; Washington, Kimpton et al. 1992). The significant increase in size, 
cellularity and organization of LNs in fetuses that responded to tgD-plasmid 
immunization compared with either control (untreated or null-plasmid-treated) or non-
responding fetuses suggests that LN development may be driven by antigenic 
stimulation. Accelerated LN development may also increase the ability of the fetus to 
respond to other antigenic challenge.   
 In addition to the oral mucosa and draining LNs, luciferase activity was also 
detected in the liver and/or lungs in a total of 7 fetuses from 5 dpi, onwards. There are 
many potential pathways by which luciferase activity may have arrived in either the 
lungs or liver (Fig. 6.2). Fluid containing plasmid may have entered the trachea during 
or immediately after oral injection. Diffusion of plasmid within the respiratory tract may 
have resulted in low levels of respiratory epithelial cell transfection. Similarly, plasmid 
solution may have been swallowed, resulting in either transfection of epithelial cells 
lining the gastrointestinal tract or non-specific absorption of plasmid through the 
intestinal mucosa, and subsequent transport of plasmid and/or protein to the liver via the  
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Figure 6.2. Potential pathways for distribution of plasmid or transgene product 
following in utero oral DNA immunization.  
 
 Oral delivery of a naked DNA plasmid solution resulted in detection of transgene 
activity in the following tissues and organs: the oral mucosa; the retropharyngeal (RPh), 
parotid, mandibular (Man) LNs, which drain the head and neck; the superficial cervical 
LNs (SCv), which drain portions of the neck, anterior portions of the thorax and 
forelimbs; lung parenchyma; and liver parenchyma. The majority of transgene activity 
was located in the oral mucosa in the epithelium and/or lamina propria. The level of 
keratohyalin expression and the integrity of the basement membrane in the fetal oral 
epithelium are factors that likely determine the amount of plasmid and transgene product 
present in the lamina propria (depicted as green hatching). Drainage of lymph from the 
oral cavity and elsewhere in the head would result in transport of protein and/or plasmid 
to regional LNs. Lymph collected from the head and neck eventually enters the lateral 
RPh LNs, from where it enters the tracheal ducts. Lymph from the left tracheal duct 
joins the venous return via the thoracic duct, while the right tracheal duct enters directly 
into the right jugular vein. Diffusion of plasmid and/or transgene product to cervical 
tissues would result in drainage to the SCv LNs. Once plasmid and.or protein enters the 
blood, it is readily distributed elsewhere in the body, including the lungs and liver. 
Alteratively, plasmid may reach the lungs via the trachea. Either plasmid or protein 
(secreted by transfected cells in the oral epithelium) may be swallowed. Swallowed 
plasmid may transfect epithelial cells lining the gastrointestinal tract. Either plasmid or 
protein may enter the bloodstream as a result of non-specific intestinal absorption in the 
fetus. Examination of the mesenteric or tracheobronchial LNs for germinal center 
development might give some indication of the levels of transgenic protein present 
outside the oral cavity.  (Sisson and Grossman 1953; Dyce, Sack et al. 2002). 
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portal vein. Alternately, transgenic protein may have been secreted into the oral cavity 
and ingested, resulting in absorption through the gut. In Gerdts et al. (2000), oral 
delivery of tgD-plasmid at 120-125 dg failed to induce tgD-specific proliferative 
responses in the mesenteric LNs, suggesting that levels of plasmid/antigen that 
potentially reached the intestines were well below the threshold required to induce an 
immune response. The observation that luciferase activity in the lungs, liver and LNs 
reached detectable levels at approximately the same time, points towards the gradual 
accumulation of transgene product in the blood of orally-injected fetuses. Future 
experiments should include analysis of serum and gastrointestinal mucosa for the 
presence of the transgenic protein.  
 As discussed earlier, the presence of functional luciferase in LNs strongly 
suggests that antigen processing and presentation occurs in the LNs. The induction of a 
protective immune response in a fetal environment otherwise lacking in danger signals 
suggests that portions of the bacterial DNA backbone must also be transported to the 
LNs. Despite the possible introduction of plasmid and/or protein into the circulation, the 
lack of induction of tolerance in orally immunized fetuses indicates that neither plasmid 
nor functional protein was able to cross the blood-thymic barrier.  
 In fetuses that were injected at 120-125 dg, luciferase activity was still present in 
the oral mucosa at 11 dpi and luciferase levels were still rising. Due to the short half-life 
of luciferase in mammalian cells (3-4 hours; Leclerc, Boockfor et al. 2000) and the short 
half-life of DNA plasmid in amniotic fluid (2-4 hours) (Gerdts, Snider et al. 2002), it can 
be surmised that prolonged antigen presence was due to the continued expression of 
plasmid by transfected epithelial cells. The persistence of transfected cells and the 
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number of cells that are transfected are critical factors when determining the efficacy of 
in utero oral DNA immunization and the duration of both the primary immune response 
and immune memory. We hypothesize that the overall efficiency of oral delivery 
increases as the age of the fetus decreases. A number of factors may contribute to this 
age-dependence: (i) the younger fetus has a lower rate of epithelial cell turnover, thus 
resulting in the prolonged survival of transfected cells; (ii) there is an increase in the 
number of nucleated cells at the epithelial surface at younger gestational age, thus, 
increasing plasmid-to-cell contact; and (iii) the epithelium appears to be more permeable 
in the younger fetus allowing for transfection of cells closer to the basement membrane; 
(iv) greater permeability of the basement membrane may allow more protein and/or 
plasmid to enter the lamina propria; (v)  the smaller oral cavity in the younger fetus 
translates into relative increases in both the plasmid concentration and injection volume: 
surface area ratio; and (vi) the faster rate of epithelial cell turnover in older animals 
result in more rapid sloughing of transfected cells. This inverse correlation between 
transfection efficiency and the age of the fetus at the time of oral injection is also 
consistent with failure to detect transgene activity following oral DNA delivery in the 
neonate.  
 Based on data obtained from transfection and expression studies, we 
hypothesized that oral DNA immunization could be extended to the second trimester as 
early as 50 to 70 dg, i.e., when the ovine fetus acquires immune competence. The 
emergence of immune competence coincides with the appearance of T and B cells in 
peripheral lymphoid tissues between 50-55 dg (Symons and Binns 1975; Press, Hein et 
al. 1993; Griebel 1998; Cahill, Kimpton et al. 1999) and Silverstein et al. (1963) 
 179 
reported that antigen-specific antibodies were detectable in fetal serum as early as 66-70 
dg following immunization with phage X174 and horse spleen ferritin. We reasoned 
that the higher level of transgene expression and the persistence of transfected cells - 
which may or may not exceed, but should be equal to, the duration of transfected cells in 
the third trimester fetus - would compensate for lower numbers of lympocytes in the 
second trimester fetus. In particular, the continued delivery of antigen to the draining 
LNs, specifically the SCv LNs, would allow for the continued activation/stimulation of 
naïve fetal lymphocytes so long as transgene expression persisted, thus allowing for 
amplification of the primary immune response. Furthermore, as immune ontogeny 
progresses, the antigenic repertoire might expand to include additional epitopes 
represented on the immunizing antigen. The continued presence of antigen might also 
prolong the survival of memory cells, thus enhancing the potential for post-natal 
protective immunity.  
 Second trimester oral DNA immunization experiments were conducted with 
fetuses aged 55-60 dg and 78-84 dg (Chapter 5). A total of 24 fetuses were orally 
immunized with plasmid encoding BHV-1 tgD and a 66% success rate (16/24) was 
observed based on detectable tgD-specific antibody titers, IFN  secretion responses 
and/or anamnestic responses in newborn lambs. IFN  secretion is a hallmark of Th1-
type immune responses and detection of IFN  responses indicated that some Th1 
activation did occur despite the reported impairment of Th1 responses in the fetus and 
newborn (Section 1.2.5). The 66% successful immunization rate was consistent with 
data obtained from transfection/expression studies showing high levels of transgene 
expression in 70% of orally injected fetuses (Section 5.4.1.). Therefore, it may be 
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possible to increase the efficiency of immune induction by further optimizing the rate of 
plasmid transfection and expression; however, differences in tgD-reactivity or the rate of 
immune development might also have influenced the ability of individual animals in an 
outbred population to respond to second trimester DNA immunization.  
 The earliest fetal age that was examined for tgD-specific immune responses was 
69-74 dg (i.e., 14 dpi). In the single fetus that was examined at this age, both tgD-
specific antibody responses and germinal centers were observed. This is consistent with 
the earliest time reported by Silverstein et al. (1963) for the detection of antigen-specific 
humoral responses. In the study by Silverstein et al., fetuses were immunized from 60 dg 
onwards, whereas in our study, fetuses were immunized as early as 55 dg (i.e., during 
the preimmune period). Due to the persistence of transgene expression following oral 
DNA immunization, it is entirely possible that a lag period (of no more than a few days) 
occurred between oral immunization and the first inductive event. In the event that such 
a lag period did occur, and despite having immunized during the preimmune period, it is 
significant to note that tolerance was not induced and this may be attributable to the 
immuno-stimulatory properties of the bacterial DNA backbone.  
 At 14 dpi, the amplitude of the tgD-specific antibody response was very low but 
statistically significant (Section 5.4.2). When the period between oral immunization and 
detection of immune responses was extended to 30 dpi and 50 dpi, there was a noted 
increase in the amplitude of primary antibody titers. We were unable to conduct a time 
course study to determine the time of peak fetal antibody titers due to the limited 
availability of fetuses and prohibitive costs; however, the observed increase in serum 
antibody titers between 14 dpi and 50 dpi supported our prior hypothesis that persistent 
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antigen might result in the continued induction of naïve lymphocytes, thus amplifying 
the primary immune response.  
 Immune induction in second trimester fetuses was also evident as histological 
changes within LNs draining the oral cavity. LNs develop from mesenchymal cell 
clusters arising from the lymphatics. In naïve 70 dg fetuses, the parotid, retropharyngeal 
and submandibular LNs were difficult to isolate due to their small size and lack of 
cellular organization. Oral DNA immunization appeared to enhance LN development. 
At 14 dpi (approximately 70 dg), there was clear demarcation between the cortex and 
medulla and medullary cords were visible. By 30 dpi (approximately 86 dg), primary 
follicles and germinal centers were clearly present in a number of immunized fetuses. In 
fetuses that were orally injected with the pSLIA-null control plasmid, LN enlargement 
and primary follicles were also observed, albeit to a lesser extent. In contrast, neither 
primary follicles nor germinal centers were detected in the retropharyngeal, SCv, parotid 
or submandibular lymph nodes of naïve fetuses examined up to 105 dg. Based on these 
observations, it would appear that induction of humoral responses does not require the 
prior development of primary follicles and stimulation with plasmid DNA drives LN 
development. Injection of circular plasmid containing CpG motifs has previously been 
reported to increase the recruitment of lymphocytes to a regional lymph node and GC 
development within that LN (Uwiera, Gerdts et al. 2001).  
 Despite the prolonged expression of the plasmid, the amplitude of fetal antibody 
titers induced by oral DNA immunization in the second trimester was relatively low 
compared with titers previously induced in third trimester fetuses (Gerdts, Babiuk et al. 
2000). Oral immunization at 55-60 dg resulted in low titers (<135) in 15 of 16 
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responding fetuses. The only exception was fetus no. 54, which had a tgD-specific titer 
of 2400. Antibody titers in precolostrum sera of newborn lambs immunized at 67-72 and 
78-84 dg, were similarly low (<150) with the exception of lamb no. 197 (titer = 333). 
Gerdts et al. (2002) had reported mean antibody titers of 5589 + 3650 (Experiment I) 
and 1083 + 352 (Experiment II) in precolostrum sera of lambs immunized at 125-130 
dg. To determine if the disparity in antibody titers was physiological or the result of 
experimental artifact, sera from lambs immunized at 55-60 dg were reanalyzed and 
compared within the same ELISA to precolostrum sera obtained from two lambs in 
Experiment I of Gerdts et al.. These two reference sera had the highest gD-specific 
antibody titers of that experiment and had been stored at -70 °C with PMSF to inhibit 
protease activity. Our ELISA revealed that titers in serum from fetuses immunized at 55-
60 dg remained unchanged, but antibody titers for the two reference sera were 561 and 
597. We concluded that the 2- to 10-fold decrease in ELISA sensitivity was the result of 
the specific batch of recombinant tgD that had been used to coat ELISA plates. Although 
the sensitivity of our ELISA was much lower than that reported in Gerdts et al., our 
ELISA did have a higher specificity.  At no time during our experimentation did tgD-
specific titers in naïve or control-plasmid immunized fetal or newborn (precolostrum) 
sera exceed a titer of 20. In contrast, the mean background titers reported for 
Experiments I and II by Gerdts et al. were 112 + 57 and 168 + 143, respectively. Based 
on these data, the fetal responses observed in our experiments appeared to be real despite 
the low amplitude of observed titers.  
 While the low amplitude of titers in the in utero immunization studies may be 
due to the specific batch of recombinant tgD used for ELISAs, this could not explain the 
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small increase in antibody titers relative to background in 10 of 16 responders; in these 
10 fetuses and newborn lambs, positive antibody titers did not exceed 50. In Chapter 5, 
we hypothesized that the low magnitude responses reflected the relative lymphopenia in 
the ovine fetus prior to 130 dg. We did not conduct FACs analysis of peripheral blood 
lymphocytes at 55-60 dg, however, the total number of lymphocytes
1
 in the peripheral 
blood of naïve fetuses aged 83-88 dg was 1.8 + 0.5 x 10
5
 cell/ml and there was no 
significant increase in the number of lymphocytes in the blood of immunized fetuses. At 
birth, i.e., when lambs were assessed for precolostrum antibody titers and persistence of 
fetal IFN  responses, the total peripheral blood lymphocyte count was approximately 1.2 
+0.5 x 10
6
 cells/ml. According to the literature the peripheral RLP undergoes significant 
expansion from 2-5 days of age onward, i.e. after parturition-associated cortisol levels 
have subsided (Taylor 2000). The low number of lymphocytes observed in the 
peripheral blood of second trimester fetuses might also explain the limited success in 
quantifying tgD-specific proliferative responses in cultures of peripheral blood 
mononuclear cells following oral DNA immunization (Fig. A.3). TgD-specific 
lymphocyte proliferation was detected in the peripheral blood of >50% of immunized 
fetuses at 30 and 50 dpi; however, the stimulation indices were well below that obtained 
in young lambs following immunization with tgD-plasmid or recombinant tgD (data not 
shown).  Results obtained in FACS and antigen-specific lymphoproliferative assays are 
consistent with the low magnitude of tgD-specific antibody titers in responders.   
 The low frequency of tgD-specific lymphocytes observed in fetuses orally-
immunized in the second trimester suggests that the expansion of the lymphocyte pool in 
the fetus may be tightly regulated by the same homeostatic mechanisms which function 
                                                 
1
 The total lymphocyte number was determined from CD5+ and CD72+ cells using FACS.  
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in the adult to prevent uncontrolled lymphocyte accumulation and increase the diversity 
of the immune repertoire (Freitas, Agenes et al. 1996). If this is the case, the majority of 
lymphocyte expansion in the fetus is antigen-independent and the selective amplification 
of a single or limited number of antigen-specific clones in an immunologically naïve 
animal, such as the fetal lamb, should not influence the ability of the immune system to 
respond to other antigens. Experiments in mice have shown that even in the event of 
severe lymphopenia, the percentage of T cells with a monoclonal specificity is restricted 
to 10% of the total number of T cells in the RLP (Rocha, Dautigny et al. 1989). 
 Despite the low amplitude of tgD-specific antibody titers, titers persisted for a 
relatively long period (i.e., up to 11.5 weeks, from the time of immunization at 67-72 dg 
until birth). Similarly, tgD-specific IFN  responses were still detectable at 10-11 weeks 
post-immunization. Therefore, the duration of antigen-specific antibody and cellular 
responses were comparable to that reported for a primary immune response achieved 
after optimized delivery of a DNA vaccine to young lambs (Section 3.3.2). In Chapter 3, 
different routes and methods of DNA vaccine delivery were compared and the duration 
of primary antibody responses were found to be enhanced by (i) delivery of plasmid to 
muscle, which has a lower rate of turnover than epithelial cells in the young lamb, and 
(ii) the use of electroporation, which increases transfection efficiency. Intramuscular 
delivery of a high dose of tgD-plasmid, followed by electroporation, induced primary 
antibody responses that persisted for an average of 11 weeks in young lambs. In 
contrast, IM injection of tgD-plasmid alone resulted in primary antibody responses that 
persisted for an average of 6 weeks only. The mechanism(s) behind the long duration of 
fetal immune responses was not examined. It is known that the ovine fetus supports a 
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population of long-lived CD4+ thymic emigrants with a half-life of approximately 20 
days that preferentially target the peripheral LNs (Cahill, Kimpton et al. 1999) and these 
CD4+ T cells may have a similarly long-lived phenotype when activated. Currently, 
little is known about the characteristics of activated fetal lymphocytes. The prolonged 
duration of primary fetal responses might also result from the simultaneous turnover of 
activated lymphocytes and induction of naïve lymphocytes, with both occurring at a 
similar rate. In this scenario, primary immune responses would persist for the duration 
that antigen is present in quantities exceeding the threshold for activation of naïve 
lymphocytes. This mechanism would be more consistent with findings from our 
electroporation studies in young lambs. The persistence of antigen as a property of in 
utero oral DNA immunization was discussed above. Fetal immunization studies with 
antigen delivered in different forms (e.g., as both a subunit protein and DNA vaccine) or 
as an inducible gene may allow determination of the mechanism(s) behind the longevity 
of the primary fetal immune response.  
   Of the 16 (of 24) fetuses that did respond to second trimester immunization, 
only two fetuses had detectable levels of both IFN -secretion and antibody responses. 
Thus, the possibility existed of having induced either tolerance in the apparent non-
responders or deviation towards Th2-type responses in some responders. Secondary 
DNA immunization in the neonate was used to test for the possible induction of 
tolerance or immune deviation. In addition, secondary immunization allowed testing for 
the survival of immune memory.  
 The survival of immune memory is the keystone of an effective vaccine and this 
is especially true of a fetal vaccine where there is a lack of natural boosting by cross-
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reactive environmental antigens from the time of immunization to birth. We had 
originally hypothesized that immune memory induced in the second trimester fetus 
would be capable of surviving until birth based on continued antigen expression by 
transfected host cells. Indeed, anamnestic responses were present in 2 of 4 neonatal 
lambs immunized at 67-72 dg, and 3 of 6 neonatal lambs immunized at 78-84 dg. 
Therefore, immune memory persisted throughout the remaining 11-12 weeks of fetal 
development, plus an additional 2 weeks after birth. The classical characteristics of an 
anamnestic response are earlier onset, increased amplitude and prolonged duration of 
effector functions. In lambs that had been immunized at 67-72 dg and boosted by IM 
injection plus electroporation, immune memory was present in the form of an earlier 
onset of a detectable increase in antibody titers, as well as a 2-fold increase in peak 
antibody titers following neonatal DNA immunization relative to controls. In lambs that 
had been immunized at 78-84 dg and boosted with IM injection of tgD-plasmid without 
electroporation, immune memory was evident in the earlier onset and prolonged 
duration of secondary antibody titers, as well as an increase in the magnitude of peak 
antibody titers.  
 The increase in magnitude of anamnestic responses was not dramatic and, 
overall, the induction of immune memory by oral immunization in the second trimester 
did not appear to provide a significant immune advantage to the neonate given the risks 
of the in utero surgical procedure. This contrasted with the finding by Gerdts et al. 
(2002), that third trimester oral DNA immunization was able to induce memory cells 
that significantly enhanced neonatal immune responsiveness to tgD. The low amplitude 
of secondary antibody titers may have been due to a combination of the low sensitivity 
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of the antibody detection method as a result of the specific preparation of recombinant 
tgD used to coat ELISA plates and the inherent reduction in the amplitude of antibody 
responses characteristic of young lambs less than 21 days of age (Section 4.4.5). We also 
propose that the number of memory cells generated in utero in the second trimester was 
restricted by the size of the peripheral lymphocyte pool and limited immune repertoire. 
Therefore, despite the ability of activated fetal effector and memory cells to survive 
gestation and the cortisol-induced apoptosis that accompanies birth, memory cells may 
not be present in numbers sufficient to enhance neonatal immune protection.  
 The duration of immune memory achieved by in utero oral DNA immunization 
was surprising given the low amplitude of fetal immune responses. Furthermore, the 
duration of fetal immune memory was comparable to the duration of immune memory 
reported for neonatal lambs following a single ID immunization with tgD-plasmid (van 
Drunen Littel-van den Hurk, Braun et al. 1998). This similarity in duration of immune 
memory was observed despite differences in lymphocyte numbers and exposure of 
memory cells in the neonate, but not the fetus, to environmental antigens. In Chapter 3, 
we found that the correlation between the duration of a primary immune response and 
immune memory (r
2
 = 0.74) was greater than that between the amplitude of the primary 
response and immune memory (r
2
 = 0.40). Due to practical limitations, e.g., the 
availability of fetuses and high cost of experimentation, the duration and peak magnitude 
of fetal immune responses were never properly explored. Of the 5 lambs with evidence 
of immune memory at birth, three lambs (nos. 253, 184 and 197) also had detectable 
fetal immune responses at birth. This observation agrees with our previous  conclusion 
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that a correlation exists between duration of the primary immune response and immune 
memory.  
 With respect to the primary immune response, the magnitude of the response 
appears to be largely a function of the number of activated lymphocytes, whereas 
duration appears to be heavily influenced by the persistence of antigen. The duration of 
immune memory, particularly that mediated by CD4+ T cells, may also depend on the 
continued presence of antigen (Gray and Skarvall 1988). To properly determine if the 
duration of primary immune responses and immune memory in the fetal lamb was 
related to the prolonged expression of antigen by transfected host cells, it will be 
necessary to compare immune responses in fetuses that have been immunized with tgD-
plasmid versus soluble, recombinant tgD protein. The lengthy duration of both the 
primary immune response and immune memory in the fetus may also support the 
existence of a subpopulation of long-lived fetal lymphocytes.  
 In conclusion, this thesis showed that the second trimester fetal lamb is immune 
competent and oral DNA immunization can be successfully carried out as early as 55-60 
dg, which coincides with the appearance of lymphocytes in peripheral lymphoid tissues 
and is a period that has previously been described as “preimmune”. Furthermore, the 
level of oral DNA transfection increased as the age of the fetus decreased at the time of 
immunization. The analysis of luciferase expression within 72 hours of oral plasmid 
injection revealed transgene expression in 100% of fetuses; however, transfection did 
not necessarily result in the effective induction of fetal immune responses. Low levels of 
transgene expression may account for failure of immunization in up to 30% of fetuses. 
In the 16 of 24 (66%) fetuses that did respond to oral DNA immunization in the second 
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trimester between 55 and 84 dg, only 2 fetuses (8.3%) had primary immune responses of 
sufficient amplitude to possibly provide immune protection in the event of an infection 
and only 1 of 6 fetuses (16%) had clear evidence of both humoral and cell-mediated 
immune memory. In the remaining responders, the amplitude of immune responses was 
limited. These data contrast with results reported by Gerdts et al. (2000; 2002) that in 
utero immunization induced significant primary immune responses and secondary 
immune responses were sufficient to afford protection to the neonate against viral 
challenge.  
 We propose that the major limitation to second trimester oral DNA immunization 
is the low number of lymphocytes present at this time. According to the literature, the 
fetal immune system undergoes two major expansions in the size of the lymphocyte 
pool. The first expansion occurs at approximately 100-110 dg with emigration of B cells 
from the spleen to the ileal PPs and is moderate (Cahill, Kimpton et al. 1999; Yasuda, 
Jenne et al. 2006). The second expansion occurs between 130 dg and birth when the ileal 
PPs undergo massive lymphopoiesis in order to fully populate the peripheral lymphoid 
tissues (Reynolds 1987). The high magnitude of antibody titers and lymphoproliferative 
responses reported in Gerdts et al. (2000; 2002), may be the result of having immunized 
at or immediately prior to expansion of the peripheral lymphocyte pool in the fetus. 
When these data are considered in relation to the data and conclusions arrived at in 
Chapter 3, there appears to be an optimal time for in utero oral DNA immunization that 
occurs around 130 dg (Fig. 6.3). This period is defined as the interval following major 
expansion of the fetal lymphocyte pool, i.e., after 110 dg when the ileal PPs becomes the 
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primary site of lymphopoeisis, but prior to maturation of the mucosal epithelium and the 
onset of parturition-associated cortisolemia.  
 The work in this thesis ties together much of the existing research in the fields of 
vaccine development, immune modulation, developmental immunity and neonatal 
infection. Major factors influencing the needle-free or oral delivery of DNA vaccines 
were identified. We also confirmed the ability of DNA vaccination to overcome the 
developmental tendency towards tolerance induction and deviation towards Th2 immune 
responses. These findings have a practical significance given the low cost of DNA 
vaccine production and its ready adaptability to different pathogens, including emerging 
diseases. A new lower age limit for fetal immunization was defined in this thesis that  
challenges existing theories regarding fetal immune competence and mechanisms of 
developmental tolerance. As an experimental model, second trimester oral DNA 
immunization in the ovine fetus may be invaluable for testing theories such as the 
Danger Hypothesis and the antigen-dependence of immune memory. 
 Of the animal species that are currently used for research purposes, immune 
ontogeny in the sheep is the most similar to that in humans and the findings in this thesis 
suggest that it may be possible to vaccine the fetus against vertically transmitted 
pathogens, such as HIV. Unfortunately, despite the fact that second trimester oral DNA 
immunization appeared to have no negative physiological effects on the fetus, our 
research also suggests that the inherent low amplitude of fetal immune responses in the 
majority of an out bred population, weighed against the risks associated with fetal 
surgery, current;y precludes the clinical application of this technology in protecting 
against vertically transmitted diseases. With ongoing advances in surgical techniques, 
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such as incorporation of advanced imaging and development of new endoscopic tools, it 
may be possible to limit surgical risks to a degree that vaccination in the second 
trimester would be considered despite its success rate of between 8 to 67%.  
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Figure 6.3.   Factors influencing the optimal age for in utero oral DNA 
immunization 
 
 The efficiency of plasmid transfection and expression may be inversely 
correlated to the age of the fetus and the degree of maturation of the mucosal epithelium. 
Also, the size of peripheral lymphocyte pool is severely limited in the second trimester 
ovine fetus and major expansion does not occur until approximately 100-125 days 
gestation. Factoring in the rise in cortisol-induced lymphocyte apoptosis that 
accompanies birth, the optimal age for in utero oral DNA immunization is proposed to 
occur between approximately 125-135 days gestation. 
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APPENDIX A 
 
ADDITIONAL FIGURES NOT INCLUDED IN MANUSCRIPTS 
 
 
 
65d gestation (n=4) 125d gestation (n=4)
 
 
 
Figure A.1.  Comparison of transgene expression following oral injection of 
luciferase plasmid in second and third trimester ovine fetuses.  
 
 Higher levels of luciferase activity were achieved in tissues from fetuses that had 
been treated at 65 dg. Tissue samples were collected 2 days after 1 mg of luciferase-
plasmid was delivered to the oral cavity of each fetus. Each data point represents the 
level of luciferase activity in a single 1-cm
2
 section of mucosal epithelium collected 
from the oral cavity at 48 hours post-injection. Levels of luciferase expression was also 
higher in 65 dg fetuses (n=3) when samples were analyzed at 3 and 5 days after oral 
delivery of luciferase plasmid. (Refer to Sections 4.3 and 5.3 for Material and Methods.) 
 65 dg (n=4)    125 dg (n=4) 
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Figure A.2. Immunohistochemical staining for MHC class II in oral mucosa from a 
120 dg ovine fetus. 
 
 MHC class II is a marker of T and B lymphocytes and professional antigen-
presenting cells. Their presence in the basal layer of the mucosal epithelium and oral 
submucosa provides a mechanism by which antigen delivered to the oral cavity can be 
sampled and transported to the draining lymph nodes.  Tissues collected from the upper 
lip (A) and dorso-rostral surface of the tongue (B) of 120 dg fetuses were stained with 
monoclonal antibody for MHC class II. Frozen tissues were cut into 6 μm sections, 
mounted onto Colorfrost Plus Slides (Fischer Scientific, Pittsburgh, PA) and fixed with 
acetone. Tissue sections were blocked in three stages: tissues were first blocked with 0.1 
mg/ml goat serum in PBS, followed by Avidin B Blocking Solution (Vector 
Laboratories, Burlingame, CA) and then with Biotin Blocking Solution (Vector 
Laboratories). Tissue sections were incubated with TH14B monoclonal antibody, 
specific for bovine MHC class II (HLA-DR ) (1:1000 dilution; VMRD, Inc., Pullman, 
WA), and then with biotinylated goat-anti-mouse IgG2a (1:1000 dilution; 
Caltag/Invitrogen, Burlington, ON). Antibody labeling was visualized using the Vector 
Elite Vectastain  ABC kit (Vector Laboratories). Slides were counterstained in 0.5M 
CuSO4 in 0.9% NaCl, followed by a 5% Giemsa solution.  
A           B 
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Figure A.3.  TgD-specific peripheral blood lymphoproliferative responses at 30 and 
50 days following in utero oral DNA immunization.  
 
 Oral DNA immunization with tgD-plasmid at 55-60 dg resulted in the induction 
of tgD-specific lymphoproliferative responses in a total of 6 of 12 (50%) fetuses. In all 
fetuses, the stimulation index was low relative to control fetuses.  
Fetuses were immunized between 55-60 dg with control plasmid (pSLIA-null) or tgD-
plasmid and peripheral blood mononuclear cells were isolated at 30 dpi (A) and 50 dpi 
(B). Triplicate cultures of 1 x 10
6
 cells were incubated for a period of 6 days in media 
alone or media containing 5 μg/ml recombinant tgD. 3H-thymidine was added to media 
for the last 16 hours of culture. The stimulation index was calculated as the mean counts 
per minute (cpm) of tgD-stimulated cells divided by the mean cpm of cells in media 
alone. The dotted line represents the upper 95% confidence interval for the group treated 
with control plasmid. Using the upper 95% CI as the threshold for antigen-specific 
proliferative responses, tgD-specific proliferative responses were observed in 50% of 
fetuses (p<0.5); however, this conclusion was deemed questionable based on 
experiences with tgD-immunization experiments in adult sheep in which stimulation 
indices were at least 10-fold greater. The low stimulation indices are likely a reflection 
of the low number of peripheral blood lymphocytes present in the second trimester ovine 
fetus.  
A        30 dpi    B        50 dpi 
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Tsang C, Kaushik RS, Mirakhur KK, Gerdts V, Babiuk LA, Griebel PJ. 2007. 
Transfection and expression following oral delivery of naked DNA plasmid in 
the ovine fetus. Dev Comp Immunol: (Accepted with revisions).
1
 
 
Tsang C, Mirakhur KK, Babiuk LA, Griebel PJ. 2007. Oral DNA immunization in the 
second trimester fetal lamb and secondary immune responses in the neonate. 
Vaccine 25: 8469-8479.
2
  
 
Tsang C, Babiuk S, van Drunen Little-van den Hurk S, Babiuk LA, Griebel PJ. 2007. A 
single DNA immunization in combination with electroporation prolongs the 
primary immune response and maintains immune memory for six months. 
Vaccine 25: 5485-5494.
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Babiuk S
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